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ABSTRACT
DNA sequence analysis and molecular modelling of T cell receptor (TCR) 
variable regions (Va and Vp genes) has been carried out to explore the relationship 
between TCR sequence and structure.
Analysis of the V a and Vp genes revealed a much greater variability between 
different TCR sequences than is seen when different antibody variable regions are 
compared.
Different variable region sequences recognising the same MHC-peptide 
specificity generally showed a higher degree of similarity, both within the framework 
and CDR regions, as compared to those sequences recognising different MHC-peptide 
specificities.
Molecular models of six TCR variable regions from DR restricted clones 
were generated in an attempt to understand the relationship between MHC restriction 
and TCR sequence and structure. This part of the analysis has highlighted the fact that 
even small differences in sequence can produce significant differences in surface 
topology.
The combined sequence and modelling analysis has led to the following 
conclusions. Closely similar MHC molecules containing identical peptides do not 
necessarily elicit a highly restricted T cell receptor population. This surprising result 
leads to the notion that therapeutic strategies in certain autoimmune diseases such as 
rheumatoid arthritis might better be targetted to the MHC peptide cavities than to a
diverse TCR population.
When peptides are presented in the context of different MHCs, the expected 
selection of different TCR sequences and topologies is observed.
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The immune system in mammals has evolved primarily to recognise and 
destroy the large variety of potential pathogens which an individual may encounter. 
The ability to specifically recognise molecules on pathogens is a basic feature of the 
adaptive immune response and is mediated by T and B cells. B cells recognise 
antigens in their native conformation either free in solution, on membranes or on the 
surfaces of cells, using surface immunoglobulin (Ig) as a specific antigen receptor. 
Binding of the antigen is followed by its processing and presentation in the context 
of MHC molecules on the surface of the B cell and interaction with T cells. This 
induces expansion of the B cell clones specific for that antigen and differentiation 
into plasma cells capable of producing and secreting large amounts of soluble 
antibody of the same specificity. The secreted antibody triggers processes such as 
complement activation or macrophage stimulation ultimately leading to removal of 
the antigen. T cells recognise antigen only in association with these specific major 
histocompatibility molecules (MHC). This phenomenon is known as MHC 
restriction. The recognition of protein antigens by T cells involves a highly specific 
interaction between a T cell antigen receptor and a peptide epitope presented in the 
groove of a specific MHC molecule on the surface of B cells or antigen presenting 
cells (APCs). In addition, accessory molecules are required to trigger the biological
1
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response (CD4, CD8, LFA-1, LFA-3 ).
An understanding of the molecular recognition events that occur in antigen 
-antibody and TCR-peptide-MHC complexes is important for the study of the 
immune system and is essential for the development of therapies for diseases that 
involve the immune system.
1.2 Biochemical characteristics o f  the T cell receptor and its
accessory molecules
1.2.1 The TCR ap heterodimer
The TCR is a member of the immunoglobulin supergene family. It is a 
multichain molecular complex with variable and conserved components (Figure 
1.1). It consists of a hypervariable disulphide linked heterodimer (TCR-a,P or 
TCR-y,8 ) that is noncovalently linked to a five chain complex ( CD3-y,8,e ; ££ or 
£r| ), CD4 or CD8 coreceptors and CD45 (reviewed by Janeway, 1992). 
Assembly of all subunits is required for efficient surface expression. The variable 
chains of the receptor ( Ti-oc, p, y, 8 ) are entirely responsible for the recognition 
of peptide-MHC complexes on the surface of antigen presenting cells (Schwartz, 
1985). Each of these chains consist of variable (V) and constant (C) domains 
stabilised by intrachain disulphide bonds, a short hinge like segment, 
transmembrane (TM) and intracytoplasmic portions. The Ti portion of the molecule 
is polymorphic and carries the T cell epitope.













Figure 1.1 Schematic diagram of the T cell receptor-CD3 complex.
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homologous chains y, 5, 2e. Another chain, CD3 co or TRAP (T-cell receptor 
associated protein) associates with the CD3 complex during the assembly of the 
TCR in the ER. It contains large cytoplasmic domains ranging from 44-81 amino 
acids. Both Ti and CD3 subunits are non covalently associated with a £ dimer. The 
£ chain is a transmembrane protein with an extracellular domain, a single 
transmembrane domain and a cytoplasmic domain of 113 amino acids (Weissman et 
al., 1988; Baniyash et a l, 1989). While the £ chain exists primarily as a homodimer 
a small % of TCRs in certain T cell clones contain heterodimers of £ complexed to 
the rj chain ( an alternatively spliced product of the £ chain) [Baniyash et a l, 1988; 
Orloff et a l, 1989; Jin et a l, 1990] or the v chain of the multi-subunit high affinity 
IgE receptor (FceRl) [Orloff et a l, 1990]. The v subunit of FceRl shares sequence 
homology in both transmembrane and cytoplasmic regions with the TCR £ chain. 
These chains are non-glycosylated and exist as disulphide linked dimers. The £ chain 
plays an important role in mediating TCR signal transduction (Chan et a l, 1994) 
The two signal transducing modules, CD3 and £ chain subunits have common 
peptide sequences within their cytoplasmic domains termed immuno-receptor 
tyrosine-based activation motifs (ITAMs) that are responsible for transducing 
signalling events.
The TCR has no intrinsic protein tyrosine kinase (PTK) activity. However 
three cytoplasmic PTKs, p59fyn, p56lck and ZAP-70 have been implicated in proximal 
TCR signalling. These cytoplasmic PTKs fall into two distinct categories which 
differ structurally: p59fyn and p56lck are members of the lymphocyte specific src- 
family (Samelson et a l, 1990, 1992; Abraham et a l, 1991) while ZAP-70 is a
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member of the syfc-family (Chan et al., 1992). The co-receptor molecules CD4 and 
CD8 are transmembrane glycoproteins and each is associated with a molecule of the 
T cell specific tyrosine kinase p56lck. This may account for their ability to influence 
the TCR complex-mediated signaling.
Another critical component of the signal transduction machinery of 
lymphocytes is CD45, which has intrinsic tyrosine phosphatase activity. It also plays 
an important role in antigen-stimulated proliferation of T cells and in thymic 
development.
1.2.2 The TCR y8 heterodimer
The y8 receptors are present on a small percentage of peripheral T 
cells ( 0.5 -10% ) in humans (Brenner et al., 1986; Bank et al., 1986; Lanier et al., 
1987) and on a majority of Thy-1+dendritic epidermal cells (Stingl et al., 1987a 
and b; Koning et al., 1987). This heterodimer appears earlier (around day 13) than 
the oc:p dimer (day 17 or 18) during ontogeny of TCR positive cells. It is found 
either as a disulphide linked or a non disulphide linked heterodimer (Lanier et al., 
1987; Krangel et al., 1987 and Hochstenbach et al., 1988). The nature of the 
ligands and precise function of this receptor remain elusive. The molecular nature of 
yS T cell recognition is fundamentally different from that of ap T cells (reviewed 
by Raulet, 1994). Most y5 T cells develop normally in mice lacking MHC Class I 
and Class II molecules ( Bigby et al., 1993; Correa et al., 1992; Grusby et al., 1993) 
which questions the role of these MHC molecules in the normal function of 
gamma-delta T cells. Analyses of gamma-delta T cell hybridomas specific for
5
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classical MHC Class n  (IE) and for TL Class I molecules indicate that the topology 
of the interaction of the y8 T cell receptor with the MHC is distinct from that of 
ap  T cells and that MHC bound peptides do not influence TCR binding (Schild et 
a l, 1994). This may suggest that some TCRs bind to MHC molecules from the side 
rather than from the top, away from the peptide binding groove. Comparative 
measurements of the lengths of the third complementarity determining regions 
(CDR3) of a , p, y, 8 and TCR chains and Ig heavy and light chains suggest the 
possibility that y8 TCRs may be more Ig like in their antigen recognition 
properties (Rock et al., 1994). They recognize native antigens without a 
requirement for degradation and presentation by antigen presenting cells (Schild et 
al., 1994).
The great diversity of y8 TCRs is created mainly by junctional 
diversification and they appear to play a role in protection against microbial 
infections. Direct evidence that y8 T cells provide immunity to infectious diseases 
was demonstrated in mice deficient for ap T cells (Hiromatsu et al., 1992; 
Mombaerts et al., 1993; Tsuji et a l, 1994; Kaufmann et a l, 1994). Mice deficient 
for both ap and y8 T cells were found to be extremely sensitive to disease caused by 
the intracellular bacterium Listeria monocytogenes, whereas mice deficient for 
either ap or y8 T cells were found to be similarly resistant to primary infections 
(Ladel et a l, 1994). In another study T cell deficient mice were shown to be unable 
to resist liver infection with Plasmodium yoelli (Tsuji et al., 1994). Stimulated y8 
cells have been shown to secrete lymphokines and to lyse target cells.
6
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1.3 TCR zene organisation
The TCR genes are rearranged and expressed in the thymus during the 
earliest stages of T-cell differentiation. (3, y  and 8 chain genes are rearranged and 
transcribed first followed by the a  chain genes. They are split into arrays of 
interchangeable coding segments scattered over large tracts of chromosomal DNA. 
Specific V, D (in the case of (3 and 8) and J segments recombine in a developing T 
cell to produce a contiguous V(D)J exon. This exon is spliced together with the C 
region at the level of RNA.
1.3.1 The TCRa gene organisation
The a  chain gene is located on chromosome 14 at 14qll and is unique in 
that the 8 TCR gene complex lies within Ja  and V a ( Caccia et al., 1985; Collins et 
a l, 1985). About 70 V a and over 70 Ja  gene segments are spread over 100 kb of 
DNA. (Figure 1.2). The Ja  segments occupy approximately 85 kb and lie about 4 
kb upstream of the single C a segment (Yoshikai et a l, 1985). Based on nucleotide 
homology of greater than 75%, the human V a gene segments may be grouped into 
32 families with at least 15 subfamilies containing a single member. Largest 
subfamilies V al and Va2 contain 9 and 7 members respectively. The C a gene is 
split into four exons. The external part of the C a region is encoded by two exons. 
The transmembrane segment and short cytoplasmic tail are encoded by a third exon 
with the 3' untranslated region of the mRNA encoded by the fourth C a exon. A 
recent study has shown that up to one-third of mature T-cells express two V a
7
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Figure 1.2 A schematic representation of the TCR oc/8 gene complex on 
chromosome 14 (taken from Moss et al., 1992).
8
Chapter 1 Introduction
chains as part of two functional and independent T-cell receptors. Cells belonging to 
this dual TCR subset may be specific for a broader range of antigens than cells with 
a single receptor (Padovan, 1995).
1.3.2 The TCR p gene organisation
The TCR P chain gene complex spans almost 685 kb on chromosome 7 at 
7q35 (Rowen et a l, 1996). It has 57 different functional Vp genes, 2 Dp genes, 13 
JP and 2 CP genes (Figure 1.3). The two Cp gene segments are separated by about 
8 kb. They are highly homologous differing in only 6 amino acids, which are not 
likely to mediate any functional differences between c p i  and Cp2 (Toyonaga et a l,
1985). Both genes have the same transcriptional orientation and consist of 4 exons 
with introns located at identical positions in each gene. Most of the extracellular C 
domain is encoded by the first two exons. The third exon codes for major part of 
TM portion and the fourth exon encodes a small cytoplasmic tail of 5-6 amino acids 
and the 3' untranslated region. Upstream of each c p  segment there is a cluster of 
seven J segments (six functional and one pseudogene) and one D segment. The Dpi 
and Dp2 segments are located about 600 base pairs 5' to the corresponding jp  
cluster. The jp  gene segments encode 15-17 amino acids of the VP region. The jp i 
cluster contains 6 functional segments and the Jp2 cluster contains 7 functional 







DB1 JB1 CB1 DB2 JB2 C82
The TCR p chain complex (taken from Moss et al., 1992).
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1.3.3 TCRy gene organisation
The Vy gene is localised in the short arm of chromosome 7 (Murre et a l ,
1986). Vy gene organisation is complex. There are 14 Vy segments, 8 of which are 
functional, located upstream of 2 sets of Jy segments (Figure 1.4). The TCRy locus 
contains four C segments one of which (Cy3) is a pseudogene. The Cyl gene is 
composed of 3 exons. The first exon encodes the extracellular domain, the second 
encodes most of the connecting peptide and the third exon encodes the remainder of 
the connecting peptide, transmembrane region, 12 amino acids, cytoplasmic tail and 
3' untranslated region. A cysteine residue is encoded by the second exon of Cyl 
which is involved in interchain disulphide bridging. Cy2 has a similar organisation 
except that Cy2 alleles contain either duplicated or triplicated second exon 
segments. Allele 2bc is present in 68% of the population while the allele 2abc is the 
minority form (Li et a l, 1988).These 3 Cy2 exons do not encode a cysteine residue 
due to which some y8 receptors do not have an interchain disulphide bond. There 
are no germline Dy segments. The human Jy gene segments are more extensive with 
three identified upstream of Cyl and 2 upstream of Cy2.
1.3.4 TCR5 gene organisation
The TCR 8 locus is unique in that many of the TCRS coding segments are 
located entirely within the V and J segments of the a  gene (Hata et a l, 1987; Chien 
et a l, 1987; Loh et a l, 1987). This unusual location results in the deletion of C8 
prior to rearrangement of V a to Ja  using specific 5' and 3' 8-deleting elements
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Figure 1.4 Genomic organisation of the human TCR y locus (taken from Male 
et a i,  1996). The V genes, some of which are pseudogenes 




termed 8Rec and vFJa (Hockett et al., 1988). At least 10 distinct human Va 
segments rearrange at the J8 locus which leads to scrambling of the two V gene 
repertoires. Genevee et al (1994) have shown that in addition to a wide junctional 
region diversity characteristic of the 8 chain there was potential for extended 
combinatorial diversity due to recruitment of at least l/3rd of the Va gene segment 
subfamily repertoire in the 8 locus recombination process (n=13) to 3 D8 and at 
least three or four J8 gene segments.
1.4 The TCR repertoire
The available TCR repertoire is determined by a number of factors 
including inherited germline gene segment repertoire, preferential rearrangement of 
certain TCR V-gene subfamilies, positive and negative selection in the thymus as 
well as peripheral tolerance induction or idiotype interactions (as a result of which 
all the expressed receptors will not be available for antigenic recognition). T cell 
repertoire is constantly changing as new T cells emigrate from the thymus.
In man, differences in genomic organisation of the TCR region may have 
important functional implications. In certain mice strains, germline V region 
deletions and allelic variation of some V regions are seen. Another genetic factor 
determining peripheral repertoire is the T cell selection during maturation. In mice, 
deletion specific for V(3 elements also occur and is determined by endogenous 
superantigens such as Mis.
Another major influence on human and murine circulating T cell repertoire 
is the effect of environmental antigens including SAgs acting as mitogens for
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subpopulations of T cells. A novel mechanism which influences T cell repertoire in a 
Vp dependent manner, independent of SAg or TCR structure has been described 
(Kay et al., 1994). A bi-allelic locus TCR BV13S2 gene was identified where allelic 
differences predominate in the non-coding region including transitions, transversions 
and frameshift deletions. Expressed protein is non-polymorphic at this locus. TCR 
BV 13S2 genotype influenced the circulating levels of Vp 13.2 CD4 T cells but did 
not affect TCR expression and function. Altered TCR repertoire is generated by 
germline non-coding polymorphism and this mechanism also provides an alternative 
explanation to SAg for Vp bias observed in certain autoimmune diseases (Paliard et 
al., 1991 and Sumida et a l , 1992).
1.4.1 Mechanisms creating diversity in the TCR repertoire
The mechanisms by which diversity is created in the TCR repertoire are 
similar to those used by B cells, with one exception. The large number of gene 
segments allows combinatorial diversity to generate many transcriptional 
permutations, thus increasing receptor diversity. Diversity is further increased by N 
region addition of non-germline encoded nucleotides at the V(D)J and Ja-C a 
junctions. The template independent DNA polymerase TdT has long been implicated 
as the enzyme responsible for the addition of N nucleotides. It is expressed almost 
exclusively in immature thymocytes and pro-B cells. It is capable of adding N 
nucleotides to artificial recombination substrates in vitro (Landau et al., 1987; 
Kallenbach et al., 1992).
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Another source of variation in some TCRs is palindromic P-nucleotide 
addition (Lafaille et al., 1989). Although an exonuclease is generally invoked for the 
loss of nucleotides, both variable nucleotide loss and gain of P nucleotides may be 
caused by asymmetric scission of closed hairpin termini prior to joining (Lieber et 
al., 1992). TCR genes, however, do not undergo somatic hypermutation, unlike 
antibodies, thus avoiding the potential for generating auto-reactive specificities 
outside the selective environment of the thymus.
The '12-23' rule governs TCR gene rearrangements. Early et al (1980) 
proposed that a gene segment with a 12 base pair spacer can only recombine with a 
gene segment containing a 23 base pair spacer. All TCR V genes have 2-tum 
recognition signals at their 3' flanking regions whereas Ja, jp  and Jy gene segments 
are associated with 1-tum 5' recognition sequence. The Dpi and Dp2 segments 
utilise a 1-tum 5' recognition and 2-tum 3' recognition sequence. Multiple 
rearrangement combinations are possible at the TCRp locus. V-D-J and V-J 
rearrangements are allowed by the '12-23' rule.
In human peripheral blood there is a marked non-random usage of 
individual V region families; several families VP4, VP5, VP6, V pi2 and Vpi3 make 
up the majority of the repertoire. Different individuals of random HLA type have a 
broadly similar profile of Vp repertoire although PCR analysis has shown that 
identical twins are more similar to each other than to the outbred population 
implying a genetic component in the repertoire (Moss et al., 1992).
The jp  repertoire shows significant variation in the usage of jp  segments in 
TCR transcripts. The Cp2 complex is utilised in about 65% of all transcripts. Within
15
Chapter I Introduction
each Cp complex there is variable usage of different J segments that does not 
correlate with relative positions in the germline complex. Analysis of sterile jp cp  
transcripts shows a similar Jp profile implying that no obvious selective pressure 
acts to dictate the Jp profile.
Very little information is available on the murine or human Va repertoires 
because of the large number of Va and Ja segments and the few monoclonal 
antibodies available to characterise them. The usage of Va segments by 
lymphocytes in human peripheral blood was studied by Moss et a l, 1992. A similar 
profile is seen in different individuals although differences of the order of 3-fold are 
seen for some Va segments such as Va4 and V ail. The repertoire is 
indistinguishable between identical twins, again suggesting a predominant genetic 
influence on the Va genes.
TCR gene rearrangement generates considerable junctional diversity due to 
'imprecision of the joining process'. This mechanism for the generation of diversity is 
important for TCR y  genes which have a relatively restricted germline gene 
repertoire.
1.4.2 Analysis of the TCR repertoire
T cell repertoire analysis helps to understand the cellular and molecular 
laws that govern the immune response in both physiological and pathological 
conditions.
Methods used to analyse TCR repertoire essentially fall into two groups, 
use of monoclonal antibodies to Va or Vp segments and recombinant techniques
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which attempt to quantitate levels of TCR mRNA.
Monoclonal antibodies have been widely applied as they have the 
advantage of speed, ease of use, reproducibility and unlimited source. It is also the 
only technique that measures cell membrane expression. However antibodies cannot 
generate information on J and junctional sequences and currently cover only a 
partial portion of the V region repertoire.
Recombinant techniques can be broadly divided into Rnase protection or 
PCR- based techniques. The former has the advantage of not needing nucleic acid 
amplification (Baccala et al., 1991).
PCR based methods that have been commonly used for the amplification of 
cDNA reverse transcribed from TCR RNA include 'quantitative' PCR (Choi et a l , 
1989; Sottini et a l, 1991), inverse PCR (Uematsu et a l, 1991), anchored PCR (Loh 
et a l,  1989 ; Rosenberg et a l, 1991 ), the use of consensus primers ( Broeren et a l, 
1991) and sequence analysis within the VDJ region of the PCR products (Uematsu 
etal., 1991).
V region family specific PCR is the most rapid method but the exponential 
nature of this reaction allows for substantial variation in efficiency to occur 
depending on the set of primers used and may account for some of the discrepant 
results. As each V region is amplified in separate reactions it is difficult to make 
quantitative comparisons of the % usage of different V regions so that it will be 
necessary to normalise TCR mRNA in samples being compared. Often in vitro 
expansion of T cell populations is necessary prior to the use of this technique which
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/  introduces an additional source of bias. Another limitation of this technique is that 
novel V regions locking the primer specificity cannot be detected.
A rapid method for cloning TCR V regions was described by Uematsu et 
a l,  1991. In this method the cDNA is circularised and two adjacent primers in an 
inward-outward fashion are used for PCR. It requires second strand synthesis, a 
blunt ligation and is further complicated by intermolecular ligation. Degenerate 
oligos have been used for the amplification of antigen receptors (Larrick et al., 
1989), DNA binding proteins (Lai and Lemke, 1991), olfactory receptors (Buck and 
Axel, 1991). Danska et al., 1990 designed degenerate primers to take advantage of 
a highly conserved region of the TCR a  and (3 chain V regions centered around the 
WY residues at amino acids 34 and 35 (Kabat numbering, 1992) and used them for 
the amplification of mouse V a chains from murine T cell clones. The TGGTA core 
is highly conserved in a number of human V a and Vp genes. Moonka and Loh 
(1993) designed a shorter consensus primer for the amplification of TCR V a and 
VP genes. The degeneracy is greater (23328 vs 216) and equimolar concentration 
ratios were used for each mixed base rather than biasing the mixture according to 
the frequency of occurence. The consensus primer has low affinity for variable 
regions which lack the TGGTA core namely Val3.1, Val9.1 and Vaw23.1. This 
method is highly specific, easy to use, sensitive, reliable and inexpensive in 
comparison to other routinely used methods.
A modification of PCR, called Anchor PCR, which creates artificial 3' ends 
on all cDNA prior to PCR to allow hybridisation of a single complementary 3' 
primer has been used. Anchor PCR allows amplification of all transcripts by the
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same set of primers. It is quantitative and not dependent on known V region 
sequence data. This technique ensures that no bias is introduced as in the case of the 
other techniques.
PCR based analysis has been less reproducible than use of antibodies. 
Cellular TCR mRNA levels may be distorted by the state of activation of T cell
subsets. Some groups expand T cells in vitro or activate whole populations with anti
CD3 antibodies to ensure that sufficient RNA is available for detection. This may 
introduce an additional bias. When allied with sequencing it gives data on the whole 
TCR transcript.
1.5 Antisen recognition b \ T cells
1.5.1 MHC restriction of T cells
The TCR recognises denatured or processed antigens only in association 
with MHC antigens, a phenomenon known as MHC restriction. On the basis of their 
MHC restriction, T cells can be separated into two main functional subsets, 
regulatory (TH/TS) and effector cytotoxic (Tc) T cells. Helper T cells (TH) recognise 
antigen in association with MHC Class II determinants whereas Tc cells use MHC 
Class I as restriction elements. Helper cells express CD4 (62 kd glycoprotein) while 
cytotoxic cells express CD8 (76 kd glycoprotein). These cell membrane 
glycoproteins are reciprocally expressed on two subsets of mature T cells in the 
blood and lymphoid tissues (CD4+CD8' or CD4 CD8+) while a large number of 
immature T cells in the thymus express both molecules CD4+CD8+ while most 
immature cells are CD4 CD8'.
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The coreceptor molecules CD4 and CD8 are members of the Ig gene 
superfamily (Doyle et al., 1987 and Norment et al., 1988). The extracellular 
domains of CD4 and CD8 interact specifically with conserved non-polymorphic 
sites on Class II (p2) and Class I MHC (a3) molecules respectively (Konig et al., 
1992; Salter et al., 1990; Cammarota et al., 1992). These interactions result in 
increasing intercellular adhesion and enhanced stimulation of T cells. They exhibit 
significantly different structural features.
The D1/D2 domains (Ryu et al., 1990 and Wang et al., 1990) and D3/D4 
domains (Brady et al., 1993) of the soluble CD4 molecule have been determined by 
X-ray crystallography. The N-terminal Ig like domain of CD4 exists as a monomer 
while in CD8 it forms an Fv like dimer. Four Ig like domains D1-D4 are present in 
the extracellular regions of CD4 while the extracellular region of CD8 consists of a 
single Ig-like domain connected to a transmembrane segment by a 'stalk' region of 
approximately 48 amino acids. There are six residues in the CDR2 like loop in both 
CD4 and CD8 which are not present in Ig V domain. The functional significance of 
these structural features is unclear but Fleury et al (1991) have shown that the 
extended CDR2 like loop in CD4 is unlikely to be involved in interactions with 
Class II molecules as deletion of this loop fails to impair CD4 Class II MHC cell 
adhesion.
The ability to distinguish "self from "nonself1 has been mapped to the 
major histocompatibility complex (MHC). The human MHC is known as the human 
leucocyte antigen (HLA) system and is located on the short arm of chromosome 6 
at 6p21.3. Klein (1986) classified MHC molecules on the basis of structure and
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function. Three classes of molecules, denoted I, II and III were identified in the 
human MHC.
There are three commonly recognised Class I loci HLA-A, B and C 
encoding classical transplantation antigens and three other loci HLA-E, F and G 
known to encode functional molecules. Two pseudogenes HLA-H and HLA-J have 
also been recognised. The Class II loci are located in the HLA-D region which is 
organised into DP, DQ and DR families with the exception of one alpha (DZa) and 
one beta chain gene DOp. There is only one HLA-DR a  chain gene (HLA-DRA), 5 
HLA-DR p chain genes (HLA-DRB 1-5) and 4 pseudogenes (HLA-DRB 6-9). 
Class III genes encode several components of the classical complement pathway, 
factor B of the alternate pathway and an enzyme involved in steroid biosynthesis, 
21-hydroxylase.
1.5.2 Peptide-MHC interactions
One of the main features of MHC molecules is their extreme polymorphism 
and over one hundred structurally distinct Class I and II molecules have been 
identified. About six different Class I and II molecules are expressed on the cells of 
a fully heterozygous individual. The expression of multiple isoforms as well as the 
structural variety available within a species ensures that at least one peptide derived 
from any pathogen is encountered. As each isoform is capable of binding to a wide 
array of distinct peptide antigens, a tremendous diversity of peptide-MHC 
complexes can be formed, allowing the immune system to respond specifically to a 
variety of pathogens. In addition to broad peptide specificity and the ability to
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present each peptide as an antigenicaUy unique complex, the MHC molecules must 
be able to retain their ligands on the cell surface at an effective free peptide 
concentration of zero, long enough for T cell recognition to occur.
The three dimensional structural analysis of several MHC molecules reveals 
an elegant solution to the multiple constraints of flexible but stable binding, with the 
ligand exposed for recognition.
1.5.2.1 Class I MHC- peptide interactions
Class I molecules are expressed on almost all nucleated cells although the 
level of expression does vary between cell types.
The three dimensional structures of three human (HLA-A2, HLA-Aw68 
and HLA-B27)[Madden et a l, 1991; Madden et a l, 1992; Silver et a l, 1992; 
Madden et a l, 19931 and two murine (H-2Kb and H-2Db)[Zhang et a l, 1992; 
Fremont et a l,  1992; Young et a l, 1994] class I molecules, in complex with single 
peptides and with mixtures of endogenous peptides, have been determined by X-ray 
crystallography. The overall domain arrangement and backbone structure of these 
complexes are very similar.
They are comprised of a glycosylated polypeptide chain ( a  heavy chain, 
Mr = 44k) in close non-covalent association with the invariant p2 microglobulin ( P 
light chain, Mr =12k). The heavy chain consists of three extracellular domains a l ,  
a2, and a3, a transmembrane region and a cytoplasmic tail, a l  and a2 are 
structurally similar and together form an eight stranded antiparallel P-sheet spanned 
by two long antiparallel helical regions while a3 has an Ig fold. The Class I p chain,
2 2
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P2 microglobulin is a single domain which has an Ig fold similar to the a3 domain. 
The a3 and p2 microglobulin associate together in a manner similar to that found in 
antibody structures. The function of the p2 microglobulin is to stabilise the Class I 
molecules and it may also be involved in transporting heavy chains to the membrane.
In both Class I and Class II molecules, the antigen binding site is a groove 
approximately 20 A long, 12 A wide and 8 A deep consisting of an eight-stranded 
p-pleated sheet topped by two antiparallel helices (Figure 1.5). In the Class I 
molecule the peptide binding site is formed by the N-terminal strands of (Xi and (X2 
domains (Bjorkman et al., 1987). It holds peptides in roughly extended 
conformation of about 8-10 residues with two or three conserved positions termed 
anchor residues (Romero, 1991; Falk, 1991; Hunt, 1992a; Jardetsky, 1991; 
Rotzschke, 1990; Van Bleek, 1990) and has allele specific binding motifs. Longer 
peptides can also fit by bulging partly out of the groove or by zigzagging within the 
cleft. In some cases the ends of the peptide may extend out of the groove although 
this decreases the stability of interaction.
Class I MHC molecules are extremely polymorphic particularly in the a l  
and a2  domains and the most highly variable residues are found to point into this 
groove and up from the tops of both helices. These polymorphic residues are 
responsible for the specificity of recognition by T cells and for the variation in 
responsiveness to particular foreign antigens. Peptide sequence specificity is 




H LA -A w 68 (class I) H LA -D R  1 (class II)
Figure 1.5 Comparison of MHC Class I and Class II crystal structures. Ribbon
diagrams of Class I HLA-Aw68 and Class II HLA-DR 1 proteins.The a  
(green) and the p domains (yellow) are shown. Peptides (blue) bind in 
the groove formed by the p-sheet and the two a  helical regions. 
Although the domain organisation of Class I (a la 2 a3 , p2m) and Class 
II (a la 2 , pip2) differ, their three dimensional structures are very 




1.5.2.2 Class II MHC- peptide interactions
Class II molecules are expressed only on a subset of cells with specific 
immunological functions namely dendritic cells, macrophages, B cells and thymic 
epithelial cells. Expression of Class II molecules can be induced on other cell types 
by cytokines, interferon-y and TNF, which also increases the expression of Class I 
molecules.
Class II molecules are heterodimers comprising heavy (a) and light (p) 
glycoprotein chains. Each chain consists of two extracellular domains (a l and o2 or 
pi and p2 ), a transmembrane region and a cytoplasmic domain. The membrane 
proximal domains a2 and p2 are structurally similar to Ig constant regions. The 
membrane distal domains a l  and pi associate to form the peptide binding region. 
This region consists of eight strands of anti- parallel P-sheet with two anti-parallel 
a-helical regions overlaying them analogous to that seen between Class I a l  and a2 
domains. There is a deep cleft between the a-helices that accommodate the bound 
peptide (Figure 1.5).
Despite their overall similarity, differences are seen in the antigen binding 
site of the Class II MHC molecule, HLA-DR 1 and Class I MHC molecules. The 
grooves of Class I MHC molecules are blocked at both ends, while those of Class II 
molecules are open. This allows the Class II molecules to bind longer (13-25 
residue) peptides (Rudensky et al., 1991; Chicz et a l 1992; Hunt et al., 1992b\ 
Newcomb et al> 1993). In the Class I molecules, the groove tapers at both ends to a 
width of approximately 5 A and is then blocked completely by bulky amino acid side 
chains, including Tyr 84 and Tip 167 that are conserved in virtually all Class I MHC
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sequences. In the Class II molecule, HLA-DR 1, the blocking side chains are 
replaced by smaller ones and are repositioned by secondary structural changes 
concentrated at the ends of the cleft. The conserved residues that bind the peptide N 
and C terminus in the Class I structure are also not found in Class II sequences. In 
the structure of HLA-DR 1 complexed with a 13 residue influenza virus peptide, the 
peptide antigen binds as a straight extended chain with a pronounced twist (Stem et 
a l, 1994). Side chains of the peptide are accommodated by polymorphic pockets of 
the MHC groove. Unlike Class I, the N and C termini extend out of the groove and 
protrude into the solvent. However the area of peptide available for direct contact 
with TCR (400-500 A2) is the same for the majority of Class I -peptide complexes. 
However in the case of some Class I molecules this area is limited to 100-300 A2 
(Fremont et a l, 1992).
1.5.3 T cell recognition of processed antigens
Antibodies recognise conformational epitopes exposed in the three 
dimensional structure of the antigen while T cells recognise sequential epitopes that 
are revealed when the molecule is unfolded or degraded.
The phenomenon whereby native antigen is converted to an altered or 
processed form that can be recognised by T cells is known as antigen processing. 
Class I molecules present peptides derived from endogenously synthesised antigens 
to CD8+ T cells. These peptides are translocated in an ATP-dependent fashion into 
the lumen of the ER for binding to Class I molecules by means of the MHC encoded 
transporters associated with antigen processing TAPI and TAP2 (members of a
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superfamily of proteins containing an ATP-binding cassette) and form heterodimers 
in the ER. Two additional genes LMP2 and LMP7 which map close to TAPI and 
TAP2 encode products that are related to subunits of a large cytoplasmic complex 
called the proteasome known as prosome, macropain or multi-catalytic protease. 
The proteasome is involved in the degradation of proteins into small peptides which 
are then transported into the ER (Figure 1.6).
Class II molecules show a converse pattern, being inhibited from binding 
peptides within the ER and being specialised to present peptide antigens derived 
predominantly from extracellular sources and degraded within intracellular vesicles 
(endosomes or lysosomes).
They associate with fragments of proteins in the endocytic route and 
present them to CD4+ T cells. Class II a  and p chains associate with a third subunit, 
the invariant chain (Ii) [Kvist et a l, 1982; Machamer and Cresswell, 1982; 
Cresswell et a l, 1987] early during biosynthesis. This heterotrimeric complex is 
transported from the ER to the trans-Golgi reticulum where it is sorted to endocytic 
compartments (Cresswell et a l, 1985; Neefjes et a l,  1990; Lamb et a l, 1991). 
Association of Class II molecules with Ii inhibits the binding of peptides to the Class 
II molecule, thus preventing binding of peptides within the ER, while limited 
proteolysis of the invariant chain within the endosomal compartment releases the 
inhibition and allows peptide binding. Proteolysis of Ii frees the Class II molecule to 
be transported from the endosomal compartment to the cell surface .The Class II 
molecule is prevented from binding peptides transported into the ER and is targetted 
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Figure 1.7 Schematic view of the assembly, intracellular transport and peptide
loading of MHC Class II molecules (taken from Cresswell., 1994).
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1.5.3.1 TCR -  peptide interactions
The interaction of the TCR with its ligand, a peptide in combination with a 
molecule of the MHC is a central event in the initiation and propagation of most 
immune responses to protein antigens. Specific ocp heterodimers present on the 
surface of most T cells are responsible for the recognition of antigenic peptides 
bound to Class I and II molecules (Davis et al., 1988; Jorgensen et al., 1992). It is 
clear from the crystal structures of Class I and II molecules that the polymorphic 
residues of MHC molecules are focused on interactions with peptide and not 
directly involved in TCR interactions.
A model was proposed by Davis and Bjorkman (1988) wherein the V(D)J 
junctional region of the TCR (equivalent to the CDR3 region of Ig) is principally 
responsible for peptide contact whereas CDR1 and CDR2 loops contact the a- 
helices of the MHC. This hypothesis explains the diversity in the CDR3 regions of 
the TCR and is compatible with the three dimensional studies of the MHC 
molecules and TCR models (Chothia et a l, 1988; Claverie et a l, 1989). Consistent 
with the model several studies have shown that the bound peptide contacts the 
CDR3 regions of both a  and p chains and that these interactions are highly specific.
The recent structure of the p chain of the murine TCR (Bentley et a l, 
1995) specific for a hemagglutinin peptide of influenza virus presented by the Class 
II molecule I-Ed showed restricted conformation heterogeneity in CDR1 and CDR2, 
which is consistent with the model of peptide-MHC recognition. However CDR1 
and CDR2 were found to be closely associated with CDR3 which implies that the
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three CDRs may not function independently. Obviously crystallographic studies of 
more TCR/peptide/MHC complexes will shed light on these interactions.
A strategy for investigating peptide-TCR interactions was developed by 
Jorgensen et al (1992). Analogs of moth cytochrome c (MCC 88-103) peptides 
altered at residues likely to contact the TCR were used to select for compensating 
changes in TCR structure. Many hybridomas specific for these altered peptides were 
generated and the analysis of their TCR sequence has given additional information 
on the nature of specificity. An important constraint that is employed in the system 
is the use of mice transgenic for either the a  or p chains of a cytochrome c/ I-Ek 
reactive TCR (5C.C7). Either the a or the p chain TCR transgenic responds best to 
a substitution at a given position but not both. Peptide reactivities can be correlated 
with changes within the endogenous (non transgenic) TCR chain. T cells generated 
from normal mice which are specific for MCC peptide (88-103) bound to I-Ek use 
Vp3 and V a ll.l  almost exclusively (Hedrick et a l, 1988). Although a different Joe 
and jp  are used there is always a conserved acidic residue glutamate or aspartate in 
the CDR3 region of the a chain and a conserved asparagine in the CDR3 region of 
the P chain. Lysine which is at position 99 in the cytochrome c peptide most likely 
contacts the TCR. Peptides with a K/E change at this position elicit responses from 
T cells that utilise the transgenic B chain (VP3) together with V a ll.l or V all.2  
with the conserved D/E replaced by a K residue. A charge-charge interaction or 'salt 
bridge' between the E residue in the Va CDR3 and the K on the peptide can be 
reversed in the case of 99E variants. T cell hybridomas that recognise E residue at 
position 99 of the peptide can also recognise D at this position but none of the other
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18 possible amino acid substitutions. These results indicate that there is a direct 
CDR3-peptide interaction such that changes in a T cell determinant of the MCC 
peptide always alters the responding TCR Voc or Vp CDR3 sequence. Peptide-TCR 
and TCR- MHC contacts are highly dependent on each other.
7.5. 3.2 TCR-MHC interactions
Ehrich (1993) used structurally very similar and well characterised panels 
of T cells generated by Jorgensen et al (1992) to survey T cell responses to peptide 
analogs presented by mutant I-Ek molecules. Each I-Ek mutant consists of a single 
amino acid substitution at a residue predicted to point up from the a-helical region 
of either the Ea or the Ep chains. The system was designed to evaluate the effect on 
the overall MHC-TCR interaction by small defined changes in either the TCR- 
CDR3 region or in the peptide. Cross reactive T cell hybridomas show very 
different sensitivities to many of the I-E«k and I-Epk mutant depending on which of 
the two peptides is being recognised. The same TCR can contact the same MHC in 
different ways. Very distant TCR-MHC contacts can be affected by changes in 
CDR3-peptide contacts. TCR-MHC contacts are 'fluid' which means that they can 
be made in a variety of ways with the same TCR and MHC. The final configuration 
appears to be significantly influenced by the peptide. The TCR-peptide interactions 
dramatically change the overall TCR-MHC interactions. TCR mediated recognition 
of a peptide-MHC complex is 'peptide centred' and CDR3-peptide interactions 
determine the ultimate configuration.
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1.6 Structure/ function analysis o f T cell specificity
That a single TCR ocp heterodimer subserves the complete recognition of 
both nominal antigen and MHC molecules in MHC-restricted responses has been 
demonstrated conclusively for both Class I and Class II restricted recognition by 
gene transfection studies. In T cell clones with dual specificity for antigen/self MHC 
and allogeneic MHC, a single TCR ocp heterodimer has been shown to mediate 
both the MHC- restricted antigen recognition and the allorecognition (Malissen et 
al., 1988; Kaye et a l, 1988). A common approach to exploring the structural basis 
of T-cell recognition has been to correlate TCR usage with antigen and MHC 
specificity in well characterised immune responses. Many studies have demonstrated 
such correlations to varying degrees for both Voc and VP expression. Predominant 
expression of murine Voc 11 family genes has been observed in the I-E subregion- 
restricted response to the antigen pigeon cytochrome c (Fink et a l,  1986; Winoto et 
a l,  1986), of Voc3 gene segments in the response to the hapten p- 
azobenzenearsonate (Tan et a l, 1988), of Voc3 in the I-Ek restricted response to the 
X repressor fragment 12-26 (Lai et a l, 1988), of Voc4 in the TNP/ H-2Kb restricted 
cytotoxic T cell clones and Voc4 and Voc2.3 among murine T cell clones specific for 
the encephalitogenic fragments p i-9 and p i -11 of MBP in PL and B10.PL mice, 
respectively. Similarly Vp elements have also been found to be preferentially used. 
Predominant expression of Vp8 in the I-Ed restricted response to sperm whale 
myoglobin (Morel et a l, 1987), VP3 in the H-2Kb /TNP response, VP 8.2 on 
encephalitogenic T cell clones in the response to mbp fragments and VP3 in the
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cytochrome c response (Fink et al., 1986; Winoto et al., 1986). Analysis of V(3 
usage among many T cell clones that are I-E-restricted and pigeon cytochrome c 
has revealed a striking correlation between Vp expression and the pattern of clonal 
MHC restriction. These data suggested that there may be duality of function of 
TCR a  and (3 proteins such that the Vp has a prominent role in MHC recognition 
while Va mediates specificity for the nominal antigen. However subsequent analyses 
have shown that TCR mediated recognition cannot be explained simply by
. /
(. i, \ { t  f  i L c ____
correlating Vp expression with MHC specificity and Va expression with antigen ^ ^
O
specificity. Examination of TCR usage in antigen specific responses can be extended 
to responses to alloantigens.
1.6.1 AUorecognition
1.6.1.1 Theories to explain allorecognition
In contrast to the low frequency of T cells that recognise conventional 
antigens, 1-10% T cells respond to an alloantigen. One of the earliest attempts to 
explain the basis for the high frequency of alloreactive cells was described by Jeme 
(1971). The repertoire of lymphocyte receptors was evolutionarily preselected to 
include germline genes that had specificity for the MHC molecules of the species.
According to the Jeme theory, for each MHC molecule there evolved a 
complementary receptor molecule and the receptor repertoire used in recognition of 
foreign antigen was derived by somatic mutation of the receptor specific for self 
MHC molecules. This avoids autoreactivity and provides the diverse repertoire 
required for immune surveillance. Another hypothesis was put forward by
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Matzinger and Bevan (1977) to explain the high frequency of alloreactive cells. A 
single type of allogeneic MHC molecule can give rise to multiple distinct 
specificities by forming binary complexes with an array of peptides derived by 
internalisation and processing of endogenous molecules. Each of these peptide- 
MHC complexes could then stimulate a separate population of T cells and hence 
account for the high precursor frequency of alloreactive cells. No restriction was 
placed on the extent of diversity permitted to the TCR repertoire (Matzinger, 1977). 
Initial attempts to assess diversity were carried out in a series of mutant mice that 
differed from wild type (C57BL/6) in the Kb molecule. The TCR repertoire to a 
small alloantigenic difference was complex and estimated to comprise at least 37 
different TCRs . One or several VPs recur with high frequency within a particular 
allo-response. Allospecific CTL were part of the repertoire devoted to recognition 
of antigen in the context of self MHC. Clones restricted by self MHC were found to 
display alloreactivity in some cases (Matis et al., 1987; Sredni et a l , 1980; Braciale 
et a l, 1981). Molecular analysis demonstrated that the same portion of the TCR 
involved in antigen recognition was involved in recognition of alloantigen.
Another hypothesis, the high determinant hypothesis, was put forward by 
Bevan (1984). The other theories were based on the assumption that the epitopes 
recognised by alloreactive cells are equivalent to those seen in conventional T cell 
responses and the difference in the magnitude of these responses was due to the 
large number of epitopes present on an alloantigen. Conventional foreign antigens 
must compete with the multitude of cellular epitopes to interact with MHC for 
presentation to T cells and therefore would be found associated with relatively few
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Class I molecules While in the case of an alloantigen, the foreign sequence on an ^  
alio MHC is present on all Class I molecules and is therefore abundant. The high 
concentration of antigen could permit stimulation of many T cells of relatively low 
affinity. Thus the difference between alio T cells and those responsive to 
conventional antigen was related to the range of affinity of the receptors that were 
stimulated. Receptors reactive to conventional antigens should have a high affinity 
which is seen in only a few T cells while alloreactive T cells would require a lower 
affinity which is seen in a higher proportion of the receptor repertoire.
1.6.1.2 Contribution o f MHC bound peptides to alio recognition
Peptide involvement in allorecognition was first observed in Class I 
molecules (Heath it al, 1989). A panel of Kb specific CTL clones was tested for the 
ability to lyse a human cell line transfected with Kb (Jurkat Kb). This analysis sought 
evidence for peptide dependence by searching for a CTL clone that recognised a 
murine peptide not expressed in human cells. Although the majority of Kb specific 
clones were able to recognise Kb expressed by the human target several could not.
To check if this lack of recognition was due to lack of presentation of a specific 
cellular peptide, cytoplasmic proteins were prepared from a murine cell line cleaved 
with cyanogen bromide to produce peptides. This demonstrated that at least some T 
cells were peptide dependent in their recognition of alloantigen. Results of 
Townsend et al (1989) provide strong support for this suggestion. Working with a 
mutant cell line RMA-S which is almost devoid of cell surface MHC Class I 
expression they concluded that ocp assembly, transport to the cell surface and the
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native conformation of Class I molecules are dependent on bound peptide. Pulsing 
the mutant RMA-S cells with high concentration of an influenza NP peptide known 
to bind H-2Db restored cell surface expression of Db to 20% of normal levels. NP 
occupied Class I molecules appear to be conformationally normal. Peptide 
involvement was also seen in the case of Class II allorecognition. Incubation of 
Class II presenting cells with exogenous antigen was observed to reduce the ability 
of alloreactive T cells to recognise Class II MHC molecules. High concentration of 
exogenous antigen inhibited presentation of a different peptide required for 
allorecognition.
Peptide mediated inhibition or enhancement of allorecognition has also 
been observed. Parham et al., (1987) described inhibition of human anti HLA -A2 
cytotoxic T cells by addition of peptides comprising sequences from N-terminal 
domains of HLA-A2. It is not clear whether this effect results from occupancy of a 
site on the TCR or from displacement of a peptide from the antigen binding groove 
of HLA-A2. The inhibitory or enhancing effects of an influenza haemagglutinin 
peptide which is known to bind to DR1 on the responses of anti-DR 1 human T cell 
clones has been studied by Eckels et al (1988). Either the displacement or 
mimicking of co-recognised endogenous peptides could lead to positive or negative 
effects respectively.
Site directed mutagenesis has been used to study the role of specific 
residues in allorecognition. HLA-DRB1*0103 differs from HLA-DRB1*0101 by 6 
base pairs clustered in the third variable region of the second exon leading to three 
amino acid changes at positions 67, 70 and 71 of the beta chain of the HLA-DR
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molecule. SDM was used to examine the role of each residue. Residue 71 in the 
alpha helix of the DR beta domain was found to influence peptide binding and plays 
a central role in allorecognition. It was also observed in an influenza HA specific 
HLA-DRB 1*0103 restricted T cell line (Coppin et a l, 1993).
Generation of an allodeterminant by the addition of a peptide has also been 
seen. Cells expressing HLA-Aw69 were converted into targets for an HLA-A2 
specific alloreactive T cell by the addition of a peptide containing sequence from the 
region of the a- helix of the ai domain of A2 that differs from Aw69 (Clayberger et 
a l, 1987). All these observations suggest that a single foreign MHC molecule can 
give rise to multiple binary complexes and thus stimulate multiple alloreactive T 
cells, each with a unique specificity.
1.6.1,3 The diversity o f TCR genes used in allorecognition
TCR Va and Vp gene usage has been studied by a number of groups. Non- 
random patterns of TCR selection have been seen in a number of cases. The 
molecular diversity of the allogeneic TCR repertoire specific for the HLA-DR4 
variant DRB 1*0404 was studied by Goronzy et al (1993). A core group of Vp 
elements ( Vp 6, 5, 2, 13.2, 18 and 7) was found to be preferentially used. Another 
study of Vp selectivity in HLA-Dwl4 alloreactive T cell clones showed the usage of 
VP 8.2. TCR genes from clones derived in vitro from mixed lymphocyte cultures 
between Dw4+ and responder and Dwl4+ stimulator cells also showed non-random 
gene usage (Yamanaka et a l, 1993). In the case of DR1 microvariation non-random 
TCR usage has been seen. Six different Va and seven v p  segments are utilised by 9
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different DR (a,pi*0101) specific TLC which suggests that the TLC do not appear 
to require specific V segments to recognise a microvariant of the DR1 alloantigen. 
However since the same V a and Vp segments are found in more than one TLC and 
these TLC are derived from different individuals, the usage of V segments in these 
TCR appears to be non-random. (Hurley et al., 1993). However since a majority of 
the amino acid sequence and the 3-D structure is shared by the two microvariants 
DR (a,pi*0101) and DR (a,pi*0102) the use of the same V segments is not 
unexpected. Five of these TCR sequences have been modelled in this thesis and they 
are discussed in more detail in Chapter 3. A CD4+ T cell clone that recognises HA 
306-320 in the context of autologous DR 1101 molecules as well as of allogeneic 
DR 1301, DR0402, DR 1501 and DR 1601 molecules was studied by (Zeliszewski et 
a l , 1993). Degenerate recognition was mediated by a single TCR as judged by both 
V- gene sequencing and competition assays. Substitutions of DR residues within the 
third HYR region resulted in a loss of T cell reactivity which is restored by 
additional substitutions in the first and second HYRs. Heterogeneity was also 
observed in the case of murine I-Abm 12 reactive T cells (Bill et a l, 1989). In this 
case the repertoire to the alloantigen was estimated to be at least 37 different TCRs.
7.7 This Thesis
Initial aims
One of the original aims of this study was to determine and then analyse the 
sequences and 3-D models of TCR V a and v p  genes used in peptide specific DR4 
Dw4 restricted clones. A strategy to sequence TCR V a and Vp genes from DR4
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Dw4 restricted clones was devised. This strategy involved the amplification of the 
V a and VP genes by a modification of PCR known as Anchor-PCR. Conventional 
PCR could not be used for the amplification of the TCR V a and Vp genes as the 5' 
portion of the sequence is always unknown. Anchor PCR requires sequence 
specificity only on the 3' end of the target fragment (Figure A2.3).
Typically, total RNA is isolated from a T cell clone and the first strand of 
cDNA synthesized using oligo (dT)i2-i8 primer. A poly dG tail is then introduced at 
the 5' end of the strand with an enzyme terminal deoxynucleotidyl transferase. The 
product is then amplified with a specific CP 3' primer and another oligonucleotide 
consisting of a poly dC tail attached to a sequence with a Not I restriction site 
termed the 'anchor'. The amplified products are then cloned into M13mpl8 and 
sequenced by Sanger's dideoxy chain termination method.
Another mechanism which bypasses the cloning steps was also devised. 
This method called PCR Sequencing allows the direct sequencing of amplified 
products. The Anchor-PCR amplified products were screened by Southern blotting 
to ensure their validity. These Southern blotted products were then subjected to 
PCR Sequencing. This method is a variation of Sanger's dideoxy method. It involves 
an annealing step where the template-primer is snap-frozen immediately after boiling 
the mixture. Subsequent labelling and termination reactions are similar to Sanger's 
method.
This method was optimised in the T cell line KM vs Priess. However it 
could not be extended to peptide specific DR4 Dw4 restricted clones, supplied from 
another laboratory, as they were found to be contaminated with mycoplasma late in
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the development of the sequencing work. Contamination of cell cultures by 
mycoplasma caused degenerative effects on TCR mRNA as well as ubiquitously 
expressed mRNAs such as glyceraldehyde 3-phosphate dehydrogenase (G3PDH). 
Control reactions using cross species G3PDH specific primers were used to detect 
this contamination.
Revised aims
Subsequently the aims of this project were revised to analyse the TCR V a 
and v p  gene sequences from DR restricted clones found in the sequence databases 
and the literature to generate 3-D models of the TCRs using a modified version of 
the antibody modelling software, AbM, namely TCRM (Searle and Rees, 
unpublished). The purpose of this analysis would be to attempt to establish a 
relationship between MHC restriction and TCR sequence and structure.
Chapter 2 describes the sequence analysis of TCR V a and Vp genes from 
Class I and II restricted clones found in the database. These sequences were 
analysed using a number of Genetic Computer Group (GCG) programs in an effort 
to understand TCR usage in the various clones. The CDRs of TCR V a and VP 
genes from Class I and II restricted clones were analysed and conserved motifs or 
residues were identified.
Chapter 3 presents the molecular models of TCR VaVp heterodimers 
generated from DR restricted clones by TCRM.
Chapter 4 discusses all the findings in the study of the TCR VaVP 
heterodimer in the context of present hypotheses.
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At the beginning of the PhD. studies several projects were looked at to 
gain experience in methods of molecular biology. The two major pieces of work 
begun are described in Appendices 1 and 2.
Appendix 1 describes the expression and purification of a catalytic antibody 
double aspartate mutant Tyr32AspLeu92Asp. This antibody was expressed in E.coli 
as Fv fragments and purified by affinity chromatography by a modification of the 
method used by Hilyard, 1991.
Appendix 2 describes the materials and methods used in the cloning and 
sequencing of TCR genes from a T cell line KM vs Priess.
Time table
October 1990 - June 1991 - Gloop2 Fv (catalytic mutant) expression
and purification.
June 1991 - September 1994 KM vs Priess TCR cloning.
September 1994 - April 1995 Short break to India while awaiting
preparation of T cell clones.




Sequence Analysis Of TCR Variable 
Domains
The comparative analysis of protein sequences is the first step in the study 
of protein structure and function. When this is coupled to three-dimensional 
information for a given family of homologous proteins it becomes a powerful tool 
for determining residues which are important for a particular structural or functional 
role.
Although the complete three-dimensional structure of the TCR VaVp 
heterodimer has not yet been determined, the separate Va and Vp structures are 
known along with a large number of TCR Va and v p  gene sequences.
2.1 Acquisition o f TCR Va and VB sequences
A  specific TCR sequence database was constructed using data from 
available DNA and protein databanks ( EMBL, NEW AT, NBRF-PIR and KABAT) 
of aligned human Va and Vp gene sequences. The sequence alignments were 
performed on the alpha and beta chains separately depending on the MHC 
restriction and peptide specificity. The sequences were obtained via anonymous ftp 
and converted to Genetics Computer Group (GCG) format for further analysis.
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2.2 Variability analysis
Variability was calculated for each chain type for sequences which 
contained V, D and J segments using the method of Wu and Kabat (1970). The 
overall variability at each alignment position is calculated as the number of residue 
types occurring at the position divided by the frequency of the most commonly 
occurring residue at that position.
Variability plots show the high overall variability present in the TCR Va 
and VP sequences (Figure 2.1). Recognisable peaks are present in the areas 
equivalent to second and third CDRs of antibodies and to a lesser extent in the first 
CDR region. A further region of high variability within a loop (the D-E loop) 
between the CDR2 and CDR3 equivalent regions of both chains is present. This 
suggests that this D-E loop region has less conserved structure than in antibodies 
and it may therefore form part of the TCR combining site.
2.3 Sequence alignment
The first step in any modelling is to convert the DNA sequence available 
into the primary structure of the gene product and search for sequence homologies 
with known sequences of other proteins. Information on DNA sequences is 
available in databanks such as those of the European Molecular Biology Laboratory 
(EMBL), Heidelberg, National Biomedical Research Foundation, Maryland or the 
NEWAT databank in the USA.
Sequence databases facilitate comparisons of newly determined sequences
as well as act as a source of data for the generation and testing hypotheses about
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Figure 2.1 Variability plots of the TCR V a and v p  sequences. Apart from
the three CDRs, a fourth variable region is seen in between CDR2 
and CDR3 in both cases (the D-E loop).
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molecular sequence organisation, function and evolution.
The major protein sequence databases are NBRF-PIR (National Biological 
Research Foundation- Protein Identification Resource) database and the PSD-Kyoto 
(Protein Sequence Database-Kyoto) database.
The PIR originated from the work of Margaret Dayhoff and was 
established at the National Biological Research Foundation in 1984. The NEW AT 
database was compiled before the PIR was available in order to examine protein 
relationships. It is a useful subset for rapid retrieval. There are also a number of 
specialized collections such as the KABAT database of sequences of proteins of 
immunological interest published by the US National Institute of Health and the 
International Haemoglobin Information Centre. PGtrans is a computer-generated 
collection of protein sequences obtained by the translation of GenBank. PseqIP is a 
non-redundant collection derived from PIR, PSD, NEW AT and PGtrans.
The three major DNA sequence databases include the DNA Data Bank of 
Japan (DDBJ), the European Molecular Biology Laboratory Nucleotide Sequence 
Data Library (EMBL) and the GenBank Genetic Sequence Data Bank (GenBank).
The National Biological Research Foundation provides some software to 
search their databanks, to compare user-specific segments with segments of the 
same length in the database, to align two sequences, to detect similarities and to 
score and display the degree of similarity.
When homology is found between more than two proteins or nucleotide 
sequences, additional information can be obtained if a multiple alignment of all 
sequences is obtained. Accurate multiple sequence alignment highlights the residues
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of common functional and structural importance. The location of identities and 
conservative substitutions can be used to guide the design of site-directed 
mutagenesis experiments whilst the identification of subtle patterns of residue 
conservation can yield improvements in the accuracy of secondary and tertiary 
structure predictions. Identification of conserved residues can suggest a local region 
that contains a motif that specifies a particular structure or function.
Programs used in this study include the Wisconsin Sequence Analysis 
Package by Genetics Computer Group (GCG) Inc. It is an integrated package of 
over 130 programs that allows nucleic acid and protein sequences to be manipulated 
and analysed. This was originally built by John Devereux and Paul Haeberli. Each 
program is designed to perform one function and complex analyses are performed 
by using several programs in succession. Tasks can be performed by selecting 
specific tools. The programs are loosely divided into six groups namely sequence 
comparisons, restriction enzyme and chemical and proteolytic cleavage site mapping 
and searching, prediction of nucleic acid secondary structure and protein secondary 
structure, pattern recognition and sequence manipulation.
A number of multiple sequence alignment GCG programs including 
PILEUP, LINEUP and PRETTY were used in the study of TCR V a and Vp 
sequences with different MHC and peptide specificities. These programs are 
described below.
2.3.1 PILEUP
The PILEUP program from the GCG package employs a simplified version
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of the progressive pairwise alignment method of Feng and Doolittle (1987) and 
performs a multiple sequence alignment from a group of related sequences creating 
a multiple sequence format (MSF) file. This method is similar to the method 
described by Higgins and Sharp (1989).
The alignment procedure begins with the pairwise alignment of the two 
most similar sequences, producing a cluster of two aligned sequences. This cluster 
can then be aligned to the next most related sequence or cluster of aligned 
sequences. Two clusters of sequences can be aligned by a simple extension of the 
pairwise alignment of two individual sequences. The final alignment is achieved by a 
series of progressive, pairwise alignments that include increasingly dissimilar 
sequences and clusters until all sequences have been included in the final pairwise 
alignment.
Before alignment, the sequences are first clustered by similarity to produce 
a dendrogram or a tree representation of clustering relationships. This dendrogram 
directs the order of the subsequent pairwise alignments. The clustering strategy 
represented by the dendrogram is called UPGMA (unweighted pair-group method 
using arithmetic averages); Sneath and Sokal, 1973. This dendrogram is not a 
phylogenetic reconstruction although the vertical branch lengths are proportional to 
the distance between the sequences. The distance along the horizontal axis has no 
significance.
It can align up to 500 sequences with any single sequence in the final 
alignment restricted to a maximum length of 7000 characters including gap 
characters inserted into the sequence by PILEUP to create the alignment. If longer
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sequences are included in the alignment, the number of sequences that PILEUP can 
align are decreased. It is an extension of the Gap program for more than two 
sequences. It tries to find global optimal alignment rather than a local optimal 
alignment. It can take more than a few minutes to run depending upon the length 
and number of sequences being aligned and so it is preferable to run them in batch.
PILEUP was used to perform a multiple sequence alignment of the TCR 
V a and v p  sequences of all the possible combinations of peptide and MHC 
restriction.
The output file created was fed into the PRETTY program which displays 
a consensus sequence for the aligned sequences on the basis of threshold and 
plurality values which define the number of identical residues which have to exist at 
a particular position for a consensus to be valid.
2.3.2 LINEUP
This program edits multiple sequence alignments and about 30 sequences 
can be edited simultaneously. A consensus sequence identifies places where the 
sequences are in conflict.
A number of computer programs have been developed to aid the 
interpretation of multiple sequence alignments. GCG programs used for the analysis 
of TCR sequences include PRETTY, PLOTSIMILARITY, FIGURE and SEQED. 
PRETTY displays multiple sequence alignments and calculates a consensus 
sequence for the sequence group created by LINEUP. It does not create the 
alignment but simply displays it. It can only handle sequence groups whose left ends
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are aligned. PLOTSIMILARITY plots the running average of the similarity among 
the sequences in a multiple sequence format. FIGURE creates figures by including 
both graphics and text. SEQED facilitates the entry and modification of sequences 
as well as assembly of parts of existing sequences into new genetic constructs.
2.4 Sequence comparison
The large number of TCR V a and Vp sequences in the database can be 
roughly divided into four groups depending on their MHC restriction and peptide 
specificity. The four groups are outlined in Table 2.1. The PILEUP analyses of these 
sequences are shown in Figures 2.2-2.11.
The diversity of the sequences in these four groups was analysed by 
calculating the APC and MPI values.
2.4.1 MPI and APC analysis
A group of sequences can be characterised by a ‘minimum pairwise 
identity’ (MPI) value which is the percentage identity shared by the two proteins in 
the group that are the least similar (Benner, 1989). TCR V a and VP sequences in 
the four groups were further separated into sets depending on the peptide and MHC 
restriction. These sets were then aligned using PILEUP (Figures 2.2-2.11). Since 
the sequences are clustered according to similarity in PILEUP, the two sequences at 
the opposite ends in a multiple sequence alignment are least similar. The percentage 
identity of the end sequences in each set was calculated to give the MPI value of 
that s e t .
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same peptide, same MHC 
same peptide, random MHC 
random peptide, alio MHC 
random peptide, random MHC
Table 2.1 Groups of TCR V a and Vp sequences
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PileUp of: ©mouse.flu.alpha
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
mouse.flu.alpha.pileup.msf MSF: 18 Type: P November 28, 1995 


































Figure 2.2 PILEUP of murine TCR V a sequences from flu restricted 
clones [Group 1]. The first column refers to the EMBL sequence 
accession numbers in the alignments.
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PileUp of: ©mouse.beta.lev.pep
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
mouse.beta.lev.pileup.msf MSF: 14 Type: P November 28, 19 95 
23:28 Check: 1673 ..
/ /
1 14
m61140 .CASSSGGNY AEQF 
m6113 9 .CASSYWGDY AEQF
m6113 8 CASSSTRDSY AEQF 
m61141 CASSSGLGGY .EQY
Figure 2.3 PILEUP of murine TCR Vp sequences from lev restricted clones 
[Group 1]. The first column refers to the EMBL sequence accession 
numbers in the alignments.
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PileUp of: mbp.alpha.pep.msf{*}
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
mbp.alpha.pep.pileup.msf MSF: 149 Type: P November 28, 19 95 


















































x 5 833 6 Y .TATGYPSL FWYVQYPGEG 
x 5 7 531 Y .TATGYPSL FWYVQYPGEG 
x5 7 5 3 4 Y .SVSGNPYL FWYVQYPNRG 
X58334 Y .SNSASDYF IWYKQESGKG 
X57 53 3 Y.TNSMFDYF LWYKKYPAEG 
X61628 F .TDSAIYNL QWFRQDPGKG 
X57532 F.TDSAIYNL QWFRQDPGKG 
X58333 Y.KTS.INNL QWYRQNSGRG 
X58322 HSTISGNEYV YWYRQIHSQG 
X6162 9 ..QNLNHDAM YWYRQDPGQG
< CDR2 > 100
LQLLLKATKA DD..KGSNKG FEATYRKETT 
LQLLLKATKA DD..KGSNKG FEATYRKETT 
LQFLLKYITG DNLVKGSY.G FEAEFNKSQT 
P Q F IIDIRSN MDKRQGQR.. VTVLLNKTVK 
PTFLISISSI KDKNEDGR.. FTVFLNKSAK 
LTSLLLIQSS QREQTSGR.. LNASLDKSSG 
LTSLLLIQSS QREQTSGR.. LNASLDKSSG 
LVHLILIRSN EREKHSGR.. LRVTLDTSKK 
PQYIIHGLKN NETNEMA... .SLIITEDRK
LRLIYYSQIV NDFQKGDIAE GYSVSREKKE
101 < CDR3 > 149
X58336 SFHLEKGSVQ VSDSAVYFCA LRG.G TDKLIFGTGT RLQVFPNIQ
X57531 SFHLEKGSVQ VSDSAVYFCA ,..LIG.F GNVLHCGSGT QVIVLPHIQ
X57534 SFHLKKPSAL VSDSALYFCA VRDTG ANNLFFGTGT RLTVIPYIQ
X58334 HLSLQIAATQ PGDSAVYFCA E . KGF. .QKLVFGTGT RLLVSPNIQ
X57533 HLSLHIVPSQ PGDSAVYFCA A ....SATF GNKLVFGAGT ILRVKSYIQ
X61628 RSTLYIAASQ PGDSATYLCA V. ..PLQAGA NSKLTFGKGI TLSVRPDIQ
X57532 RSTLYIAASQ PGDSATYLCV C .... SGT ASKLTFGTGT RLQVTLDI.
X58333 SSSLLITASR AADTASYFCA P. ,..L ...GG GNKLTFGGGT RVLVKPNIQ
X58322 SSTLILPHAT LRDTAVYYCI V. ..RAYSG. NTPLVFGKGT RLSVIANIQ
X61629 SFPLTVTSAQ KNPTAFYLCA SSIRVFWDSR NTEAFFGQGT R L T W E D . .
Figure 2.4 PILEUP of myelin basic protein specific human TCR V a sequences 
(without sequenced Vp partners) [Group 2]. The first column refers to 
the EMBL sequence accession numbers in the alignments.
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PileUp of: @mbp.beta.pep
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100









X5832 6 . . . .LLFWVA
x5 7 5 3 6 MGTRLLCWAA 
X5833 0 ...RLLCCVA
X5832 8 MGSRLLCWVL 
X58331 ..........
> < CDR2 > 100
X58325 MYWYKQDSKK FLKIMFSYNN KELIINETVP N.RFSPKSPD KAHLNLHINS
X5753 5 MYWYKQDSKK FLKIMFSYNN KELIINETVP N.RFSPKSPD KAHLNLHINS
X58324 LFWYRQTMMR GLELLIYFNN NVPIDDSGMP EDRFSAKMPN ASFSTLKIQP
X58323 LFWYRQTMMR GLELLIYFNN NVPIDDSGMP EDRFSAKMPN ASFSTLKIQP
X5832 9 LYWYRQSLGQ GPEFLIYFQG TGAADDSGLP NDRFFAVRPE GSVSTLKIQR
X58326 LYWYRQSLGQ GLEFLIYFQG NSAPDKSGLP SDRFSAERTG GSVSTLTIQR
X5753 6 LYWYQQILGQ GPKLLIQFQN NGWDDSQLP KDRFSAERLK GVDSTLKIQP
X5833 0 VYWYRKKLEE ELKFLVYFQN EELIQKAEII NERFLAQCSK NSSCTLEIQS
X58328 VSWYQQTPGQ GLQFLFEYFS ETQRNKGNFP .GRFSGRQFS NSRSEMNVST
X58331  KGEVP DG . YNVSRLK KQNFLLGLES
101 < CDR3 > 135
X58325 LELGDSAVYF CASSQGRSSN QPQHFGDGTR LSILE
X57535 LELGDSAVYF CASSQGRSSN QPQHFGDGTR LSILE
X58324 SEPRDSAVYF CASSLTGFGD SPLHFGNGTR LTVTE
X58323 SEPRDLAVYF CASSL.ELGT EAF.FGQGTR LTVVE
X58329 TERGDSAVYL CASSWSGRDG DTQYFGPGTR LTVLE
X58326 TQQEDSAVYL CASSREF..S SEQFFGPGTR LTVLE
X57536 AKLEDSAVYL CASS..LLRS WEQFFGPGTR LTVLE
X58330 TESGDTALYF CASSKPGTSP NEQFFGPGTR LTVLE
X58328 LELGDSALYL CASRSSG.GI YEQYFGPGTR LTVTE
X58331 AAPSQTSVYF CASREFR... DTQYFGPGTR LTVLE
Figure 2.5 PILEUP of myelin basic protein specific human TCR VP sequences
(without sequenced V a partners) [Group 2]. The first column refers to 
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PileUp of: ©murine.alpha.pigeoncytochromec
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
murine.alpha.pigeoncytochromec MSF: 132 Type: P August 25, 1995 
17:27 Check: 2963 ..
Name: m2087 6 Len: 132 Check: 9914 Weight: 1.00
Name: m20875 Len: 132 Check: 3 049 Weight: 1.00
/ /
1 < CDR1
m20876 ....... LTQ VCCASQLGLK EQQVQQSPAS LVLQEAENAE LQCSF SIFTNQ
m2 0875 MKSLLSSLLG LLCTQVCWVK GQQVQQSPAS LVLQEGENAE LQCNF STSLNS
> < CDR2 > 100
m20876 VQWFYQRPG GRLVSLLYNP SGTKQSGRLT STTVIKERRS SLHISSSQIT
m20875 MQWFYQRPG GSLVSLFYNP SGTKHSGRLT STTVIKERRS SLHISSSQTT
101 < CDR3 > 132
m20876 DSGTYLCA MEPTNTGK LTFGDGTVLTVKPNIQ 
m2 0875 DSGTYLCA LVSSNTNK WFGTGTRLQVLPNIQ
Figure 2.6 PILEUP of murine TCR Va sequences (with Vp partners) from pigeon 
cytochrome c restricted clones [Group 2]. The first column refers to the 
EMBL sequence accession numbers in the alignments.
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PileUp of: dmurine.beta.pigeon.cytochromec
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
murine.beta.pigeon.cytochromec.msf MSF: 116 Type: P August 16, 
1995 17:31 Check: 1737 ..
Name: m20878 Len: 116 Check: 2204 Weight: 1.00
Name: m20877 Len: 116 Check: 9533 Weight: 1.00
/ /
1 < CDR1 > <
m20878 LMNTKITQSP RYLILGRANK SLECQQHLGH NAMYWYKQSA EKPPELMFLY
m20877 LMNTKITQSP RYLILGRANK SLECEQHLGH NAMYWYKQSA EKPPELMFLY
CDR2 > < CDR3
m20878 NLKQLIRNET VPSRFIPECP DSSKLLLHIS AVDPEDSAVY FCASSQEGGA
m20877 NLKQLIRNET VPSRFIPECP DSSKLLLHIS AVDPEDSAVY FCASSQDQNS
> 116 
m2 0 8 7 8 NYAEQFFGPG TRLTVL 
m20877 DYT. . .FGSG TRLLVI
Figure 2.7 PILEUP of murine TCR Vp sequences from pigeon cytochrome c 
restricted clones [Group 2], The first column refers to the EMBL 
sequence accession numbers in the alignments.
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PileUp of: class2.pair.alpha.pep{*}
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
.pair.alpha.pep.pileup.msf MSF: 153 Type: P November 26 





m97710   DSVTQMEGPV TLSEEAFLTI NCTYTATGYP
m97706   DSVTQMEGPV TLSEEAFLTI NCTYTATGYP
m8 63 61 MLLLLVPAFQ VIFTLGGTRA QSVTQLDSQV PVFEEAPVEL RCNYSSSVSV
X63455 MLLLLVPVLE VIFTLGGTRA QSVTQLGSHV SVSEGALVLL RCNYSSSVPP
cl-la ...................... QSVTQLDSQV PVFEEAPVEL RCNYSSSVSV
m97708   IQVEQSPPDL ILQEGANSTL RCNFSDS.VN
m97720   IQVEQSPPDL ILQEGANSTL RCNFSDS.VN
m97722   IQVEQSPPDL ILQEGANSTL RCNFSDS.VN
m97724   NEVEQSPQNL TAQEGEFITI NCSYSVG.IS
m97718   QQVKQSPQSL IVQKGGISII NCAYENTAFD
m97704   QQVKQSPQSL IVQKGGISII NCAYENTAFD
m97714   ENVEQHPSTL SVQEGDSAVI KCTYSDSASN




m8 6 3 61 
X63455  




































































101 < CDR2! > 150
m97710 VQVSDSAVYF CALSD..Q.N GN..KLVFGA GTILRVKSYI QNPDPAVYQL
m97706 VQVSDSAVYF CALSR..S.S GSARQLTFGS GTQLTVLPDI QNPD.....
m8 6 3 61 VHISDTAEYF CAVRF. . SLQ GGSEKLVFGK GTKLTVNPY.
X63455 AHMSDAAEYF CAV...SESP FGNEKLTFGT GTRLTIIPNI QNPDPAVYQL
cl-la VHISDTAEYF CAV SE TGGFKTIFGA GTRLFVKANI QNPDP....
m97708 SQTTDSGVYF CAVS.. . ASG AGSYQLTFGK GTKLSVIPNI QNPDPAVYQL
m97720 SQTTDSGVYF CAVG... FSD GQ..KLLFAR GTMLKVDLNI QNPDPAVYQL
m97722 SQTTDSGVYF CAVG.. . DYG QS...FVFGP GTRLSVLPYI QKPDPAV...
m97724 SHPRDSAVYI CAV... . .YS QGAQKLVFGQ GTRLTINPNI Q .........
m97718 SQPGDSATYF CAASKRGAGG TSYGKLTFGQ GTILTVHPNI QNP......
m977 04 SQPGDSATYF CAASR. .... ..ANNLFFGT GTRLTVIPYI QNPDPAVYQL
m97714 TQPEDSAVYF CAASR. . .GG GATNKLIFGT GTLLAVQPNI QNPDPAV...
m97712 PKPEDSATYL CAVP... TTT DSWGKLQFGA GTQVWTPDI QNP......
m97716 SKLSDSATYL CWILPNNAG ...NMLTFGG GTRLMVKPHI QNPDPAV...
Figure 2.8 PILEUP of human TCR V a sequences (with sequenced Vp partners)
from Class II restricted clones. The first column refers to the EMBL
sequence accession numbers in the alignments.
58
Chapter 2 Sequence Analysis o f TCR Variable domains
PileUp of: @class2.beta.paired.pep 
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
class2.beta.paired.pep.msf MSF: 321 Type: P August 14, 1995 
11:48
/ /
1 < CDR1 >
m97723  SAVISQKPSRDICQRGTSLTIQCQ . V . DSQVTM
m97713 ................. SAVISQKPSRDICQRGTSLTIQCQ.V .DSQVTM
m97719 ................. GAWSQHPSWVICKSGTSVKIECRS . LDFQAT.
m97717 ................. GAWSQHPSWVICKSGTSVKIECRS. LDFQAT.
m97721 ................. GAWSQHPSRVICKSGTSVKIECRS . LDFQAT.
m97707 ................. ETGVTQSPTHLIKTRGQQVTLRC . SS QSGHNT.
m863 62 PGLLCWVLLCLLGAGPVDAGVTQSPTHLIKTRGQHVTLRC.SP ISGHKS.
m977 09 ................. EAGVTQSPTHLIKTRGQQATLRC . SP ISGHTS .
m977 05 ................. KAGVTQTPRYLIKTRGQQVTLSC . SP ISGHRS .
X63456 IRLLCRVAFCFLAVGLVDVKVTQSSRYLVKRTGEKVFLEC.VQ DMDHEN.
m97715 ................. KAGVTQTPRYLIKTRGQQVTLSC . SP ISGHRS .
m97725 ................. DGGITQSPKYLFRKEGQNVTLSC . EQ NLNHDA.
z2 65 94 IGLLCCAALSLLWAGPVNAGVTQTPKFQVLKTGQSMTLQC.AQ DMNHEY. 
m97711 ................. NAGVMQNPRHLVRRRGQEARLRC . SP MKGHSH .
< CDR2 >
m97723 .MFWYRQQPGQSLTLI. ATANQGSEATYESGF .VIDKFPISRPNLTFSTL 
m97713 .MFWYRQQPGQSLTLI. ATANQGSEATYESGF .VIDKFPISRPNLTFSTL 
m97719 TMFWYRQFPKQSLMLM. ATSNEGSKATYEQGV .EKDKFLINHASLTLSTL 
m97717 TMFWYRQFPKQSLMLM. ATSNEGSKATYEQGV .EKDKFLINHASLTLSTL 
m97721 TMFWYRQFPKQSLMLM. ATSNEGSKATYEQGV .EKDKFLINHASLTLSTL 
m977 07 .VSWYQQALGQGPQFI. .FQYYREEENGRGN. FP.PRFSGLQFPNYSSEL
m863 62 .VSWYQQVLGQGPQFI. .FQYYEKEERGRGN. FP.DRFSARQFPNYSSEL
m977 09 .VYWYQQALGLGLQFL. .LWYDEGEERNRGN. FP.PRFSGRQFPNYSSEL
m97705 .VSWYQQTPGQGLQFL. .FEYFSETQRNKGN. FP.GRFSGRQFSNSRSEM
X63456 .MFWYRQDPGLGLRLI. YFSYDVKMKE.KGD. IPEG.YSVSREKKERFSL 
m97715 .VSWYQQTPGQGLQFL. .FEYFSETQRNKGN. FP.GRFSGRQFSNSRSEM 
m97725 .MYWYRQDPGQGLRLI. YYSHIVNDFQ.KGD. IAEG.YSVSREKKESFPL 
Z26594 .MSWYRQDPGMGLRLIH .YSVGAGITD.QGE. VPNG.YNVSRSTTEDFPL
m97711 .VYWYRQLPEEGLKFM. VYLQKENIID.ESGM .PKERFSAEFPKEGPSIL
< CDR3 >
m9 7 7 2 3 TVSNMS PEDS SIYLC. .S . . .VEDRDRVYNE. QFFGPGTRLTVLEDLKNV
m97713 TVSNMSPEDSSIYLC..S.. .VAGQGT..DE. QYFGPGTRLTVTEDLKNV 
m97719 TVTSAHPEDSSFYIC..S.A ...SKTGR.GE. QYFGPGTRLTVTEDLKNV 
m97717 TVTSAHPEDSSFYIC..S .. ..ASRASSYNE. QFFGPGTRLTVLEDLKNV 
m97721 TVTSAHPEDSSFYIC..S.A ...LGTGS..GY .TFGSGTRLTWEDLNKV 
m977 07 NVNALELDDSALYLCAS. . . SLMGDRG. .SPL .HFGNGTRLTVTEDLNKV 
m86362 NVNALLLGDSALYLCAS... SFPGNRGYWYGY .TFGSGTRLTWED.... 
m97709 NVNALELEDSALYLCAS... SL.GQGT..YE. QYFGPGTRLTVTEDLKNV 
m97705 NVSTLELGDSALYLCAS... SKEPRGNQ..P . QHFGDGTRLSILEDLNKV 
X63456 ILESASTNQTSMYLCAS... SSTGLPY...GY .TFGSGTRLTWEDLNKV 
m97715 NVSTLELGDSALYLCAS... SSTTSGSN..E . QYFGPGTRLTVTEDLKNV
m97725 TVTSAQKNPTAFYLCAS... SLDSWDT  QYFGPGTRLTVLEDLKNV
Z26594 RLLSAAPSQTSVYFCAS... R.DFLSG...E. QYFGPGTRLTVTEDLKNV 
m97711 RIQQWRGDSAAYFCAS . . . SPTVS .... YE . QYFGPGTRLTVTEDLKNV
Figure 2.9 PILEUP of human TCR Vp sequences (with V a partners) from Class
II restricted clones. The first column refers to the EMBL sequence
accession numbers in the alignments.
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PileUp of: @classl.pair.alpha.pep
Symbol comparison table: GenRunData:pileuppep.cmp CompCheck: 1254
GapWeight: 3.000 
GapLengthWeight: 0.100
classl.pair.alpha.pileup.msf MSF: 283 Type: P November 26, 1995 




S607 95  ....RTMKTF AGFSFLFLWL QLDCMSRGED VEQSLFLSVR EGDSSVINCT
X74394 ..........................................................................................................................................
x7 4 3 9 6 ...........................................................................................................................................
13 8312  QEV TQIPAALSVP EGENLVLNCS
S6 9564...... ...........................................................................................................................................
m81774 MMKSLRVLLV ILWLQLSWVW SQQK....EV EQNSGPLSVP EGAIASLNCT
S69559...... ...........................................................................................................................................
m l55 65  MAMLLGASVL ILWLQPDWVN SQQKNDDQQV KQNSPSLSVQ EGRISILNCD
S60793...... ...........................................................................................................................................
569563 ...... .............................................................................................. ............................................
x743  92 ...........................................................................................................................................
S69553...... ...........................................................................................................................................
CDR1 > < CDR2 > 100
X74390 ...........................................................................................................................................
s 6 0 7 95 YTDSSSTYLY WYKQEPGAGL QLLTYIFSNM DMKQDQRLTV LLNKKDKHLS
x7 4 3 9 4 ...........................................................................................................................................
X74396 ...........................................................................................................................................
13 8312 FTDSAIYNLQ WFRQDPGKGL TSLLLIQSSQ REQTSGRLNA SLDKSSGRST
5 69 56 4 ...... ...........................................................................................................................................
m81774 YSDRGSQSFF WYRQYSGKSP ELIMSIYSNG DK.EDGRFTA QLNKASQYVS
S69559...... ...........................................................................................................................................





101 < CDR3 > 150
X743 90 ................ CAVKG IS.GGSYIPT FGRG.TSLIV HPYIQ....
S60795 LRIADTQTGD SAIYFCAEKN SKLGGSYIPT FGRG.TSLIV HPYIQNP...
x7 43 94  CAVN TG. GFKTI. . FGAG. TRLFV KANIQ.....
x743 9 6  CAVN KG.N.DMR. . FGAG . TRLTV KPNIQ.....
13 8312 LYIAASQPGD SATYLCAALD TG.RRALT.. FGSG.TRLQV QPNIQ....
S69564 .............EYFCAV. . GATGNQFY . . FGTG. TSLTV IPNIQNPD . .
m81774 LLIRDSQPSD SATYLCAVYH SGSARQLT.. FGSG.TQLTV LPDIQNPDPA
S69559 .............TYFCAASK GGSQGNLI. . FGKG.TKLSV KPNIQNPD. .
ml5565 LHIVPSQPGD SAVYFCAAKG AGTASKLT.. FGTG.TRLQV TLDIQNPDPA
s  6 07 93  AASI TNSGYALN. . FGKG . TSLLV TPHIQNP . . .
S69563  MYYCALIP GG. .QKLL. . FARG. TMLKV DLNIQNPD . .
X74392 .................. CAA RLLTYKYI. . FGTG.TRLKV LANIQ....
S69553 .............MYFCAYRG LGWLQTSSS LELALCLLSS QVHIQNPD. .
Figure 2.10 PILEUP of human TCR V a sequences (with Vp partners) from Class
I restricted clones [Group 4]. The first column refers to the EMBL
sequence accession numbers in the alignments.
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Pileup of : Qclasslprb.msf
classl.pair.beta.pileup.msf MSF: 314
Check: 6520 ..
Type: P July 25, 1995 19:32
/ /
1 < CDR1
S 6 9 5 6 6  ...........................................................................................................................................
ml5564 ........................ GVSQNPRHN ITKRGQNVTF RCDPISEHNR
S 69 5 5 6 ...... ...........................................................................................................................................
x7 4 3 9 7 .........................................................
m81773 MGSWTLCCVS LCILVAKHTD AGVIQSPRHE VTEMGQEVTL RCKPISGHDY
x7 4 3 9 5 ...........................................................................................................................................
x7 4 3 91 ..........................................................
S 6 9 5 7 1  ...........................................................................................................................................
S 69569 ...... ...........................................................................................................................................
S60794 .MSISLLCCA AFPLLWAGPV NAGVTQTPKF RILKIGQSMT LQCTQDMNHN
x7 4 3 9 3 ..........................................................
S6 0 7 9 6 ...... ...........................................................................................................................................
m24089 MGTRLLFWVA FCLLGADHTG AGVSQSPSNK VTEKGKDVEL RCDPISGHTA
> < CDR2 > 100
S6 9 5 6 6 ...... ...........................................................................................................................................
m l 5 5 6 4  LYWYRQTLGQ GPEFLTYFQN EAQLEKSRLL SDRFSAERPK GSFSTLEIQR
S 69556 ...... ...........................................................................................................................................
X74397 ...........................................................................................................................................
m81773 LFWYRQTMMR GLELLIYFNN NVPIDDSGMP EDRFSAKMPN ASFSTLKIQP
x7 4 3 9 5 ...........................................................................................................................................
x7 4 3 91 ...........................................................................................................................................
S 69571 ...... ...........................................................................................................................................
S 69569 ...... ...........................................................................................................................................
s 6 0 7 94 YMYWYRQDPG MGLKLIYYSV GAGITDKGEV PNGYNVSRST TEDFPLRLEL
x7 4 3 9 3 ...........................................................................................................................................
S6 07 96 ...... .............................................................................................. ............................................
m24089 LYWYRQSLGQ GLEFLIYFQG NSAPDKSGLP SDRFSAERTG GSVSTLTIQR
S6 9566  
m l5 564  
S6 9556  
x7 4 3 9 7 
m81773  
X74395
X743 91 .......... CASR...S. .
S 69 571   LYL CASS. . .QDL
S6 9569  MYFC AAGE . . . TSG
s60794 AAPSQTSVYF CASSYA.GAL
x7 4 3 9 3 ....................CS












LNTDTQYFGP GTRLTVLEDL K ........
AFDGEAFFGQ GTRLTWEDL ..........
ILSYEQYFGP GTRLTVTEDL K .........
AG.DTQYFGP GTRLTVL..............




.......... CASSYS.A A . .SGHGYTFGS
SEPRDSAVYF CASSLT.TER 
.......... CASSTG.QGW
Figure 2.11 PILEUP of Class I restricted TCR Vp sequences (with sequenced V a
partners) [Group 4]. The first column refers to the EMBL sequence
accession numbers in the alignments.
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Another way of characterising a group of sequences is by calculating the percentage 
of residues that are ‘absolutely positively conserved’ (APC) throughout the 
alignment. The MPI and APC values of each of these sets in the four groups were 
calculated (Table 2.2 and 2.3) and are shown in graphical form in Figures 2.12 and 
2.13.
The lower the MPI and APC values are for the group, the greater the 
sequence divergence within the group. It was found that both APC and MPI values 
decreased as the peptide and MHC molecule was made random in both TCR Voc 
and Vp sequences. Group 1 which had different TCR sets with the same peptide 
and MHC combination showed the highest values of both APC and MPI. The order 
of similarity increased from Group 1 > Group 2 > Group 3 > Group 4. Group 4 
which has TCR sets with random peptide and MHC had low values of APC and 
MPI suggesting that sequences in the different sets in this group are far more 
diverse than those in other groups.
After calculating the overall diversity in these sequences in the four groups 
the overall similarity in these sequences was calculated by a GCG program 
PLOTSIMILARITY.
2.4.2 PLOTSIMILARITY
PLOTSIMILARITY plots the running average of the similarity among the 
sequences in a multiple sequence format using a user specified sliding window of 
comparison. The window of comparison is moved along all sequences, one position 
at a time and the average similarity over the entire window is plotted at the middle
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Group Peptide MHC APC (%) M PI (%)
Group 1 same peptide same MHC
Hu matrix peptide HLA-A2.1 16.66 22.22
Human dust mite DR1 18.66 25.33
Lev H-2b 35.71 46.42
Tumour necrosis protein H-2Kb 50 64.28
Group 2 same peptide random MHC
Myelin basic protein DR family specific 9.16 27.5
Betv DR family specific 20.83 31.66
Pigeon cytochrome c I-Ek, I-Eb 68.93 68.93 .
Group 3 random peptide alio MHC




Varied HLA-B27 9.09 28.71
Group 4 random peptide random MHC
Varied (Va sequences with no Vp 
partners) Class I 0 4.76
Varied (Va sequences with no vp 
partners) Class II 0 5.55
Varied (Flu matrix peptide + HA) HLA-DR1, HLA-A2 5 9.165
Varied (Va sequences with 
partners)
vp
Class I 5.55 16.66
Table 2.2 APC and MPI values of TCR V a sequences.
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1 1  i  I
20
. I I  I
(UVHLA-A2.1 hdnVDHI lcv/H-2b tnp/H-2Kb
I A PC ■  MPI
Mbp/DR Betv1/DR Pigcytc/I-E
A PC ■  MPI
Random peptide/ alio MHC
APC ■  MPI






C tassl/nonpair C tastll/nonpair FliVHA/DR1/A2 Classl/pair
A PC ■  MPI
Figure 2.12 APC and MPI values of TCR V alpha sequences shown as histograms
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Group Peptide MHC APC (%) M PI (%)
Group 1 same peptide same MHC
Human dust mite HLA-DR1 19.23 19.23
Tumour necrosis protein H-2Kb 0 37.5
Flu matrix peptide HLA-A2.1 29.41 41.17
Lev H-7b 50 64.28
Group 2 same peptide random MHC
Betv DR family specific 4.32 22.58
Myelin basic protein DR family specific 9.165 17.5
Pigeon cytochrome c I-Ek, I-Eb 88.79 88.79
Group 3 random peptide alio MHC
Varied (Vp sequences with Va 
partners) HLA-DR1 13.33 30
Varied (Vp sequences with no Va  
partners) HLA-DR1 15.38 33.84
Group 4 random peptide random MHC
Varied (Flu matrix peptide + HA) HLA-DR1, HLA-A2 0 5.88
Varied (Vp sequences with Va  
partners) Class I 5 15
Varied (Vp sequences with no Va  
partners) Class II 4.16 25
Varied (Vp sequences with no Va  
partners) Class I 13.89 28.57
Table 2.3 APC and MPI values of TCR V(3 sequences
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Same peptide/ same MHC
B
hdm/DR1 tnp/H-2Kb FHVHLA-A2.1 lcv/H-2b
A PC ■  MPI
Same peptide/ random MHC
Mbp/DR PigcytcA-E
I A PC ■  MPI
Random peptide/ alio MHC
A PC ■  MPI
Random peptide/random MHC
fliVHA/DR1/A2 C ta» l/p a ir  C tassll/nonpsir Ctaratl/nonpair
| A PC B  MPI 1
Figure 2.13 APC and MPI values of TCR V beta sequences shown as histograms.
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position of the window. The average similarity at a position in an alignment is the 
arithmetic average of the scores of all possible pairwise symbol comparisons among 
the sequence symbols at that position. The average similarity across the entire 
alignment is the sum of the separate window similarities divided by the number of 
windows and it is plotted as a dotted line.
A measure of the level of identity among all the sequences in a multiple 
sequence alignment can be plotted by using the -IDEntity command line option 
while a measure of the level of conservation in a profile created from a multiple 
sequence alignment can be plotted by using the -PROfile command line option.
The default file plotsimpep.cmp has a value of 1.5 for perfect symbol 
matches and values less than 1.5 (depending upon the evolutionary distance) for 
non-matches. FETCH can be used to copy these files and they can then be modified 
to suit one’s needs.
TCR V a and v p  multiple sequence sets in the four groups were aligned by 
PILEUP. The average similarity across the various alignments was calculated (Table 
2.4) by PLOTSIMILARITY.
The trend seen in the case of APC and MPI values is not duplicated across 
the spectrum. The sequence sets in Group 2 were found to have consistently high 
values and these are comparable to the values seen in Group 1. The similarity scores 
exhibited by Groups 3 and 4 were much lower than the values seen in Groups 1 and 
2 (Figure 2.14). Additionally the similarity across the three CDRs in the TCR V a 
(Table 2.5) and Vp sequence sets (Table 2.6) in Groups 2, 3 and 4 was calculated. 
Similarity plots of CDRs in TCR V a (Figure 2.15) and Vp (Figure 2.16) show a
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Group Peptide MHC V a VP
Group 1 same peptide same MHC
Flu matrix peptide HLA-A2.1 0.625 0.7
Human dust mite HLA-DR1 0.4 0.5
Tumour necrosis protein H-2Kb 0.1 0.25
Lev H-2b 0.925
Group 2 same peptide random MHC
Betv DR family specific 0.775 0.4165
Myelin basic protein DR family specific 0.525 0.725
Pigeon cytochrome c I-E\ I-Eb 1.1 1.375
Group 3 random peptide alio MHC




Varied HLA-B27 0.25 -
Varied HLA-DR1 - 0.325
Group 4 random peptide random MHC
Varied (Vp sequences with 
partners)
Va
Class I 0.1 0.1
Varied (Va sequences with no Vp 
partners) Class II - 0.2
Varied (Vp sequences with no Va  
partners) Class I 0.225 0.15
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1.8 -  -








a*Pha j j l S l j  beta
Figure 2.14 Similarity plot of TCR V alpha and V beta sequences
lcv/H-2b Flu/A2.1 hdm /D m  tnpAH-2Kb Pigcytc/I-E Batv1/DR Mbp/DH allo/DRI aHo/B27 C lnonpair Ctlnonpair Clpoir
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Group Peptide MHC CDR1 CDR2 CDR3
Group 2 same peptide 
Betv
Myelin basic protein 
Pigeon cytochrome c
random MHC 
DR family specific 











Group 3 random peptide












Group 4 random peptide
Varied (Va sequences with Vp 
partners)
Varied (Va sequences with no Vp 
partners)





































-  CDR1 C D R 2  —  C D R 3
Figure 2.15 Similarity plot of CDRs in TCR V alpha sequences
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Group Peptide MHC CDR1 CDR2 CDR3
Group 2 same peptide random MHC
Betv DR family specific 0 0.025 0.275
Myelin basic protein DR family specific 0.675 0.625 0.625
Pigeon cytochrome c I-E\ I-Eb 1.425 1.5 0.75
Group 3 random peptide alio MHC
Varied (Va sequences with 
partners)
vp
HLA-DR1 0.475 0.35 0.575
Varied HLA-B27 " “ ”
Group 4 random peptide random MHC
Varied (Vp sequences with 
partners)
Va
Class I 0.05 0.05 0.375
Varied (Va sequences with no VP 
partners) Class II 0.3 0.25 0.3
Varied (VP sequences with no Va  
partners) Class I 0.5 - -






















»  CDR1 C D R 2  * C D R 3
Figure 2.16 Similarity plot of CDRs in TCR V beta sequences
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similar pattern to that seen in the case of APC and MPI values.
Generally the CDRs in Group 2 had higher values than the CDRs in 
Groups 3 and 4. Lower values were seen as the peptide and MHC were made 
random.
2.4.3 Similarity based on chemical side chain character
While exact conservation of residues at equivalent positions (identity) may 
not be present, the possibility that similar sidechains at particular positions can 
maintain specificity at the structural level was investigated. Seventeen out of the 
twenty amino acids were classified into four groups, based on their chemical 
similarity.
Group A consisting of hydrophobic amino acids: alanine, isoleucine, 
leucine, methionine, phenylalanine, valine, tryptophan and tyrosine.
Group B consisting of uncharged hydrophilic amino acids capable of 
hydrogen bonding: asparagine, glutamine, serine and threonine.
Group C consisting of positively charged amino acids: lysine, arginine and
histidine.
Group D consisting of negatively charged amino acids: aspartate and 
glutamate.
The residues cysteine, proline and glycine are left out from this 
classification as they do not fall into any specific group and in addition may impose 
a structural change that cannot readily be predicted.
A simple scoring matrix was derived from the Gribskov table (Table 2.7).
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A, I, L, M, 
F, V, W, Y
N, Q, S, T K, R, H D, E
0.475 -0.178 -0.15 - 0.406 A, I, L, M, 
F, W, V, Y
-0.178 0.5 0.217 0.425 N, Q, S, T
-0.15 0.217 0.811 0.233 K, R, H
- 0.406 0.425 0.233 1.25 D, E
Table 2.7 Scoring matrix derived from the Gribskov table.
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Gribskov and Burgess rescaled the Dayhoff table (Dayhoff et al., 1978) by dividing 
each value by the sum of its row and column and normalising to a mean of 0 and 
standard deviation of 1. Perfect matches were set to have a value of 1.5 and no 
matches on any row were better than the perfect matches.
The seventeen amino acids were initially aligned into the four groups A, B, 
C and D. The sum of the values of each row and column in a group was divided by 
the number of individual elements in that particular group. Each matrix element 
denotes this average score. It can be noted from the matrix that when a hydrophobic 
residue (A, I, L, M, F, V, W and Y) is substituted by another hydrophobic residue 
it is assigned a score of 0.475. However when it is substituted by an uncharged 
hydrophilic residue (N, Q, S and T), a positively charged residue (K, R and H) or a 
negatively charged residue (D and E) it is assigned negative scores of -0.178, -0.15 
and -0.406 respectively. These scores clearly reflect the difference in the 
physicochemical properties of the amino acids in the various groups.
Similarly residue substitutions within groups B, C and D are assigned 
scores of 0.5, 0.811 and 1.25 respectively. The values in this matrix seem to be 
assigned logically as higher scores are assigned for group substitutions. 
Substitutions across more diverse groups are assigned lower scores. A high score of 
1.25 is seen when an aspartate is substituted by glutamate or vice versa.
This matrix was then used to assign scores to each CDR position in the 
various TCR V a and v p  sequence sets in Groups 1 to 4.
For example, at position 1 in CDR1 ofmbp specific TCR Va sequences
(Figure 2.4), there are three threonines, one alanine, one glutamate, one
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aspartate, one asparagine and three serines. The 3 threonines, 3 serines 
and 1 asparagine belong to Group B giving a score o f 7 x  0.5, the 
glutamate and aspartate belong to Group D giving a score o f 2 x 0.425 
while alanine gives a score o f -0.178.
The total score at a position is calculated by the formula,
sum of individual scores / number o f sequences in that set, 
maximum score
In the given example, the total score at position 1 in CDR1 ofmbp 
specific TCR Va sequences
= 3.5+0.85+(-0.178)! 10 = 0.4172 = 0.834
0.5 0.5
In the case of CDR1 and CDR2 position of TCR V a sequences, higher
scores are seen in mbp specific TCR V a sequences (Group 2) as compared to those
in TCR V a sequences in Class I restricted clones (Group 4) [Figure 2.17]. It should
be noted that the Class II paired TCR V a and Vp sequences include sequences
which are derived from DR1 alloreactive clones and DR1 restricted flu specific
clones cl-1 and HA1.7. The CDR1 and CDR2 scores seen in Class II sequences
(where there is only a slight variation in the MHC restriction within the sequence
set) are comparable to those seen in DR family specific mbp specific TCR V a and
Vp sequences. As in the case of CDR1 and CDR2, CDR3 scores of the mbp specific
TCR V a sequences (Group 2) show values which are comparable to that seen in
Class II restricted TCR Va sequences.
Even though high scores are seen for residues at CDR3 positions in Group
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mbp/alpha/cdrl
mbp/alpba/cdr2
C D R  position C D R  position
class 2/pa ir/alpha/cdr2
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C D R  position
Figure 2.17 CDR1 and CDR2 scores of TCR V alpha sequences from 
groups 2, 3 and 4.
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Figure 2.18 CDR3 scores of TCR V alpha sequences from the four groups
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Figure 2.19 CDR1 and CDR2 scores of TCR V beta sequences from 
groups 2, 3 and 4
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Figure 2.20 CDR3 scores of TCR V beta sequences from the four groups.
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1 (lev specific murine TCR V a sequences) as compared to those in Group 4 (Class I 
paired TCR V a sequences) [Figure 2.18], the similarity scores in the CDR3 
positions do not show a great difference across the groups.
High scores are also seen for residues at CDR1 and CDR2 positions in mbp 
specific TCR VP sequences (Group 2) as compared to TCR VP sequences in Class 
I restricted clones (Group 4) [Figure 2.19]. However CDR3 positions in mbp 
specific DR restricted TCR Vp sequences and Class I restricted TCR Vp sequences 
vary in their scores only at the central CDR positions corresponding to the most 
accessible portion of the loop (Figure 2.20).
2.5 Summary of Results
A  large number of TCR V a and VP sequences are increasingly becoming 
available due to rapid advances in sequencing. These sequences were obtained via 
anonymous ftp from the various protein and DNA databanks. The sequences were 
then aligned and assorted depending on their MHC restriction and peptide 
specificity.
Analysis of the TCR Va and Vp gene sequences showed a high variability 
in the TCR sequences as compared to antibodies. In addition to the three CDRs 
seen in the case of antibodies, another region of high variability has been seen within 
a loop (the D-E loop) between the CDR2 and CDR3 equivalent regions of both 
chains. The D-E loop region has less conserved structure than in antibodies and it 
may form part of the TCR combining site.
Analysis of the TCR CDR lengths revealed that they show a more
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restricted range than antibodies. The CDR1 in both a  and P chains is not longer 
than 12 residues which is in sharp contrast to the much longer loops seen in CDR 
LI in antibodies. The CDR2 region in TCR a  chains has the same length as 
antibody light chains. The P chain CDR2 is 14 residues long which is the same as 
the minimum length for CDR H2 in antibodies. TCR CDR3 regions vary in length 
from 5-15 residues. This is a broader range than antibody k chains but a much more 
restricted range than antibody heavy chains.
Multiple sequence alignments of TCR sequences of all possible 
combinations of peptide and MHC restriction was carried out by PILEUP. These 
sequences can be roughly divided into four groups depending on their MHC 
restriction and peptide specificity.
The diversity of the sequences in the four groups was analysed by a 
calculation of the APC and MPI values. The APC values of a sequence set are 
generally lower than the MPI values. Only in three instances, equal APC and MPI 
values are seen. No significance is attached to the equal APC and MPI values seen 
in the TCR set which is I-E restricted and specific for pigeon cytochrome c as there 
are only two sequences in that particular set. The TCR Vp set which is DR1 
restricted and specific for house dust mite also has equal APC and MPI values 
which may suggest a significant role for these conserved residues.
When the APC and MPI values of each of the sequence sets in the four 
groups were calculated it was observed that when the peptide and MHC molecule 
was random in a particular set the values were lower. It was found that both APC 
and MPI values decreased as the peptide and MHC molecule was made random in
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both TCR V a (Figure 2.12) and Vp sequences (Figure 2.13). The sequences were 
much more divergent as the peptide and MHC specificity was varied.
However when the overall similarity of these sequences was calculated by 
PLOTSIMILARITY it was found that similarity scores of sequence sets in Group 1 
were comparable to those in Group 2. The sequences in Groups 3 and 4 were 
generally more divergent than the sequences in Groups 1 and 2. It may be significant 
to note that the three sequence sets [Pigcytc/I-E (Pigeon cytochrome c specific and 
I-E family restricted) , Betvl/DR (BETV 1 specific and DR family restricted) and 
Mbp/DR (myelin basic protein specific and DR family restricted) in Group 2 which 
show a high degree of similarity all show MHC family specific restriction. In 
principle it still obeys the general rule since the variation in the MHC restriction is 
still very small.
In the case of the sequence set which is I-E restricted and specific for 
pigeon cytochrome c, the similarity scores are much higher than those seen in the 
group with similar peptide and MHC restriction. This may be due to the fact that 
this particular sequence set has only two sequences and any significance is therefore 
difficult to establish. Similarity scores of the CDRs in this particular set were also 
much higher than those found in any other sequence set.
Generally the CDRs in sequence sets with the same peptide and MHC 
family specific restriction had a much higher similarity score as compared to those 
seen in sets with divergent peptide and MHC specificity. Whether the similarity in 
the CDRs of sequences also reflects conservation of residues at the individual 
positions was also examined. The amino acids were classified into four groups
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depending on their physicochemical properties. Glycine, Cysteine and Proline were 
left out of this scheme as they do not exhibit a common behaviour.
A simple scoring matrix was derived from the Gribskov table (Table 2.7). 
This matrix was then used to assign scores to each CDR position in the various sets 
of TCR Va and Vp sequences in the four groups. Group substitutions were 
assigned higher values as compared to substitutions across more diverse groups. 
The average of the amino acid scores in a particular group was then calculated.
There is a high conservation of residue character at CDR positions in the 
sequence sets with same peptide and MHC specificity. A sharp decrease in the 
CDR1 and CDR2 scores is seen in TCR Va and v p  sequence sets with random 
peptide and MHC as compared to those sets with same MHC and peptide 
specificity.
Even though the CDR3s of TCR Va and Vp sequences with same peptide 
and MHC specificity show higher average scores as compared to sequences with 
random peptide and MHC specificity, the CDR3s do not show a sharp decrease in 
residue similarity at corresponding positions in sequence sets across the four groups 
(Figures 2.18 and 2.20). The CDR3 positions in the various sequence sets vary in 
their scores only at the central CDR positions corresponding to the most accessible 
portion of the loop.
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Molecular Modelling of TCR Variable 
Domains
Information on the 3-D structure of TCR 0$  chains is currently limited to 
molecular models generated from the growing database of TCR sequences and the 
two crystal structures of the TCR V a and Vp single fragments. Problems in the 
expression of soluble TCR in large quantity and the natural presence of 
carbohydrate on the molecule have hindered the elucidation of the complete 
structure of the TCR. Considerable effort has therefore been directed at protein 
engineering of secreted forms of the extracellular portions of TCRs that could be 
amenable to crystallographic analysis.
Recent crystallographic analysis of the P chain (Bentley et a l, 1995) of the 
14.3.d clone (specific for a HA peptide of influenza virus A/PR/34 (H1N1) in 
association with the MHC Class II I-Ed molecule) and the a  chain (Fields et a l, 
1995) from the 1934.4 clone (specific for the N terminal nonapeptide of mbp in 
association with the MHC Class II I-Au molecule) confirms the structural similarity 
between T and B cell receptors. The a  and p chains are members of the Ig 
superfamily with the extracellular portion predicted to have a structure similar to a 
membrane anchored form of an Ig Fab fragment.
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As in the case of Fab fragments, there is one variable (V) Ig domain and 
one constant (C) Ig domain in each chain. The Ig domain is composed of two 
antiparallel p sheets interacting face to face to form a P-sandwich structure, with a 
disulphide link between the two sheets (‘the Ig fold’) [Novotny et al., 1983]. The V 
domain is a nine stranded p-sandwich and the C domain a seven stranded sandwich. 
The Va/Vp and Cot/CP domains associate into dimers which have a P-barrel 
structure.
It was proposed that the TCR binding site for the MHC-peptide complex is 
composed of loops connecting the P-strands of the V a and VP domains (Davis and 
Bjorkman, 1988; Chothia et a l,  1988). These loops, three from each domain are 
hypervariable in sequence and are termed complementarity determining regions or 
CDRs 1, 2 and 3. The sequence variability of TCR CDRs 1 and 2 is lower than for 
antibody CDRs 1 and 2 due to a more restricted V gene pool. However there is a 
higher degree of variability in the CDR3 region of TCR mainly due to the larger 
number of J gene segments for the TCR compared to antibodies. This led to the 
suggestion that the CDR1 and CDR2 of both the a  and p chains of the TCR interact 
preferentially with the less diverse a  helices of the MHC molecule while CDR3 
contacts the more variable peptide. Unlike antibody V domains, the TCR has a 
fourth hypervariable loop (Jores et a l, 1990) that has been proposed to be involved 
in the interaction of superantigens (Figure 3.1).
A number of features unique to the individual a  and P chains were 
identified in the two crystal structures. The Cp domain contains a large insertion
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COOH COOH
Figure 3.1 A ribbon representation of m86361 TCR VaVp heterodimer.
The CDRs of the V a domain (red) and the Vp domain (blue) 
are labelled 1-4. The figure is generated using MOLSCRIPT.
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between residues 219 and 232 which forms a protruding solvent exposed loop on 
the external face of Vp. Although the function of this loop is unknown its location 
in the 3D structure of the p chain suggests that it could be involved in contacts with 
the CD3 components of the TCR/CD3 complex.
The most striking feature of the V a domain is its folding topology which 
differs from that of all other Ig superfamily members. There is a switch in a 
polypeptide strand from one P sheet to the other such that the V a c” strand is 
hydrogen bonded to the d strand of the adjacent sheet instead of the c’ strand in the 
same p sheet as seen in antibodies and the v p  chain. This structural difference may 
have functional implications. The strand switch removes a surface protusion from 
the molecule thereby enabling two V a homodimers to pack as a parallel dimer of 
dimers in the crystal structure. Whether the ap-TCRs dimerize in a similar manner is 
unknown. However a model of the (VaVp)2 tetramer was constructed from the 
(V aV a)2 tetramer and known Vp structure. This model has similarity to the MHC 
Class II dimer of dimers observed in HLA-DR1 crystal structures and suggests a 
geometry for docking the TCR with peptide/MHC complex similar to that 
suggested by Jorgensen et al, 1992. Another orientation of the TCR was suggested 
by Hong et al, 1992 which appears to be at 180° to this orientation. Whether the 
TCRs recognise peptide-MHC in a single/ multiple orientation is still unknown 
although models from this group suggest this is unlikely in some if not all complexes 
(Wedderbum et a l , 1995)[Figure 3.5].Structural information on TCR/peptide/MHC 
complexes is essential to resolve this issue.
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In the absence of crystal structures, models for the interaction between 
TCR and MHC/peptide have been proposed by a number of groups including this 
laboratory. These models are based on the 3D structures of the MHC/peptide 
moiety and the expected structural similarity between the TCR and Ig Fab. Methods 
that were developed to model antibody V domains have been extended to generate 
structures for TCR V domains. In this thesis, a modification of the antibody 
modelling algorithm AbM called TCRM is used to generate six models of human 
TCR V domains, 5 molecules from DR1 alloreactive clones namely m97708, 
m97712, m97718, m97723, m97724 and the molecule m86361 from a DR4 
restricted clone isolated from the site of inflammation in an RA patient (Table 3.1). 
The TCR a  and P chain sequences are analysed prior to their use in the modelling 
method.
3.1 TCR Sequence analysis
TCR alpha and beta chain sequences were obtained via anonymous ftp 
from the OWL non-redundant protein database running under VAX/VMS which 
contains entries from several DNA and protein databanks (SWISSPROT, 
GENBANK, NBRF-PIR, BROOKHAVEN, PDQ-KYOTO, NEWAT86, NBRE­
NEW). The sequences were then aligned pairwise and ordered as previously 
described. This list was then edited so as to only contain one copy of each of the 
variable gene segments. The aligned sequences were truncated two positions after 
the second conserved cysteine and then realigned using a block of antibody 
sequences. The antibody VH and VL domains were initially structurally aligned to
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Table 3.1: The T lymphocyte clones which express the modelled TCRs
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give conservation of the forty conserved residues described by Chothia et al., 
(1988). Structural information was included in this final alignment procedure as the 
P sheet framework in the antibodies was given a greater gap penalty than the loop 
regions. Both the alpha and beta chain sequences show higher average identity to 
light chains than to the heavy chains. The distribution of the identity along the 
sequence differed for light and heavy chains. The region making up the D-E strands 
is much less conserved in a  and (3 sequences than in antibodies.Detailed analysis of 
the frequencies of occurence of residues at positions equivalent to positions vital for 
maintaining the structure of antibodies was carried out to quantify the light and 
heavy chain character of the two types of TCR sequences (Searle, unpublished). 
Positions 15, 157 and 159 which are involved in Vh-Ch contacts are also conserved 
in light chains. Both a  and p chains showed greater homology to the heavy chains at 
these positions than to light chain sequences. Positions 46, 54, 56, 128 and 150 
which are involved in V l-V h contacts show greater homology to light chains rather 
than heavy chains. There is virtually no heavy chain character at four of these five 
positions while position 54 in both a  and |3 chains show some light and some heavy 
character.
To quantify the light and heavy chain character of the TCR frameworks, a 
new similarity index was devised to compare one set of sequences to two others 
(Searle, unpublished). The score for each residue is calculated as the sum of the 
differences between the frequencies of each residue type in the two chain types at 
each position. The calculation was performed for TCR a  and p chain framework 
regions (residues 1-22, 34-48, 62-91, 105-118 in the a  chain and residues 1-23,
92
Chapter 3 Molecular Modelling o f TCR Variable Domains
34-47, 65-92, 107-120 in the P chain). In figures 3.2 and 3.3 where the line is above 
0 the TCR sequences show more light chain character and where it is below heavy 
chain character.
The scores at each framework position can be summed for each chain and 
give an indication of the overall homology of the test chain type to the others. For 
TCR a  chains the light chain score was 20.9 and the heavy chain score was 7.44. 
For TCR p chains the scores were 19.56 and 9.21 respectively. Light chain dimers 
were used as the framework structure in building the model as both the a  and P 
chains appear to have greater light chain character especially in the domain packing 
residues.
3.2 TCR Modelling
There are two essential factors to be considered prior to modelling of 
TCRs. The sequences of both the a  and p chains of a single clone must be known. 
The peptide antigen and MHC specificity should be known. Ideally the MHC 
restriction should be to an MHC molecule with a solved structure. Using these 
restrictions the choice of sequences for use in modelling becomes very limited. Only 
14 pairs of human TCR sequences could be acquired from the database. Of these 14 
pairs, eleven were from DR1 restricted alloreactive clones while two were DR1 
restricted and specific for Influenza HA peptide 307-319. One pair was isolated 
from a DR4 restricted T lymphocyte clone present at the site of inflammation in a 
RA patient.
The fine specificity of TCR interaction with the influenza hemagglutinin
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Figure 3.2 Similarity plot for TCR V a chains. Negative values indicate greater 
similarity to antibody heavy chains while positive values greater 
similarity to antibody light chains. Only the framework regions are 
included in the plot. The total scores shown are the sum of positive 
scores and the sum of negative scores indicating the overall similarity to 
antibody light and heavy chains. Overall similarity of a  chains is greater 
to light chains than to heavy chains.
94
Chapter 3 Molecular Modelling of TCR Variable Domains
2
Totals: Light 19.56 
Heavy 9.21
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Figure 3.3 Similarity plot for TCR v p  chains. Negative values indicate greater 
similarity to antibody heavy chains while positive values greater 
similarity to antibody light chains. Only the framework regions are 
included in the plot. The total scores shown are the sum of positive 
scores and the sum of negative scores indicating the overall similarity to 
antibody light and heavy chains. Overall similarity of P chains is greater 
to light chains than to heavy chains.
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peptide HA 307-319 in the context of the DR1 (DRA, DRB1 0101) and DR4 
(DRA, DRB1 0404) was studied in the two human T cell clones derived from 
different individuals. Models of these two TCRs (HA 1.7 and cl-1) specific for the 
peptide HA 307-319 were generated and they showed that the conserved 94E in 
the TCR V a chain could interact with the lysine at position 316 in the peptide, a 
known TCR contact residue. The molecular model from the TCR HA 1.7 was 
subsequently docked on to the HA307-319/DR1 complex and the resulting complex 
was used to direct site specific mutagenesis experiments (Wedderbum et al., 1995) 
[Figures 3.4 and 3.5].
Another study was carried out by Hurley et al., 1993 to understand the 
biological consequence of DR1 microvariation. Class II molecules DR1 are naturally 
occuring variants found frequently in the human population. TCR utilised by human 
alloproliferative T lymphocyte clones which can distinguish between two 
microvariants of DR1 [DR(a,pl*0101) and DR(a,pi*0102)] were characterised by 
cDNA sequencing (Hurley et al., 1993). The two DR molecules differ only at p- 
chain residues 85 (Val/Ala) and 86 (Gly/Val). In the DR structure these residues lie 
on an a- helix at the top of the DR molecule near the end of the antigen-binding 
cleft. Although the amino acid sequence differences appear to be subtle, DR1 
molecules encoded by the two alleles may bind different repertoires of antigenic 
peptides and can be distinguished in vitro by alloreactive T lymphocytes. The effect 
of this limited diversity on aspects of the normal human immune response such as 
the binding of specific antigenic peptides and on the selection and utilisation of the 
TCR repertoire may be substantial. These clones were characterised by cDNA
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Figure 3.4 Molecular models showing the predicted interaction between TCR
HA1.7 and the HA 307-319/DR1 complex. The Va and Vp chains are 
shown in blue and orange, respectively and the MHC a  and P chains in 
pink and yellow, respectively. The peptide is shown in white and is 
orientated N terminus (right) to C terminus (left) in A) and B).
A) Sideview of the TCR- MHC complex showing the proximity of 
residue TCR Va 94E (space-filled red) to peptide residue 316K. B)
End view of the TCR-MHC complex obtained by rotation of view A) 
by 90°. The CDR3 loops of the Va and vp  chains can be seen to be 
located above the peptide while the CDR 1 and CDR2 regions are 
positioned over the MHC helices. Figures were taken from 
Wedderburn, L.R et al., 1995.
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Figure 3.5 View of the TCR-MHC complex in which the peptide-MHC
complex has been rotated through 180° with respect to the TCR.
The peptide residue 316K is seen to be outside the interaction 
interface. Figure was taken from Wedderbum et al., 1995.
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sequencing to analyse the effect of DR1 microvariation on TCR diversity and to 
understand the implications of that diversity on normal immune responses and in 
transplantation. In this thesis, five of these TCR molecules specific for the DR 
(ap 1*0101) microvariant have been modelled. In addition to these five models the 
TCR from a DR4 restricted T cell clone WM-3 isolated from the synovial fluid of a 
RA patient was also modelled.
TCRM is a modification of the antibody modelling algorithm AbM 
designed to predict the structure of the TCR VocVp heterodimer. It combines the 
advantages of knowledge based and ab initio methods. CDR loop conformations 
generated by a combination of ab initio calculations and selection of loop 
conformations from structural databases based on sequence homology and loop 
length were built on to an antibody framework (Martin et al., 1989; Searle and 
Rees, 1996 Unpublished). This method is carried out in a series of steps which are 
outlined below.
3.2.1. Sequence alignment
The sequences from the six clones were loaded onto TCRM separately and 
the alpha and beta chains were aligned against the sequence of light chain dimers 
including Rei. Gaps are inserted so as to maximise the similarity of the target 
sequence with the database sequences. The sequence is considered to be aligned 
when it is the same length as the antibody sequences against which it is being 
aligned. The framework regions of antibodies (denoted LFR1-4 and HFR1-4) are 
highly conserved and are normally easy to align.
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3.2.2. Framework selection
The alpha and beta target sequences are compared with each of the light 
chain sequences in the database in turn, giving a series of similarity scores. This 
similarity calculation is designed to find the database sequence which most closely 
matches the conserved framework regions of the target sequence. Apart from the 
beta chains of models m97723 and m97724, all the alpha and beta chains in the six 
models are most homologous to the Rei light chain. The similarity scores of each of 
the chains is shown in Table 3.2. TCR frameworks were modelled using the light 
chain dimer Rei (Epp et a l, 1975). Where the Rei and TCR sequences differed the 
TCR sidechains were inserted using a maximum overlap approach (MOP) and the 
framework minimised to a derivative of 0.1 in Discover (Biosym). In the MOP 
procedure a framework is chosen from one single structure on the basis of sequence 
similarity. Loops are then sampled from the Brookhaven database, which fit the 
required length. These loops are then scored according to sequence identity and the 
most similar loop is chosen as the final conformation.
3.2.3 Side chain construction
The CDRs were modelled onto this framework using CAMAL (Martin et 
al, 1989). The loop regions modelled in the a  and the p chains in the six models are 
shown in Table 3.3.
For loops of less than six residues, CONGEN (Bruccoleri and Karplus, 
1987) was used to generate conformations. The lowest energy conformation was 
chosen.
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TCR Chains Light chain dimer Similarity score
m86361 V a lrei 28.30
vp lrei 31.13
m97708 Va lrei 33.01
vp lrei 29.52
m97712 V a lrei 32.38
vp lrei 30.48
m97718 V a lrei 37.50
vp lrei 27.10
m97723 Va lrei 31.37
vp lbec 36.04
m97724 V a lrei 33.01
vp lbec 51.82
Table 3.2: Similarity scores of the alpha and beta chains to the most 
homologous light chain dimer framework
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TCR CDR Sequence Position Length
m86361 NYS[S(SVS)V]YLF 24-34 11
m97708 NFS[D(SVN)N]LQ 24-33 10
m97712 SYT[V(SGL)R]GLF 24-34 11
m97718 Al AYE[N(TAF)D]YFP 24-34 11
m97723 NFS[D(SVN)N]LQ 24-33 10
m97724 SYS[V(GIS)A]LH 24-33 10
m86361 YL[S(GST)L]V 50-57 8
m97708 IPSGT 49-53 5
m97712 LYSAGEE 50-56 7
m97718 A2 IRPDVSE 50-56 7
m97723 IPSGT 49-53 5
m97724 LSSGK 49-53 5
m86361 AVRFS[L(QGG)S]EKLV 92-105 14
m97708 AVSA[S(GAG)S]YQLT 88-100 13
m97712 A3 AVPT[T(TDS)W]GKLQ 90-102 13
m97718 AASKRG[A(GGT)S]YGKLT 91-106 16
m97723 AVG[D(YGQ)S]FV 88-97 10
m97724 AVY[S(QGA)Q]KLV 88-98 11
m86361 NKSQT 68-72 5
m97708 VATER 64-68 5
m97712 TKKE 67-70 4
m97718 A4 [N(KSA)K] 67-71 5
m97723 VATER 64-68 5
m97724 NIQEK 64-68 5
m86361 SPI[S(GHK)S]VS 24-33 10
m97708 SPI[S(GHT)S]VY 24-33 10
m97712 TD 1 QVD[S(QVT)M]MF 24-33 10
m97718 D l RSL[D(FQA)T]TMF 24-34 11
m97723 QVD[S(QVT)M]MF 24-33 10
m97724 EQNLNHDAMY 24-33 10
m86361 QY[Y(EKE)E]R 48-55 8
m97708 WY[D(EGE)E]R 48-55 8
m97712 i n TAN[Q(GSE)A]TY 48-57 10
m97718 D Z TS[N(EGS)K]AT 49-57 9
m97723 TAN[Q(GSE)A]TYE 48-58 11
m97724 YSHIVNDFQ 48-56 9
m86361 ASSFP[G(NRG)Y]WYGYT 92-106 15
m97708 ASSL[G(QGT)Y]EQY 92-103 12
m97712 D l SVA[G(QGT)D]EQY 94-104 11
m97718 SAS[K(TGR)G]EQY 95-105 11
m97723 SVED[R(DRV)Y]NEQF 94-106 13
m97724 ASS[L(DSW)D]TQY 92-102 11
m86361 FPNY 69-72 4
m97708 FPNY 69-72 4
m97712 PNLT 71-74 4
m97718 B4 [H(ASL)T] 71-75 5
m97723 RPNLT 70-74 5
m97724 EKKE 69-72 4
Table 3.3 Sequence position, length and conformational search construction 
scheme for each of the 48 loops, [ ] construction area, ( )=chain 
closure.
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Knowledge based methods which rely on the crystallographic database of protein 
structures have had limited success in predicting loop conformations in general 
(Tramontano et al., 1989). The MOP or canonical structure approaches have 
succeeded in modelling only five of the six CDRs in antibodies. This is due to the 
fact that the third CDR of the heavy chain, H3 is more variable in sequence, length 
and structure than any of the other CDRs. This extra variability arises from V-D-J-C 
splicing. To deal with the CDR H3 problem several groups have attempted to use 
ab initio methods to model the combining site (Bruccoleri and Karplus, 1987). In 
these methods the total conformational space accessible to a particular CDR is 
sampled. Typically the central region of the polypeptide backbone, having 
characteristic bond length and bond angles (rigid geometry), is constructed between 
the end points of the loop by a ‘chain closure’ algorithm. This algorithm was 
modified to introduce an energy minimisation procedure which greatly expanded the 
domain of conformational space searched during the chain closure procedure. This 
modification is incorporated into the conformational search program CONGEN 
(Bruccoleri and Karplus, 1987) which allows the user to choose any set of standard 
bond length and bond angles such as the CHARMM (Brooks 1983) standard 
geometry parameter sets. Other approaches such as minimisation or molecular 
dynamics either fail to saturate conformational space or are unable to deal with the 
problem of long CDRs. In all these methods, the selection criteria are defined in 
such a way so as to allow the unambiguous identification of the correct structure 
within the ensemble of candidates for each CDR. The position of variability in these 
molecules at the end of the antigen binding groove provides a unique
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model of variation
For loops of six or seven residues, Ca distance constraints within the loop 
were used to search the Brookhaven database (Bernstein, 1977) for structural 
segments which matched with a tolerance of 3.5 standard deviations. Sidechains 
were replaced with those of the desired loop sequence in CONGEN and were 
energy screened using a solvent modified Gromos potential (Aqvist, 1985). A 
torsional screen using the initial database loops was then performed to choose the 
final conformation. For loops greater than seven residues a combination of database 
searching and conformational searching for the central five residues of the loop was 
performed. The energy screen and torsional screen were then performed on the 
generated conformations. In all cases each loop was constructed in the absence of 
the others. Distance constraints for antibody CDR loop regions were used to extract 
database conformations for the CDRs. For CDR Al and CDR B1 the CDR LI 
constraints were used. For CDR A2 and CDR B2, CDR L2 and CDR H2 
constraints were used respectively. For both CDR A3 and B3 the CDR L3 
constraints were used. The five residue segment predicted to be the D-E loop in 
both chains was also modelled using CONGEN. The final model was energy 
minimised in Discover to a derivative of 0.1.
Since there is no complete ap  TCR structure the accuracy of this method 
was tested by generating a model of CD4, a member of the Ig superfamily more 
distantly related to antibodies than TCR. When this model was compared with the 
X-ray structure of CD4, the CDR had the following backbone RMS deviations: 
CDRAl and B1 (1.6 A), CDRA2 and B2 (2.4 A) and CDRA3 and B3 (1.3 A)
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[Wedderbum et al., 1995]. This close agreement with the x-ray structure gave 
sufficient confidence to proceed to the construction of the TCR model.
3.3 Comparison of the eizht models generated from the DR
restricted T cell clones.
The two TCR models generated from HA307-319/DR1- specific T cell 
clones which also recognise peptide presented by DR4 (DRB 1*0404) Class II 
molecules by using the TCRM algorithm (Wedderbum et al., 1995) were compared 
to the six models generated from the DR restricted clones in this thesis.
In all these models the p sheet framework is conserved and the 
arrangement of the antigen binding loops is similar to that in antibodies with the 
third hypervariable loop of each domain sandwiched between the first and the 
second hypervariable loop pairs (Figure 3.6) This arrangement of CDRs has 
previously been used to suggest a mode of binding of the MHC to the TCR in which 
the first and second CDRs of each chain interact with the MHC a  helices and the 
two CDR3 loops interact with the peptide (Davies and Bjorkman, 1988; 
Wedderbum e ta i ,  1995).
3.3.1 CDR1
The conformation of CDR A 1 in all the eight models appears to be 
stabilised predominantly by hydrophobic interactions and not by intraloop hydrogen 
bonding as observed in CDR Bl. Residues Tyr25 and Leu (at position 32 in 
m97724, m97708 and m97723 and at position 33 in m97712, m86361, HA 1.7 and
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E) F)
Figure 3.6 C a backbone worms of the six models [A) m86361 B) m97708,
C) m97712, D) m97718 E) m97723 and F) m97724]. Loop A l is coloured 
yellow; A2, red; A3, green; A4, brown; B 1, blue; B2, magenta; B3, 
cyan and B4, ochre. The framework regions are coloured rose pink. 
Figures were generated using GRASP.
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cl-1) which are highly conserved in mouse and human a  chain sequences pack 
against each other in the A1 loop. The most common substitution at both positions 
is phenylalanine ( position 25 in m97708 and m97723 and position 33 in model 
m97718) which preserves the hydrophobic packing interactions (Table 3.4). In 
contrast, CDR1 loops in VL and VH domains is mainly stabilised by the 
hydrophobic side chain of residue 29 which intercalates between two p- pleated 
sheets. The models m86361, cl-1 and HA1.7 have identical CDR A l which may be 
significant in that they contact similar a  helices in the DR molecule.
The conformation of CDR B1 in the crystallised P chain is stabilised by its 
interaction with residue Gln25 buried within the interior of the domain beneath the 
hypervariable loop. Both the O and the N of the side chain amide group of Gin 25 
form a total of 3 hydrogen bonds to main chain atoms of CDR B1 thus providing a 
supporting scaffold for the loop as it passes from one P sheet to the other. This 
pattern is seen in the models m97724, cl-1 and HA1.7. In the other models, position 
25 is occupied by a small residue proline(2), valine(2) or serine(l). Residue 29 is 
located approximately midway along the Ig CDR1 forming an optimum anchorage 
point to stabilise the conformation of this loop. This position is occupied by Phe, 
Leu, He or Val. Only in a very small fraction a polar residue occurs at this position. 
In the TCR this position is mainly occupied by histidine with its sidechain partially 
exposed to the solvent. Histidine is substituted by valine in models m97712 and 
m97723 and by gin in model m97718. Either methionine or valine is present at the 
penultimate position (Table 3.5).
The TCRs show a more restricted range of CDR lengths than antibodies.
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TCR Model Al loops
m97708 N F S D s V N N L Q
m97723 N F S D s V N N L Q
m97724 S Y s V G I S A L H
m97712 S Y T V s G L R G L F
m86361 N Y S S s V S V Y L F
cl-1 N Y S S s V S V Y L F
HA 1.7 N Y S s s V S V Y L F
m97718 A Y E N T A F D Y F P
Table 3.4 Al loops of the eight TCR models derived from DR1 and DR4 
restricted clones. The second position is always occupied 
by a tyrosine or phenylalanine. Leucine is conserved at 
the penultimate position in all models except model m97718.
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TCR Model B1 loops
m86361 S P I S G H K S V S
m97708 S P I S G H T S V Y
m97724 E Q N L N H D A M Y
m97712 Q V D S Q V T M M F
m97723 Q V D S Q V T M M F
cl-1 A Q D M N H E Y M S
HA 1.7 V Q D M D H E N M F
m97718 R S L D  F Q A T  T M F
Table 3.5 B 1 loops of the eight TCR models derived from DR1 and DR4 
restricted clones. Either methionine or valine is present at the 
penultimate position.
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Length of Al and B1 in TCRs is never longer than 12 residues. In these eight 
models, the length of Al varies between 10 and 11 residues. In antibodies the 16 
and 17 residue CDR LI have a bulge in the side of the loop. The shorter length of 
the TCR CDR suggests that TCR sequences do not have a bulge in the loop.(Figure 
3.7). Plot of A l and B1 loop backbones for the six models m97708, m97712, 
m97718, m97723, m97724 and m86361 is shown in figures 3.8 and 3.9 
respectively.
3.3.2 CDR2
There is a conserved serine at the third position in all A2 loops except in 
model m97718 (Table 3.6). The B2 loops in these models are varied (Figure 3.10)
Length of A2 varies between 5 and 7 which is similar to the length of Ab 
L2. The length of B2 varies between 8 and 11 residues which is considerably shorter 
than H2. The second CDRs show a variation in their length which suggests that B2 
may be more involved in MHC contacts rather than the shorter A2 (Table 3.7)
As in the case of A l, the two models m86361 and cl-1 have identical A2 
with a slight variation seen in the model HA 1.7. It is relevant that both the Al and 
A2 loops in these three models are nearly identical. This supports the hypothesis 
that the A l and A2 contacts the non polymorphic residues of the DR molecule. Plot 
of A2 and B2 loop backbones for the six models m97708, m97712, m97718, 
m97723, m97724 and m86361 is shown in figures 3.11 and 3.12 respectively.
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Figure 3.7 Overlapped CDR1 loops (Al : yellow; B1 : blue) of the six models 
(m86361, m97708, m97712, m97718, m97723 and m97724). The 
framework residues are coloured green. The chains have been 
overlapped using five residues either side of the CDR.
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Figure 3.8 Plot of Al loop backbones for the six models (top: m97718, m86361 
and m97708; bottom: m97712, m97723 and m97724). Figures were 
generated using Insight.
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Figure 3.9 Plot of B1 loop backbones for the six models (top: m86361, m97708 and 
m97718; bottom: m97723, m97724 and m97712). Figures were 
generated using Insight.
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TCR A2 loops
m97708 I P S G T
m97723 I P S G T
m97724 L S  S G K
m97712 L Y  S A G E E
m97718 I R P D V S E
HA1.7 Y T S A A T L V
m86361 Y L S G S T L V
cl-1 Y L S G S T L V
Table 3.6 A2 loops of the eight TCR models derived from DR1 and DR4 
restricted clones. There is a conserved serine in the third 
position of all models except model m97718.
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Figure 3.10 Overlapped CDR2 loops (A2: red; B2 magenta) of the six models 
(m86381, m97708, m97712, m97718, m97723 and m97724). The 
framework residues are coloured green. The chains have been 
overlapped using five residues either side of the CDR. Figures were 
generated using Insight.
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TCR Model B2 loops
m86361 Q Y Y E K E E  R
m97708 W Y D E G E E R
m97724 Y S H  I V N  D F Q
m97718 T S N E G S K A T
m97712 T A N Q G S E A T Y
cl-1 Y S V G A G I  T D Q
HA 1.7 F S Y D V K M K E K
m97723 T A N  Q G S E A T Y E
Table 3.7 B2 loops of the eight TCR models derived from DR1 and DR4 
restricted clones.
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Figure 3.11 Plot of A2 loop backbones for the six models (top: m97718, m86361 and 
m97708; bottom: m97712, m97724 and m97723). Figures were generated 
using Insight.
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Figure 3.12 Plot of B2 loop backbones for the six models (top: m86361, 
m97708 and m97712; bottom: m97718, m97723 and m97724).
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3.3.3 CDR3
X ray analysis of antigen antibody complexes shows that the loops created 
by the V(D)J junction (CDR3) of Ig H and L chains are always involved in Ag 
contact. Similarly the CDR3 loop of both a  and p TCR chains seem critical for 
peptide recognition. The CDR3 length distribution of all known Ag receptor 
polypeptides from mouse and humans was analysed by Rock et al (1994).
In Ig light chains, CDR3 regions are short and of conserved length but 
those of H chain are long with a wide range of lengths. This may reflect the fact that 
Igs recognise a variety of different antigenic surfaces, from small molecules to large 
pathogens. For ap  TCR chains, the CDR3 length distributions are significantly 
constrained and are about equal in length. This probably reflects the requirement for 
a  and P chains of the TCR to contact both the MHC and bound peptide. In yS 
TCRs the y chain CDR3 loops are short with a narrow length distribution and the 8 
chain CDR3s are long with a broad length distribution.
By considering all elements that contribute to the variability of the 
junctional (CDR3) region such as the number of D and J elements used, the D 
element reading frame, junctional diversity and N region nucleotide addition, Davis 
and Bjorkman calculated that the number of possible CDR3 sequences was the 
largest for yS TCR and least for Ig (irrespective of somatic mutation) and 
intermediate for ap  TCR.
Length of A3 and B3 in these models varies between 10 and 16 residues. In 
all the models the CDRs A3 and B3 are sandwiched between the CDRs A l, A2 on 
one side and B 1 and B2 on the other side. There is a high concentration of glycines
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in both A3 and B3. The disorder that was observed in the CDR A3 loops in the 
homodimer was not observed in the case of these heterodimers. There is a motif AV 
present in all the models except model m97718 where valine is substituted by 
alanine (Table 3.8).
It has been proposed the CDR A3 contacts the central portion of the 
peptide while CDR B3 contacts the N-terminal portion. Loops A l and A2 interact 
primarily with the a l  helix of the Class II molecule while B1 and B2 interact with 
the a2  helix.
There is a EQY motif present in the B3 loop in the 5 models derived from 
DR1 alloproliferative clones.(Table 3.9). The exceptions being model m97723 
where tyrosine is replaced by phenylalanine and in model m97724 glutamate is 
replaced by threonine. This motif is not seen in models m86361, cl-1 and HA1.7. 
This may be significant as these three TCR molecules present peptides that are DR4 
restricted. Model m86361 is characterised by a long B3 loop. Presence of common 
motifs in the CDR3 regions of these TCR models suggests the recognition of a 
limited repertoire of peptides by DR1 alloproliferative clones (Figure 3.13). Plot of 
A3 and B3 loop backbones for the six models m97708, m97712, m97718, m97723, 
m97724 and m86361 is shown in figures 3.14 and 3.15 respectively.
3.3.4 HV4
Length of A4 and B4 varies between 4 and 5 residues. The fourth 
hypervariable loop A4 is five residues long except in the case of model m97712 
(Table 3.10). The B4 loop is four residues long except in the case of m97723 and
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TCR A3 loops
m97723 A V G D Y G Q S F V
m97724 A V Y S Q G A Q K L V
cl-1 A V S E T G G F K T I
m97708 A V S A S  G A G S Y Q L T
m97712 A V P T T T D S W G K L Q
HA1.7 A V S E S P F G N E K L T
m86361 A V R F S L Q G G S E K L V
m97718 A A S K R G A G G T S Y G  K L
Table 3.8 A3 loops of the eight TCR models derived from DR1 and DR4 
restricted clones. The motif AV is present in all the models 
except in model m97718 where the valine is substituted by 
alanine.
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TCR Model B3 loops
m97718 S A S  K T G R G E Q Y
m97712 S V A G Q G T D E Q Y
m97724 A S S L D S W D T Q Y
cl-1 A S R D F L S G E Q Y
HA 1.7 A S S T G L P Y G Y T
m97708 A S S L G Q G T Y E Q Y
m97723 S V E D R D R V Y N E Q F
m86361 A S S F P G N R G Y W Y G Y T
Table 3.9 B3 loops of the eight TCR models derived from DR1 and 
DR4 restricted clones. In the five DR1 alloproliferative 
clones, a EQY motif preset in the TCR models. Exceptions 
are the model m97723 where the tyrosine is replaced by 
phenylalanine and model m97724 where the glutamate is 
replaced by threonine.
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Figure 3.13 Overlapped CDR3 loops (A3: ochre; B3: cyan) of the six models 
(m86361, m97708, m97712, m97718, m97723 and m97724). The 
framework residues are coloured green. The chains have been 
overlapped using five residues either side of the CDR. Figures were 
generated using Insight.
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Figure 3.14 Plot of A3 loop backbones for the six models (top: m97708, m86361 and 
m97718; bottom: m97712, m97724 and m97723). Figures were generated 
using Insight.
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Figure 3.15 Plot of B3 loop backbones for the six models (top: m97708, m86361 
and m97718; bottom: m97723, m97712 and m97724). Figures were 
generated using Insight.
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TCR A4 loops
m97723 V A T E  R
m97708 V A T E  R
m97724 N I Q E  K
m97712 T K K E
m97718 N K S A K
HA 1.7 K K S E  T
cl-1 N K S Q T
m86361 N K S Q T
Table 3.10 A4 loops of the eight TCR models derived from DR1 and DR4 
restricted clones. There is a high concentration of charged 
residues in all the loops.
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m97718 (Table 3.11). As these loops form part of the relatively flat continuous 
surface with the CDRs, they could potentially be involved in interactions with the 
peptide-MHC complex. Plot of A4 and B4 loop backbones for the six models 
m97708, m97712, m97718, m97723, m97724 and m86361 is shown in figures 3.16 
and 3.17 respectively.
In the A4 loops of the five models the last two residues are always charged 
( Table 3.10). In m86361 and cl-1, there is no charged residue seen at either of these 
positions.
3.3.5 Frequency o f residues
In the Va CDRs, there is a high frequency of serine, alanine, valine and 
glycine while in the Vp CDRs there is a high frequency of serine, threonine, tyrosine 
and glutamate.
3.3.6 Speculations about canonical classes
Chothia and Lesk proposed that antibodies have only a few main chain 
conformations or canonical structures for each CDR. Comparison between the 3-D 
structures of different Fab fragments show that all the CDRs can be assigned to one 
of a restricted number of main chain conformations or canonical structures with the 
exception of the heavy chain CDR3. Sequence variations at most positions in the 
loops do not affect the main chain conformations but variation at a few key 
positions gives rise to specific interactions which cause a switch to a different 
canonical conformation. A canonical class is defined by the number of residues and
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TCR Model B4 loops
m86361 F P  N Y
m97708 F P  N Y
m97724 E K K  E
HA 1.7 E K K  E
cl-1 S T  T E
m97712 P N  L T
m97723 R P  N L T
m97718 H A  S L T
Table 3.11 B4 loops of the eight TCR models derived from DR1 and DR4 
restricted clones.
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Figure 3.16 Plot of A4 loop backbones for the six models (top: m97708, m97718 and 
m86361; bottom: m97712, m97724 and m97723). Figures were 
generated using Insight.
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Figure 3.17 Plot of B4 loop backbones for the six models (top: m97708, m86361 
and m97718; bottom: m97712, m97724 and m97723). Figures were 
generated using Insight.
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the presence of particular residues at key positions in the loop and or surrounding 
framework. These classes are apparent in the large number of antibody crystal 
structures available. However in the case of TCR, the crystal structure of only a 
single V a and a single Vp fragment are available. The CDRs in the eight models are 
assorted into classes depending on the similarity in length and conformation. 
However these speculations can only be confirmed when several TCR crystal 
structures are solved.
When each CDR is examined individually, the CDRs appear to be diverse. 
On the basis of just differences in length and conformation, five possible canonical 
classes of A2 loops are seen in the TCRs from DR restricted clones namely Class 1 
(containing the 5 residue loops from m97708 and m97723); Class 2 (containing the 
5 residue loop from m97724); Class 3 (containing the 7 residue loop from m97712); 
Class 4 (containing the 7 residue loop from m97718) and Class 5 (containing the 8 
residue loops from m86361, HA 1.7 and cl-1). Similarly 5 canonical classes of A4 
loops are also seen in these TCRs, namely Class 1 (containing the 5 residue loops 
from m97708 and m97723); Class 2 (containing the 5 residue loop from m97724); 
Class 3 (containing the 4 residue loop from m97712); Class 4 (containing the 5 
residue loop from m97718) and Class 5 (containing the 5 residue loop from 
m86361).
3.4 Results and Discussion
Structural information on the TCR is limited to models mainly due to 
problems in producing protein suitable for crystallographic analysis. In the absence
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of a crystal structure of the complete TCR, molecular modelling was carried out to 
predict its structure by a modification of the antibody modelling program AbM. This 
method makes use of the fact that the extracellular portion of the TCR resembles a 
Fab fragment. Prediction of the TCR structure from the primary sequence requires 
modelling of the conformation of the CDR loops on to the known framework or p- 
barrel structure.
Initially the TCR sequences were aligned against antibodies. This is 
relatively easy because of the high conservation of certain key residues such as the 
cysteines at the start of CDR1 and CDR3, a WY motif at the end of CDR1, the 
LLIY motif at the start of CDR2, an RF motif at the end of CDR2 and an FG motif 
after CDR3.
The TCR a  and P chain frameworks show characteristics of both light and 
heavy chains. The residue motifs at the ends of the CDRs and the interface residues 
between the chains show more light chain character while the lengths and sequences 
of both CDR A3 and B3 regions are more similar to heavy chains than to light 
chains. The non CDR loops in the framework other than the D-E loop all have the 
same length as antibody k chains. In the similarity plots, regions of the sequence 
were seen to be similar to each chain type but the data for interface residues 
suggest that the two chains may associate as in the case of a light chain dimer 
(Novotny and Haber, 1985). This led to the choice of a light chain dimer as the 
framework structure in building the TCR model. The CDRs were then modelled 
onto this framework using CAMAL.
Accuracy of this method was tested by generating a model of CD4, a
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member of the Ig supeifamily more distantly related to Abs than TCR. All the CD4 
CDR equivalent regions were modelled accurately. Problems arose only in the case 
of CDR2 which has a different conformation to either light or heavy chains. It is 
more similar to a heavy chain CDR than a light chain CDR and had to be modelled 
using a heavy chain take off angle. There was close agreement of the CD4 model 
with the x-ray structure which gave enough confidence to build the model.
The six models generated by this method suggest a mode of binding of the 
MHC to the TCR in which the first and second CDRs of each chain were over the 
MHC a  helices and the CDR3 loops were above the peptide. This explains the high 
variability of the CDR3 regions as compared to the other CDRs. CDR A1 and A2 
contact one a  helix while B1 and B2 contacts the other. The D-E loops interact 
with the MHC and are variable. The CDR A1 does not display as wide a length 
distribution as CDR LI in antibodies. There are no A 1 loops longer than 12 residues 
which means that they do not have the bulge seen in LI loops. In the modelled 
arrangement of the TCR MHC complex such a bulge would clash with the MHC a  
helix.
Five TCR utilised by human alloproliferative T lymphocyte clones which 
can distinguish between two microvariants of DR1 [DR(a,(31*0101) and 
DR(a,pl*0102)] have been modelled. Since six different V a and 7 Vp segments 
are used by the nine DR (a,p 1*0101) specific clones it appears that specific V 
segments are not required to recognise a microvariant of the DR1 alloantigen. The 
same V a (17.1-V, 22.1, 13.1) and Vp (2.1, 4.1-V) segments are seen in more than 
one TLC and these TLC are derived from different individuals. Thus it appears that
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the usage of V segments in TCR which recognise DR (a,p 1*0101) is non random. 
In the five models two V a (13.1) and 2 Vp (4.1-variant) gene segments are 
repeated. Because the majority of the primary amino acid sequence and presumably 
the resultant 3-D conformation are shared by the 2 DR1 molecules, use of the same 
V gene segments is expected. The non random V gene segment utilisation specific 
for DR1 molecules differs from that observed in other alloreactive TCR specific for 
DR4 (VP 6 and VP 8.2), DPw2 (Vp 3.3) and B27 (VP 4 and VP subgroup 4) and 
has a preference for V a 17.1-V, 22.1, and 13.1; and Vp 2.1, 4.1, 5.1 and 18.1. The 
nonrandom usage may reflect the recognition of a common DR1 framework. 
However since the same Vp segment can be used to recognise both Class I (HLA- 
B27) and Class II (DR1) alloantigens, this interaction must be flexible. In general, 
the number of different Vp families utilised seem to be much more restricted than 
V a families.
Since it has been postulated that the V gene segments interact with DR 
molecules through CDR1 and CDR2 regions these regions were examined for 
sequence similarities. Although shared residues and lengths are seen, these regions 
are found to vary even within a related subgroup. Comparison of A1 and A2 
regions in these 5 DR1 models shows more extensive sharing of specific residues as 
compared to the B1 and B2. This conflicts with the observation noted in the 
original study. It is interesting to note that the three models m86361 (DR4 
restricted) , cl-1 and HA 1.7 (flu specific , DR1 restricted) have identical A1 loops 
and very similar A2 loops. It may be possible that these three TCR contact the same 
residues on the DR molecule. B 1 and B2 loops do not show any identity. However
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this difference in conservation may suggest that the a  and (3 chains perform different 
functions. Majority of Va and Vp sequences observed are identical to previously 
reported sequences which suggests that the variability within the human population 
is limited. The two DR1 microvariants may have been selected for altered Ag 
binding profiles. Variation in the binding of self peptides may result in the 
recognition of DR1 molecules by different sets of TLC. A3 and B3 regions were 
then examined for common motifs which may indicate recognition of a limited 
peptide repertoire. Although in this particular study, a motif EQY is seen at one end 
of the B3 loops in the 5 DR1 models and a motif AV is seen at the other end in the 
A3 loops, it is not really clear what roles these motifs play in the actual recognition. 
It is possible that these particular five molecules bind a limited repertoire of 
peptides.
It can be concluded that TCRM can be used to generate models of the 
TCR which have predictive value. Structural information obtained from the a  chain 
has not yet been incoiporated into the TCRM algorithm. This algorithm can be 





4.1 Sequence analysis o f TCR Va and VB zenes
Various conclusions can be drawn from the sequence analysis of TCR Va 
and V|3 genes. The overall diversity (calculated by determining the APC and MPI 
values) of different TCR Va and VP sequence sets with random peptide and MHC 
restriction was found to be much higher than that found in TCR Va and Vp 
sequence sets with same peptide and MHC restriction (Tables 2.2 and 2.3). 
Typically, TCR Va sequences from HLA-A2.1 restricted flu matrix peptide specific 
clones (Group 1) have APC and MPI values of 16.66 and 22.22 respectively as 
compared to 0.0 and 4.76 for Class I restricted sequences (with no sequenced 
partners) [Group 4]. In the case of Vp sequences, the APC and MPI values of 
HLA-A2.1 restricted flu matrix peptide specific clones are 29.41 and 41.17 as 
compared to 5 and 15 for Class I restricted sequences (with sequenced partners).
The overall similarity of the sequences which have the same peptide and 
MHC restriction is higher than those with random peptide and MHC. Typically, 
TCR V a sequences from HLA-A2.1 restricted flu matrix peptide specific clones 
(Group 1) have a plotsimilarity value of 0.625 as compared to 0.1 for Class I 
restricted sequences (with sequenced partners) [Group 4]. In the case of VP 
sequences, the plotsimilarity value of HLA-A2.1 restricted flu matrix peptide 




CDRs of sequences with same peptide but random MHC restriction are 
also more similar as compared to the CDRs in sequences with random peptide and 
MHC. Typically the plotsimilarity values of CDR1, CDR2 and CDR3 of DR 
restricted mbp specific TCR Va sequences (Group 2) are 0.5, 0.35 and 0.325 
respectively as compared to 0.05, 0.05 and 0.325 seen in the case of Class I paired 
TCR Vp sequences (Group 4). Similarly the plotsimilarity values of CDR1, CDR2 
and CDR3 of DR restricted mbp specific TCR Vp sequences (Group 2) are 0.675, 
0.625 and 0.625 respectively as compared to 0.05, 0.05 and 0.375 seen in the case 
of Class I paired TCR Vp sequences (Group 4).
When the CDRs are individually examined by using a simple scoring 
scheme derived from the Gribskov table, following trends are seen.
CDR1
It is found that corresponding positions in CDR1 of sequences with same 
peptide but random MHC restriction (Group 2) have higher scores than sequences 
with random peptide and MHC (Group 4) which are less similar. Typically the 
average score of CDR1 in mbp specific DR restricted TCR Va sequences (Group 2) 
is 0.57 as compared to 0.22 in the case of Class I restricted TCR Va sequences 
(Group 4). Similarly in the case of mbp specific DR restricted TCR VP sequences 
(Group 2) the average CDR1 score is 0.55 as compared to 0.2 in the case of Class I 
restricted TCR v p  sequences (Group 4).
CDR2
Similarly it was found that corresponding positions in CDR2 of sequences
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with same peptide but random MHC restriction (Group 2) have higher scores than 
sequences with random peptide and MHC (Group 4) which are less similar.
An average score of 0.60 is seen in the case of CDR2 of mbp specific DR 
restricted TCR Va sequences as compared to an average score of 0.15 in CDR2 of 
Class I restricted TCR Va sequences with random peptide and MHC specificity. 
Similarly an average score of 0.64 is seen in the case of CDR2 of mbp specific DR 
restricted TCR Vp sequences as compared to an average score of 0.22 in CDR2 of 
Class I restricted TCR Vp sequences with random peptide and MHC specificity. In 
the case of CDR1 and CDR2, the similarity observed in the sequence sets with the 
same MHC and peptide specificity also reflects conservation of residue character at 
the individual positions.
CDR3
Even though the CDR3s of lev specific murine TCR V a sequences show 
higher average scores as compared to sequences with random peptide and MHC 
specificity (Class I restricted sequences), the CDR3s do not show a sharp decrease 
in residue similarity at corresponding positions in sequence sets across the four 
groups. The average scores of CDR3s do not seem to differ dramatically when the 
specificity is changed. In the case of CDR3, the similarity observed in the sequence 
sets with the same MHC and peptide specificity reflects conservation of residue 
character at the individual positions. The average similarity scores of CDR3 
positions in sequences with random MHC and same peptide specificity (0.39 for 
mbp specific DR restricted TCR V a sequences) are comparable to the scores seen 
in sequences with random peptide and MHC specificity (0.38 for Class I restricted
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TCR V a sequences). CDR3 positions in mbp specific DR restricted TCR Vp 
sequences and Class I restricted TCR v p  sequences vary in their scores only at 
middle positions as compared to average scores in other cases. Thus the nature of 
conservation among these sets can be studied by using a scoring scheme derived 
from the Gribskov table.
4.2 TCR Modellin2
The use of new ab initio methods and the available TCR a  and p chain 
structure enables the prediction of structures for which only the amino acid 
sequence is known. Using a combined algorithm which generates TCR Fv 
frameworks from a crystallographic database, and predicts CDR conformations by a 
number of methods, models with predictive value can be generated.
The residue motifs at the ends of the CDRs and the interface residues 
between the two TCR V a and Vp chains show a greater similarity to the antibody 
light chains. Similarity plots also suggest a high light chain character in both the 
chains which led to the choice of light chain dimer framework for the modelling of 
TCRs.
Various conclusions can be drawn from the molecular modelling of the 
TCR variable domains of DR restricted clones. TCR Model m86361 was generated 
from a DR4 restricted T lymphocyte clone isolated from the site of inflammation of 
a rheumatoid arthritic patient (Korthauer, U; 1992). The five other models were 
generated from alloproliferative T lymphocyte clones (Hurley, C.K., 1993).
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TCR models show a conserved ‘p barrel’ structure or framework region. 
The characteristic folding pattern of Ig domains, first seen in the Fab structure 
determined by Poljak and colleagues. It consisted of two antiparallel p-sheets 
packed to form a P sheet ‘sandwich’, the two halves of the sandwich being held 
together by a disulphide bond.
Each CDR is a loop connecting two p- strands and has a fixed orientation 
on the framework depending on its length and other characteristic sequence motifs. 
Due to their close proximity to one another, mutational changes introduced into a 
CDR can be propagated to adjacent CDRs or to the framework itself. Although the 
three dimensional structure of Fv regions is well conserved they are not identical in 
all TCRs.
Depending on the overall topography of the antigen combining site, 
antibodies are classified into three groups, namely cavity antibodies, groove 
antibodies and planar antibodies. Similarly the TCR models can be differentiated on 
the basis of surface topology exhibited by their combining site. Models m97723 and 
m97724 clearly show a flat or planar topology as seen in Hy-Hel-10 antibody 
(Padlan et al., 1989). However the four other models show a protrusion of the 
CDR3 loops not seen in the case of antibodies (Figure 3.6). They exist due to the 
difference in the binding mechanism of both antibodies and TCRs. The CDR3 loops 
must protrude from the surface to make contact with the peptide lying in groove of 
MHC helices. This suggests a reason why the TCR does not bind isolated peptide 
because an exposed pair of loops cannot form a strong association with the peptide. 
Only when the peptide lies in the MHC groove a strong non covalent association
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could be formed. When the groove is empty the binding affinity of the TCR for the 
MHC will be reduced because water will be present in the groove reducing the 
hydrophobic interactions between MHC and TCR. Most of the binding energy in 
antibody -antigen complexes is contributed by these interactions while the specificity 
is produced by hydrogen bonds or charge charge interactions.
Groove or cavity type topology is not seen in these models which does not 
necessarily mean that they do not exist in nature. It is interesting to note that the p 
chain in the two models m97723 and m97724 were modelled on the lbec light chain 
dimer while all the other chains in the six models were found to have greater 
homology to lrei light chain dimer (Table 3.2).
The models generated so far indicate a mode of binding of the TCR to the 
MHC and peptide. Several features of TCRs can be explained by this arrangement. 
TCRs show less defined regions of variability than antibodies. In the five models, 
two V a and two Vp gene segments are used. Use of the same V a segments is 
expected at the sequence level as majority of the same amino acid sequence and the 
resulting 3-D conformation are shared by the two DR1 micro variants. Comparison 
of A1 and A2 loops in these 5 DR1 models shows that there is more extensive 
sharing of specific residues as compared to B1 and B2 (B1 and B2 loops do not 
show much similarity in sequence). However when the A2 and B2 loops are 
overlapped it is found that they do not show a similar conformation. Identical A1 
and very similar A2 loops are observed in the three models m86361 (DR4 
restricted) and the flu specific DR1 restricted TCR cl-1 and HA1.7. This may 
suggest that these TCR molecules contact the same residues on the DR molecule.
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As A1 and A2 are found to be more homologous than B1 and B2 it can be 
concluded that these TCR molecules will also recognise peptide/MHC complexes in 
a similar orientation to that seen in the case of flu peptide HA 307-319/DR 1/ HA 1.7 
TCR complex (Figure 3.4) where the relatively conserved TCR V a chain is placed 
over the invariant DRa helix and the TCR VP is placed over the polymorphic DRP 
chain.
This suggests that TCR V a and Vp chains perform different functions in 
recognition. Generally the majority of V a and v p  sequences observed are identical 
to previously reported sequences suggesting that variability within the human 
population will be limited. This observation supports other studies of V gene 
segment diversity which have demonstrated only subtle allelic variation. When the 
CDR3 regions, the region of the TCR postulated to interact with peptide, was 
examined common motifs were found which seem to suggest that they probably 
bind a limited repertoire of peptides and it may suggest a similar kind of binding 
mechanism to the peptide antigen. A single model of TCR (m86361) infiltrating the 
rheumatoid synovium is also presented. This model shows also shows similarity to 
the TCR molecules from DR1 restricted flu HA specific clones.
4.3 Implications from sequence analysis and modelling
The advent of PCR-based methods for the evaluation of TCR repertoire 
has increased the sensitivity and scope for investigation of T cell populations in the 
rheumatic diseases. PCR analysis of TCR usage in synovial samples of patients with 
autoimmune diseases like rheumatoid arthritis gives variable results with some
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groups claiming evidence for the effect of uncharacterised superantigens expanding 
or deleting T cells with particular Vp regions while others have seen oligoclonal 
expansion of TCR V a and Vp genes where a specific TCR is expanded against a 
background of polyclonal nonexpanded receptors.
The sequence and structural data here suggest that this simple model 
whereby T cell oligoclonality is dictated by the degree of variation in MHC alleles 
may be too simplistic. If true, it would be expected that closely similar MHC alleles 
containing identical peptides would elicit closely similar TCRs. This is clearly not 
the case. Small variations in sequence in either the a l  or a2 helix at positions that 
contact peptide may cause sufficiently large conformational perturbations as to 
reduce binding below the required threshold. However a different TCR may see this 
altered complex more readily. This leads to the proposal that extensive variation in 
T cell clonality may occur even for closely similar MHC-peptide complexes. 
Different MHCs are expected to select different CDR1 or CDR2 sequences or 
structures (different TCRs). Small changes in peptide sequence propagate changes 
in a l  and a2 conformation which is sufficient to disrupt TCR binding. This has been 
seen in the case of antibodies where a single residue difference between hen egg 
white lysozyme (HEL) [Q121 to H 121] and turkey egg white lysozyme (TEL) 
causes a large drop in affinity of the murine monoclonal anti- turkey egg lysozyme 
antibody D1.3 (Braden et al., 1996). This suggests that very small changes at a 
protein- protein interface can have dramatic effects on binding affinity. This leads to 
the proposal that extensive variation in T cell clonality may occur even for closely
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similar MHC-peptide complexes. When peptides are presented in the context of 
different MHCs, the expected selection of different TCRs is seen.
One consequence of this effect in autoimmune diseases such as rheumatoid 
arthritis (RA) where an unknown antigen driven response can give rise to a large 
number of T cell clones. One suggestion for therapeutic intervention in RA and 
related diseases is the use of monoclonal antibodies to delete particular members of 
a polyclonal cell population (T cells, B cells etc).
Monoclonal antibodies exert their influence on the immune system in two 
ways namely, immunosuppression and tolerance induction. They have been effective 
in controlling several models of autoimmune diseases including experimental 
autoimmune encephalomyelitis (EAE), experimental myasthenia gravis, autoimmune 
arthritis and adjuvant or collagen arthritis.
In several rodent EAE models of multiple sclerosis, a limited range of T 
cell receptors specific for myelin basic protein-MHC class II complexes are 
expressed by pathogenic T cells capable of transferring disease. In the mouse PL/J 
strain EAE model the disease is induced by CD4 T cell clones specific for myelin 
basic protein peptide (MBP1-9) restricted by I-Au utilise a limited set of TCR 
rearrangements comprising a single Va4 member with bias towards VP8.2 and 
considerable junctional conservation (Heber-Katz et al., 1989). EAE has been 
treated by therapies based on structural features of the trimolecular complex such as 
peptide analogues, anti-TCR Vp antibodies and TCR peptides from CDR2 and 
CDR3 (Acha-Orbea et al., 1988; Wraith et al., 1989; Offner et al., 1991).
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However in the case of RA, study of the TCR repertoire in rheumatoid 
synovitis gives conflicting results (Sottini et al., 1991; Paliard et al., 1991). Since no 
consistent pattern has emerged with respect to synovial over or under representation 
of particular variable regions and expansion of particular variable regions and 
expansion of particular junctional regions it might be impractical to target T cells 
directly.
Therapeutic strategies may be better targeted at the peptide binding site 
within the MHC where drugs may be derived that can bind to those parts of the 
pocket not normally susceptible to polymorphism.
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APPENDIX-1
Gloop2 Fv Expression And Purification
A l . l  Introduction 
Al.1.1 Structure of the antibody molecule
The antibodies form a central part of the body’s defence against infectious 
agents and other potentially harmful foreign macromolecules. Their function is to 
bind to surfaces on the antigen in a high affinity complex and trigger its 
neutralisation and elimination, either by stimulating phagocytic cells or by activating 
the complement cascade to cause lysis of cells. The antibody structure combines 
specific epitope recognition and common effector functions in a single multidomain 
molecule. There are five major classes of Ig (IgA, IgD, IgE, IgG and IgM) that 
vary both in structural and functional properties.
An IgG molecule is a multichain protein, consisting of two identical heavy 
(y-type) and two identical light ( both either k  or -X type) chains linked by 
disulphide bonds to form a Y shaped molecule. There are two antigen binding sites, 
one on each of the Fab ("antigen binding fragment") arms, and one Fc 
("crystallisable fragment") region which is the site for the common effector 
functions. The Fabs are linked to the Fc region by the hinge region, which varies in 
length and flexibility in the different antibody classes and isotypes.
The tight chain is composed of one variable (V) and one constant (C) 
domain and the heavy chain one V and three C domains. The V and C domains have
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little sequence homology to each other but there is extensive homology within the V 
and C domains. The cysteines of the disulphide bridge between the sheets and the 
tryptophan that packs against it are the only residues that are conserved in all Ig 
domains (Lesk and Chothia, 1982 ). These residues form the central core of the 
domain interface.
Each V domain contains three hypervariable regions of sequence, termed 
complementarity determining regions (CDRs) (Wu and Kabat, 1970) which form 
the antigen combining site (ACS), while the remaining sequences in the V domain 
are termed the framework regions (Kabat et al., 1977; Kabat et al., 1987).
The immunoglobulins from the other four classes have essentially the same 
structure but vary in the number of C domains.
A1.1J.1 The Ig domain structure
Early studies showed that all antibody domains form compact globular 
structures with a characteristic fold called the Ig fold (Poljak, 1973). Each domain is 
composed of 2 anti parallel sheets which form a bilayer structure stabilised by a 
disulphide bond between the two layers (the (3- sandwich). The V domain is a nine 
stranded (3- sandwich and the C domain a seven stranded (3- sandwich. The domains 
(V h/V l, Ch/C l) associate into dimers to form a p- barrel structure.
The domain dimers are linked by flexible polypeptide segments and there 
is limited interaction between domains within each chain. The hinge region between 
ChI and Ch2 is the most flexible area of the molecule and is rich in prolines and
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cysteines. The length of the hinge varies in the human IgG subclasses and is related 
to the conformation of Ig and with activity in effector functions (Alzari et al., 1988). 
Another site of flexibility is the switch region which links the V and C domains. A 
ball and socket model has been proposed for this region to describe the observed 
flexibility between the domains (Lesk and Chothia, 1988).
Al.1.2 The Antigen Combining Site (ACS).
The antigen combining site (ACS) is formed by the juxtaposition of six 
hypervariable loops or CDRs, three from the light chain V domain and three from 
the heavy chain V domain. Analysis of CDR conformation showed that for five of 
the loops, conformations were limited to a small number of structural classes called 
canonical structures.
Each canonical structure describes a preferred conformation for a CDR, 
the preference being determined by key residues whose presence controls a 
particular main chain conformation (Chothia and Lesk, 1987; Chothia et al., 1989). 
Two CDRs (LI and H3) have been proposed to be the most important in 
determining ACS topology and are the most variable in length (de la Paz et al., 
1986). H3 has the greatest heterogeneity in both length and sequence and lies in the 
centre of the combining site. It has a distinct role in determining specificity. 
Unlike the five other CDRs which have one or a small set of main chain 
conformations (Chothia and Lesk, 1987; Chothia et al., 1989) H3 has no 
canonical structures. This extensive variation of CDRH3 is due to well known 
processes of combining D and J minigenes with possible addition of N or P
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segments.
The CDRs of each chain are supported on a framework region which 
consists of conserved strands that fold to form a sandwich. One surface of each 
sandwich associates to form a barrel structure when a light and heavy chain comes 
together. Supported on this barrel scaffold the six CDRs pack together in the 
tertiary structure to form a relatively flat platform with a surface area of about 700 
A2. All six CDRs are involved in the interaction in the anti-lysozyme complexes.
Al.1.3. Anti-lysozyme complexes
As the three dimensional structure of hen egg lysozyme has been 
determined to high resolution (Blake et al., 1965), it serves as an ideal model 
antigen. Additionally structures of lysozyme from other species are available like 
human (Artimiuk and Blake, 1981) and turkey (Bott and Sarma, 1976). The 
antigenic response to HEL has been the subject of various studies. Smith-Gill et al 
(1984) and Harper et al (1987) have shown that the entire surface of HEL is 
potentially antigenic. Structures of three anti-lysozyme antibodies D1.3 (Amit et al., 
1986; Bentley et al., 1990; Bhat et al., 1990), HyHEL-5 (Sheriff et al., 1987), 
HyHEL-10 (Padlan et al., 1989) have been solved by X-ray ciystallography. In the 
three anti- lysozyme antibodies the epitopes have been found to almost non­
overlapping though a small overlap is seen between D1.3 and HyHEL-10. A striking 
feature of the interaction of these three antibodies with lysozyme is the shape 
complementarity of the two surfaces as revealed by the total exclusion of water
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from the interface over an area of about 700 A2 for both the antigen and antibody. 
Water exclusion plays an important role in stabilising the complex. The structures of 
a number of anti-peptide antibodies that cross react with native HEL like Gloop2 
have also been determined (Jeffrey, 1989). The Gloop2 system has been studied in 
great detail in the laboratory.
A l.1.4 The Gloop2 system
Gloopl to 5 are a group of monoclonal antibodies specific for the loop 
region of HEL, which comprises of residues 57-84. The antibodies were raised 
against a peptide-bovine serum albumin conjugate and crossreact with native HEL 
(Darsley and Rees, 1985a and b). Gloop2 binds the loop antigen with an affinity of 
108 M'1 and to HEL with an affinity of 107 M'1 (determined by solid phase RIA) 
[Roberts et a l, 1987].
The epitopes recognised by Gloopl and Gloop2 are indistinguishable 
(Darsley and Rees, 1985a). The epitope on HEL has been determined by serological 
mapping of Gloop2 using a panel of avian lysozymes and it has been further refined 
by NMR spectroscopy. A catalytic site was designed in the combining site of 
Gloop2 using the aspartic protease active site as a basis for the model. The site 
consists of 2 aspartate residues at positions 32 (LI) and 92 (L3) in the light chain. 
Two single mutants Tyr32Asp, Leu92Asp and the double mutant 
Tyr32AspLeu92Asp were made by site directed mutagenesis (Hilyard, 1991).
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Al.1.5 Fv expression
For X-ray crystallographic studies, the double Asp (Tyr32AspLeu92Asp) 
mutant was expressed as Fv fragments in E.coli and purified by affinity 
chromatography. The Fv fragments are non-covalently associated heterodimers of 
the H and L chain variable domains.
Their stability can be improved if they are produced as a single chain by 
inserting a linker peptide between the H and L chains (ScFv). ScFv have the specific 
antigen binding affinity comparable to that of unmodified Fab fragments and have 
been used in tumour imaging and in the form of recombinant immunotoxins for 
tumor therapy. Fv fragments can also be stabilised by introducing a disulphide bond 
between the two chains (Glockshuber et al., 1992).
Bacterial systems offer an alternative to mammalian expression when 
glycosylation is not required. The E.coli secretion expression system was chosen 
mainly because of the speed and convenience of E.coli molecular biology 
manipulations. It also allows characterisation of many variants in a relatively short 
time. This expression system targets the recombinant protein to the periplasm of the 
bacterial cell, where the oxidising environment allows for the formation of 
disulphide bonds. In the case of antibody fragments, the probability of producing 
correctly folded protein is increased. The level of proteases in the periplasm is lower 
than in the cytoplasm reducing the risk of degradation of the recombinant protein.
The mutant Fv was purified by affinity chromatography. This method 
selects for antigen binding function and enables a large volume of crude supernatant 
to be concentrated into a small volume of pure protein. Thus it selects for correctly
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folded functional Fv with sufficient purity for crystallographic studies.
A1.2 Materials and Methods
Al.2.1 Optimised expression and secretion conditions
Al.2.1.1 Induction of expression
A freshly transformed bacterial colony containing the pelB-GL2 Fv 
plasmid was used to inoculate an overnight culture. The culture was diluted to 1% 
inL-broth containing ampicillin (100 pg/ml) and 1% glucose and grown at 250 rpm, 
30°C for 15 hours. The cells were pelleted by centrifugation using a GSA rotor in a 
Sorval RC-5 centrifuge at 7000 rpm for 10 minutes and the supernatant discarded. 
The cells were then gently washed in half the culture volume of 50mM NaCl. The 
50mM NaCl wash was repeated and the cells resuspended in L-broth containing 
ampicillin (100 pg/ml) and ImM IPTG (Boehringer). The culture was incubated for 
a further 17 hours at 250 rpm, 30°C.
After the induction period, the culture was centrifuged in the GSA rotor at
10,000 rpm, 4°C for 30 minutes and the supernatant was harvested. Protease 
inhibitors were added to a final concentration of 1 pM leupeptin (Boehringer) and 
O.lmM EDTA. The supernatant was filtered through 0.45 pM Durapore hydrophilic 
membrane (Millipore) to remove cell debris and stored at -20°C.
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A l .2.1.2 Preparation o f cell fractions
At time points during the induction, an aliquot of culture equivalent to 2 
ODssonm units of cells was taken and centrifuged at 13000 rpm for 15 minutes at 
4°C. The supernatant was removed and stored at -20°C (the supernatant fraction). 
The cell pellet was resuspended in 500 pi of 20% w/v sucrose, 30 mM Tris-HCl pH 
8.0, and 50 pi stored at -20°C (whole cell fraction). A 2 pi aliquot of 0.25M EDTA 
pH 8.0 was added to the remaining 450 pi and incubated at 30°C for 15 minutes. 
The solution was transferred to a cold microfuge tube and centrifuged at 13000 rpm 
for 5 minutes at 4°C. The supernatant was discarded and the pellet resuspended in 
500 pi ice cold water by brief vortexing. After incubation at 4°C for 10 minutes and 
centrifugation for 5 minutes, the supernatant was removed and stored at -20°C (the 
periplasmic fraction).
The Fv was purified from the crude supernatant by affinity 
chromatography.
Al.2.2 Purification of DD-Fv on a lysozyme affinity column
A 100ml sample of crude supernatant from a W3110/pelB-GL2DD Fv 
culture was loaded onto a prewashed 3ml lysozyme Sepharose column and washed 
with 10 volumes of phosphate buffered saline (PBS). The protein was eluted with 
50mM diethylamine and samples separated by SDS-PAGE. Western blotting with 
anti-VL antisera showed that there was immunoreactive material in the 
breakthrough and the wash fractions in addition to the diethylamine eluted fractions.
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The affinity of DDFv for lysozyme was not high enough for affinity chromatography 
under these conditions. Therefore purification of DDFv by loop peptide affinity 
chromatography was tested.
Al.2.3 Preparation of loop peptide
The loop peptide, a loop fragment of HEL consisting of residues 57-84 
was synthesised by a modification of the method used by Hilyard, 1991.
5g of hen egg white lysozyme (Sigma) was dissolved in 330 ml 5% formic 
acid. It was then subjected to proteolytic digestion with pepsin at 37°C. The 
reaction was stopped by the addition of an equal volume of water after 16 hours and 
then freeze dried. The freeze dried material was resuspended in 15 ml 1% formic 
acid and spun at 6000 rpm for 10 minutes to get rid of high molecular weight 
contaminants.
The supernatant was then loaded onto a 100 ml G-25 medium Sephadex 
column pre-washed with 1% formic acid. The peptide is eluted with 1% formic acid 
and its purity was checked on a fast gel and by high pressure liquid chromatography 
(Figure A l.l).
Al.2.4 The use of blocked Sepharose to remove non-specific 
contaminants
Sepharose matrix adsorbs proteins non-specifically, often due to charged 
groups from the glycine blocking agent (Pharmacia LKB instructions). A blocked
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Figure A 1.1 Pure loop peptide is seen in lanes 1 and 2 along with the protein 
marker in lane 4.
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Sepharose column was used to remove non-specific proteins. The Sepharose was 
blocked in 0.2M glycine pH 8.0 overnight at 4°C and washed with acetate buffer 
(pH 4).
A 800ml sample of crude supernatant from a W3110/pelB-GL2Fv DD 
culture, adjusted to 0.25M NaCl, was loaded onto a prewashed 5ml loop-Sepharose 
column. The column was washed in 10-20 volumes of low salt wash (Tris HC1 pH
8.0 containing 0.25M NaCl) and 3 volumes of high salt wash (Tris HC1, pH 8.5 
containing 0.5M NaCl). The protein was eluted in 50mM diethylamine. Under these 
conditions it was possible to purify the mutant Fv to over 95% purity. The final 
yield of Fv purified protein ranged from 1-2 mg/litre estimated by absorbance at 
280nm [Gloop 2Fv molar extinction coefficient is 38300 M^cm'1 (Field, 1988)].
Al.2.5 Analysis of the VL polypeptide by Western blotting
Protein samples were separated by SDS-PAGE (as described in 
Appendix 3) and transferred onto a nitro cellulose membrane (Schleicher and 
Schuell) in contact buffer (40mM Glycine, 50mM Tris, 20% ethanol) using graphite 
electrodes (Multiphore apparatus, LKB). The membrane was blocked in low salt 
buffer (LSB: lOmM Tris, pH 7.6; 0.9 % w/v NaCl; 0.05 % w/v Tween 20) for 1 
hour at room temperature and then incubated with the first antisera (rabbit anti- 
GL2VL IgG prepared by H. Field) at 1/200 dilution in LSB overnight at 4oC. After 
washing twice for 10 mins in LSB, the membrane was incubated with 1/2000 
dilution of goat anti-rabbit IgG alkaline phosphatase conjugate (Sigma) in LSB for 1 
hour at room temperature. The membrane was washed as described above and then
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developed in 75mM Tris-HCl, pH 9.6; 4mM MgC12; 0.005% w/v nitroblue 
tetrazolium; 0.0025% w/v 5-bromo-4chloro-3-indolyl phosphate.
A1.3 Results 
Al.3.1 Cellular distribution of the VH and VL polypeptides
Western blotting of bacterial extracts with either anti-GL2VL or anti- 
GL2VH antisera verified the expression and secretion of both the VH and VL 
polypeptides in BMH 71.18 cells containing the pel B GL2 DDFv vector.
Cell fractions were taken from a 500ml culture of BMH 71.18/ pel B- 
GL2DDFv. The culture was induced with ImM IPTG at 0.5 ODssonm units and 
samples taken at 0 and 17 hours after induction. Cell fractions were prepared as 
described in Section 1.2. The samples were separated by SDS-PAGE (Figure A1.2) 
and visualised by Western blot with anti-VL antisera (Figure A 1.3)
VH and VL polypeptides were seen by Coomassie staining in the cell and 
periplasmic fractions 5 hours after induction. There was no detectable 
immunoreactive material in the periplasmic fraction after induction; this may be due 
to the periplasmic contents passively leaking into the supernatant through holes in 
the cell wall. VH and VL were detected in the supernatant by Western blot analysis 
after induction for 17 hours.
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Al.3.2 The effect of host strain on the expression level of VH and 
VL polypeptides.
Parallel inductions were performed with the strains W3110 and BMH 
71.18 to compare the relative levels of VH and VL expression. The yield of secreted 
product from the two strains was similar.
Al.3.3 Purification of the loop peptide
The Fv was purified from the crude supernatant by affinity 
chromatography on a loop peptide column. This loop peptide was prepared by a 
modification of a method used by Hilyard K.L. (DPhil thesis, University of Oxford). 
This method was chosen as it enables the protein to be purified with antigen binding 
function and a large volume of crude supernatant can be concentrated into a few 
millilitres of pure protein (Figure A 1.4).
A1.4 Discussion
The yield of purified mutant Gloop2 DDFv ranged between 1-2 mg/litre of 
culture. This variation may be due to losses during purification as yields were only 
estimated after affinity chromatography by Coomassie staining and absorption at 
OD280nm Inefficient induction of expression or plasmid loss during the induction 
could also account for this variation.
For Fv production, levels in the 100-500 mg/1 range are achievable in E.coli 
compared to low mg/1 levels from mammalian expression systems. The double Asp
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Figure A 1.2 Coomassie staining showing supernatant fraction (0 and 17 hours in 
lanes 3 and 8 respectively), washed cell fraction (0 and 17 hours in 
lanes 4 and 9 respectively), periplasmic fraction (0 and 17 hours in 
lanes 7 and 10 respectively). Only the supernatant fraction after 
induction for 17 hours had Fv protein.
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Figure A 1.3 : Western blot showing supernatant fraction (0 and 17 hours in
lanes 3 and 8 respectively), washed cell fraction (0 and 17 hours in 
lanes 4 and 9 respectively), periplasmic fraction (0 and 17 hours in 
lanes 7 and 10 respectively) with anti-VL antisera. Only the 
supernatant fraction after induction for 17 hours had Fv protein.
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Figure A 1.4 Coomassie staining of pure Fv protein in lane 2 along with protein 
marker in lane 1.
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(Tyr32AspLeu92Asp) mutant antibody was shown to retain binding affinity for 
peptide. Catalytic assays with both iodinated and unlabelled peptide antigen 
indicated that modification of peptide occurs on incubation with the mutant Fv. A 
different modification to the unlabelled peptide was observed in the wild type Fv 
(Hilyard, 1991). X- ray crystallographic studies could be used to investigate the 
nature of peptide modification. Large quantities of mutant Fv had to be produced 
for crystallographic studies. Large scale production of Gloop2 DDFv will be 
attempted in a 5 to 7 litre bench top fermenter. Initial experiments with similar Fv 
proteins have yielded approximately 10 mg/ml by fermentation. The pure antibody 
protein produced can be used for X-ray crystallographic and NMR studies.
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APPENDIX-2 
KM vs Priess TCR Va and V(3 gene 
cloning
A2.1 Vp gene sequence analysis
One of the original aims of this project was to analyse TCR Va and Vp 
gene usage in peptide specific DR4 Dw4 restricted T cell clones. A strategy to 
sequence TCR Va and Vp genes from the T cell line KM vs Priess was devised. The 
materials and methods used in the study of KM vs Priess cell line are outlined in this 
section. However these methods could not be extended to the study of peptide 
specific DR4 Dw4 restricted T cell clones as they were contaminated with 
mycoplasma.
KM vs Priess cell line and a DR4 Dw4 restricted T cell clone HF53 was 
kindly given by David Sansom from Bath Institute of Rheumatic Diseases.
A2.1.1 RNA extraction
Efficient extraction of total RNA is a pre requisite for subsequent cDNA 
synthesis and cloning. A major technical problem in the isolation of RNA is the
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inhibition of RNAse activity. To minimise the deleterious effects of RNAses, all 
solutions and equipment for RNA work were treated with diethyl pyrocarbonate 
(DEPC). Electrophoresis tanks were cleaned with detergent solution, rinsed in 
water, dried with ethanol and then filled with a solution of 3% hydrogen peroxide 
for 10 minutes at room temperature. The tanks were then rinsed with DEPC treated 
water.
Many approaches to RNA isolation involve the simultaneous disruption of 
tissue and denaturation of all cellular proteins including RNAses. Rate of protein 
denaturation must exceed the rate of RNA hydrolysis. Most rapid denaturation of 
proteins involves the use of guanidine thiocyanate and 2  mercapto ethanol during 
tissue disruption. Guanidine thiocyanate in association with N-lauryl sarcosine acts 
to disrupt nucleoprotein complexes allowing RNA to be released into solution and 
isolated free of protein. Intact RNA is purified from contaminants by 
phenol/chloroform extraction based on the rapid one-step procedure of 
Chomczynski and Sacchi (1987). RNA selectively partitions into the aqueous phase 
free from DNA and protein and is easily concentrated by precipitation with iso­
propanol. LiCl precipitations can result in the loss of RNA smaller than 5.8S and 
carryover of I i + salts can inhibit subsequent cDNA synthesis reactions. Various 
methods used for the extraction of RNA are outlined below.
A2.1.1J RNA extraction with guanidinium thiocyanate
Lysed T cells were resuspended in 5 mis of Solution D and 20 mis of 
pre chilled Solution I (guanidinium thiocyanate in buffer containing tris-HCl and
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EDTA, pH 7.4; Solutions I, II,III and IV were supplied with Amersham's RNA 
extraction kit) was added in a tissue disruption tube. The cells were sonicated in 40 
second bursts at 10 watts until the solution was less viscous. To the homogenate 0.3 
volumes ethanol was added and the mixture was incubated at -20°C for 10 minutes. 
After centrifugation at 0°C for 5 minutes at 10000 rpm, the pellet was resuspended 
in 10 ml pre chilled Solution I. The cells were sonicated again and after the addition 
of 30 mis of Solution II (LiCl in water) the mixture was incubated at 4°C overnight. 
After centrifugation at 10000 rpm at 4°C for 90 minutes the supernatant was 
discarded. The pellet was resuspended in 35 ml Solution III (LiCl and urea in water) 
by alternate vortexing for 30 seconds and incubation at 40°C. After centrifugation at 
10000 rpm for 60 minutes at 4°C the protein film was discarded and 5 mis of 
Solution IV (RNA buffer) was added to the pellet. After incubation at -20°C for 2 
hours the pellet was resuspended by alternate vortexing for 30 seconds and 
incubation in 40°C water bath. The solution was then extracted once with phenol 
and twice with CHCI3. RNA was precipitated with 2 volumes ethanol and the pellet 
was resuspended in 1 ml DEPC water. A quicker method was necessary for the 
routine extraction of RNA.
A2.1J.2 RNA extraction using phenol chloroform isoamyl alcohol 
extraction
106 T cells from the DR4 Dw4 restricted T cell clone were resuspended 
in 500 pi of 4M guanidinium thiocyanate (Sigma G-6639); 25mM sodium citrate,
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PH 7; 0  .5% sarcosyl; 0.1 M 2  mercapto ethanol (solution D). 50 pi 2M sodium 
acetate, pH 4; 500 pi phenol (water saturated); 100 pi CHCl3-isoamyl alcohol 
(49:1) were sequentially added and the mixture was shaken vigorously for 10 
seconds. After cooling the mixture on ice for 15 minutes it was spun in a microfuge 
for 10 minutes. The aqueous layer was then extracted twice with an equal volume of 
CHCl3-isoamyl alcohol. RNA was precipitated by the addition of an equal volume of 
isopropanol and an overnight incubation at -20°C. The pellet was resuspended in 
0.3 volumes of solution D and after another isopropanol precipitation the pellet was 
washed twice with 70% ethanol and once with absolute ethanol. The pellet was then 
resuspended in 50 pi DEPC water.
A2.1.1.3 RNA extraction by RNAzol method
106 cells from the DR4 Dw4 restricted T cell clone were resuspended 
in 1.1 mis Phosphate Buffered Saline (PBS). The cells were then lysed by the 
addition of 0.2 ml of RNAzol (Biotecx Lab, Inc). RNA was solubilised by passing 
the lysate several times through the pipette. The homogenate was then extracted 
with CHCI3. To the aqueous layer, an equal volume of isopropanol was added and 
the mixture was incubated at 4°C for 15 minutes. RNA was pelleted by 
centrifugation at 13000 rpm for 15 minutes at 4°C. The RNA pellet was washed 
once with 75% ethanol by vortexing and subsequent centrifugation for 8  minutes at 
7500 rpm at 4°C. The pellet was dried under vacuum for 15 minutes and 
resuspended in ImM EDTA pH 7. Isolated RNA exhibited a A26o/A28o ratio of 1.7-
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2.0. A lower ratio is indicative of contamination with guanidine thiocyanate carried 
over during the subsequent steps.
This method was used for all subsequent RNA extractions.
A2.1.1.4 Gel analysis o f RNA transcripts
The quality of RNA transcripts was assessed by loading a 5 pi aliquot 
of the sample on a 1% HCHO gel along with ribosomal RNA markers (Figure A2.1) 
RNA transcripts (0.5-2 pg) were resuspended in 1 X MOPS [3-(N-morpholino) 
propane sulphonic acid] buffer (20 mM MOPS; 5 mM sodium acetate, pH 5.0; 
ImM EDTA, pH 7.0); 2.2 M formaldehyde and 70% (v/v) deionised formamide. 
The samples were denatured by heating at 65°C for 15 minutes followed by rapid 
cooling on ice. After the addition of 1 pi of 1 mg/ml ethidium bromide and 0.1 
volume of gel loading dye (0.025% xylene cyanol; 0.025% bromo phenol blue; 4% 
glycerol) the samples were loaded immediately onto denaturing gels containing 
1.0% agarose and 3.7% formaldehyde in 1 X MOPS buffer. The samples were 
separated by electrophoresis at a limiting current of 75 mA for 3-4 hours.
RNA was visualised by UV fluorescence as in the case of DNA. The 
28S and 18S eukaryotic ribosomal RNAs exhibit a near 2:1 ratio of ethidium 
bromide staining in undegraded samples. In degraded samples this ratio will be 
reversed as the 28S ribosomal RNA is characteristically degraded to an 18S-like 
species.
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8  S
Figure A2.1 Total RNA from KM vs Priess cells seen in lanes 3 and 5 along with the 
marker in lane 1
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A2.1.2 cDNA synthesis
The first strand of cDNA can be synthesised using an enzyme RNA- 
dependent DNA polymerase, the reverse transcriptase (RT). This enzyme can 
synthesise a complementary DNA strand initiating from a primer using either single­
stranded RNA or DNA templates. Two different forms of reverse transcriptases are 
available commercially, Avian RT and Murine RT. Moloney Murine Leukemia 
Virus Reverse Transcriptase (M-MuLV RT) has much lower RNase H activity than 
Avian Myeloblastosis Virus Reverse Transcriptase (AMV RT), significant especially 
when synthesising cDNA from long mRNAs. Intact mRNA template remaining after 
cDNA synthesis can interfere with RT-PCR by competing with the cDNA as PCR 
template. Both reverse transcriptases lack 3' H 5' exonuclease function. First strand 
cDNA synthesis may be accomplished by extension with random hexamers, the 
downstream primer or thymidylic acid oligomers like oligo (dT)is and oligo
(dT)i2-18.
Random hexamers are not preferred for reverse transcription as multiple 
primers bind to a single RNA creating either a cDNA that is prematurely terminated 
or one that is fully extended but consisting of several unlinked fragments that will 
become dissociated during PCR. For cloning of cDNAs, the most frequently used 
primer is Oligo (dT)i2 i8 which binds to the poly(A) tract at the 3' terminus of 
eukaryotic cellular mRNA molecules.
A2.1.2.1 Comparison of reverse transcription reaction conditions
The relative efficiency of different available reverse transcriptases and
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buffer systems was compared in order to choose the optimal reaction conditions for 
RACE. The different protocols were tested by RT-PCR using total RNA extracted 
from a T cell line KM vs Priess as a control.
Total RNA was washed with 75% EtOH, resuspended in DEPC treated 
water at 0.2 pg/pl. 5 pi aliquots of RNA were taken in microfuge tubes in the 
presence of the appropriate 1 x reverse transcription buffer and primers. All 
reactions were terminated by the addition of 4 pi of 0.5 M EDTA, pH 8 .
8  pi aliquot of each reverse transcription reaction was added to a 50 pi 
PCR mix containing the Vp gene specific primer set AN Poly C and Cp. PCR 
amplification was carried out as described in Section 2.4.4. A 10 pi aliquot of each 
PCR reaction was analysed on a 1% agarose gel. The intensity of the 600 bp PCR 
product generated from the Vp gene coding sequence was used as an indication of 
efficiency of each reaction. This comparison was not designed to be quantitative or 
comprehensive but rather to establish the most appropriate reaction conditions using 
available reagents.
Cp gene specific primed cDNA synthesis
Total RNA extracted from a T cell line KM vs Priess was used for cDNA 
synthesis in the presence of 0.5 pg of a Cp gene specific primer. A Cp gene specific 
primer
5’ GGGACACTTAAGGGTAGAGCAGGTACT 3' (Tm = 82°C) 
was designed and synthesised on an Applied Biosystems DNA Synthesiser 
(described in detail in Section 2.4.1). The reaction was performed in the presence of 
0.5 mM dNTPs; 10 mM DTT; 75 mM KC1; 50 mM Tris HC1, pH 8.3; 3 mM MgC12 
and 200 units of M-MLV RT in a reaction volume of 20 pi. This reaction was
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carried out at 37°C for 60 minutes.
Oligo dT primed synthesis of first strand of cDNA
Protocol 1
Reverse transcription was performed using Superscript with Gibco BRL 
supplied buffer for 60 minutes at 37°C. This reaction was carried out in the presence of 
50 mM Tris HC1, pH 8.4; 50 mM KC1; 2.5 mM MgC12; 100 pg/pl BSA; 0.5 pg Oligo 
(dT)i2-i8 and 200 units of Superscript enzyme. The reaction volume was 30 pi.
Protocol 2
cDNA synthesis was carried out in the presence of 50 mM Tris HC1, pH 8.3; 
50 mM KC1; 10 mM DTT; 0.5 pg Oligo (dT)12-i8 and 200 units of M-MLV RT (Gibco 
BRL) for 60 minutes at 37°C. The reaction volume was 30 pi.
Protocol 3
1 pg of total RNA from the T cell line KM vs Priess was used for Oligo dT 
primed cDNA synthesis using 0.5 pg of Oligo (dT)i2-i8 annealed at 70°C for 10 
minutes. Reactions were performed using 0.5 mM dNTPs; 10 mM DTT; 75 mM KC1; 
50 mM Tris HC1 (pH 8.3); 3 mM MgCl2 and 200 units of Moloney Murine Leukemia 
Virus Reverse Transcriptase (BRL) in a final volume of 20 pi, at 37°C for 60 minutes. 
The reaction was terminated by the addition of 4 pi of 0.5 M EDTA, pH 8.0. The 
progress of this reaction was monitored by incorporating 10 pCi a -32P dCTP 
radiolabel. This method was used for all subsequent cDNA synthesis.
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A2.1.2.2 cDNA quantitation
DE-81 filters are positively charged and will strongly adsorb and retain 
nucleic acids including oligonucleotides that are too small to be precipitated efficiently 
with tri chloro acetic acid (TCA). Unincorporated nucleotides stick less tightly to the 
filters and are removed by washing the filters extensively in 0.5M Na2HP0 4, pH 7. The 
efficiency of this reaction can be calculated by measuring the proportion of radioactive 
precursor incorporated into the cDNA. This can be done by two methods namely 1) 
Differential precipitation of the nucleic acid products with TCA and 2) Differential 
adsorption of the products onto positively charged surfaces eg DE-81.
1 pi of cDNA was spotted onto the centre of two DE-81 filters. One filter 
was used to measure the total amount of radioactivity in the reaction. This filter was 
washed thrice with 0.5M Na2HP0 4 , pH 7.0 for 2 minutes. It was then rinsed with water 
for a minute followed by a wash in 70% ethanol for 4 minutes and then dried. Each of 
the filters (washed and unwashed) was inserted into scintillation vials and the amount of 
radioactivity on each filter was measured. 32P can be determined on dry filters by 
Cerenkov counting (in the 3H channel of a liquid scintillation counter). The amount of 
radioactivity on the unwashed filter can be compared with the amount of radioactivity 
on the washed filter and the % incorporation calculated (Table A2.1).
A2.1.2.3 cDNA purification
22 pi cDNA was loaded onto a 3 ml G-50 Sephadex column washed with
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Fra<: t i on cpm
1 6 5 . 7
2 16
3 27
4 3 1 0 0 . 7
5 32098
6 7 1 5 L .7
7 9 6 1 8 . 7
8 1 9 0 4 3 2 . 7
9 1 9 8 1 2 9 5 . 6
10 1 8 9 7 4 3 2 . 5
I 1 1 4 6 7 6 5 4 . 2
12 1 2 9 8 6 0 3 . 5
13 2 9 9 8 1 4 . 7
14 7 0 4 1 5 . 0
15 5 5 6 6 3 . 7
16 2 9 0 5 6 . 0
17 2 8 7 9 5 . 0
18 2 3 8 3 6 . 3
19 2 4 1 8 8 . 3
20 1 5 0 2 7 . 7
Table A2.1 Counts per minute in the fractions collected from a Sephadex G-50
column during KM vs Priess cDNA purification as described in section 
A2.1.2.2. Fraction 5 contained the cDNA.
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TEN buffer (10 mM Tris HC1; 1 mM EDTA, pH 8 ; 100 mM NaCl). 20 fractions (100 
pi each) were collected and the radioactivity was measured in a Cerenkov counter 
(Table A2.1). Fraction 5 contained the cDNA.
A 4 pi aliquot of the sample was run on a 1% alkaline gel containing 2.5 ml 
1M NaOH and 100 pi 0.5 M EDTA, pH 8.0. The gel was fixed in 7% TCA overnight. 
It was then dried and subjected to autoradiography at -70°C (Figure A2.2).
A2.1.3 G-Tailing with Terminal deoxynucleotidyl Transferase
Terminal deoxynucleotidyl transferase (TdT) catalyses the repititive addition 
of mononucleotides from a dNTP to the terminal 3'-OH of a DNA initiator 
accompanied by the release of inorganic phosphate. This enzyme was first purified from 
calf thymus by Bollum (1958).
It provides a unique method for the labelling of the 3' termini of DNA with 
32P for subsequent utilisation in hybridisation assays. The enzyme to substrate ratio is 
critical for obtaining uniform addition of labelled nucleotides. Lower ratios produced 
probes of varying lengths and reduced incorporation rates. All types of double stranded 
DNA ends (blunt ends, 3-overhangs, 5'-overhangs) can be tailed with TdT in the 
presence of a cobalt-based buffer. The reaction volume was made up to 100 pi with 
water and the cDNA was purified by 3 precipitations with 1 volume 4 M ammonium 
acetate and 3 volumes of ethanol. The pellet was washed with 70% ethanol and spun 
for 15 minutes. It was then dG tailed using either of the two methods.
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Figure A2.2 Autoradiograph of KM vs Priess cDNA seen along with <j)X 174 RF 
DNA marker.
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Protocol 1
The cDNA pellet was resuspended in 37.775 pi water and dG tailed in the 
presence of 0.5 M potassium cacodylate (pH 7.2); 10 mM C0 CI2 ; 1 mM DTT; 24.5 
pM dGTP and 15 Units TdT (Gibco BRL) in a final volume of 50 pi for 30 minutes 
at 37°C. The tailed cDNA was then diluted to a volume of 100 pi.
Protocol 2
The cDNA pellet was resuspended in 9.5 pi water and dG tailed in the 
presence of buffer with 1 M potassium cacodylate; 125 mM Tris HC1; 1.25 mg/ml 
bovine serum albumin, pH 6 .6 ; 0.75 mM CoCl2; 0.75 mM dGTP and 50 units TdT 
(Boehringer Mannheim) in a final volume of 20 pi for 15 minutes at 37 °C. The 
tailed cDNA was then diluted to a volume of 100 pi.
Reverse transcription reactions were diluted prior to RACE to limit the 
amount of initial template for RACE to favour exponential amplification of specific 
sequence over non specific background. Excess nucleotides and RT primer have to 
be removed from the first strand reaction prior to RACE and therefore a stringent 
purification procedure was required. Contaminating proteins were removed by 
performing extractions with phenol and chloroform. Tris-buffered phenol, 
chloroform and isoamyl alcohol (25:24:1; v/v) were added to an equal volume of 
DNA. Phases were mixed by vortexing and separated by centrifugation at 13000 
rpm for 5 minutes. The upper aqueous phase containing DNA was transferred to a 
new microfuge tube and then extracted twice with chloroform. The aqueous phase 
was used as template for Anchored PCR.
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A2.1.4 RACE method
The RACE method (Rapid Amplification of cDNA ends) first described by 
Frohman (1988) has also been described as one-sided PCR or Anchored PCR. It 
was designed to rapidly produce, isolate and characterise unknown cDNAs. In 
theory, with the use of nested primers, transcripts can be amplified to generate a 
pure product containing the desired cDNA. It is quicker than other methods in that 
the reverse transcribed products can be analysed within 1 - 2  days after the 
experiment. However there is an enormous potentialfor the generation of artifacts 
by this method.
The most obvious artifact is the non specific amplification of cDNAs to 
generate gene products which have no sequence homology to the gene of interest. 
There are other PCR products which are undesirable either because they are 
truncated or because they are derived from contaminating genomic sequences. 
Truncated cDNA 3’ ends are produced when the oligo (dT)i2-i8 primer anneals to a 
A rich region in the transcript upstream of the poly (A) tail. This can be avoided to 
some extent by decreasing the concentration of the oligo (dT)i2-is primer to 15 
ng/reverse transcription.
For the 5' ends, a primer which binds inappropriately to the message of 
interest within the region to be amplified causes premature termination of the 
reverse transcription reaction at that site creating truncated ends. To overcome this 
problem, primers having a high A+T content can be used and the reverse 
transcription reaction can be carried out at 52°C. Primers with a high G+C content 
are more likely to produce artifacts.
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Anchored PCR (An PCR) is a useful method for analysing RNA transcripts 
where the sequence at the 5' end is unknown. The procedure involves reverse 
transcription of mRNA using oligo (dT)i8 or a gene specific primer, homopolymer 
tailing of the cDNA with dGTP and then amplification by PCR using a non specific 
anchor oligo (dC) at the 5' end and a gene specific primer at the 3' end (Loh, 1989 
and Frohman, 1988) [Figure A2.3].
If the oligo (dT)ig primer is not completely removedfrom the cDNA prior 
to the homopolymer tailing step the reaction will fail even if the same cDNA can be 
amplified using 3' and 5' gene specific primers. (Jitra Kriangkum, 1992). Presence of 
the oligonucleotide does not interfere with the homopolymer tailing itself as all the 
cDNA was found to be tailed. The reaction is inhibited by dG tailed oligo (dT)i8. 
When a series of An PCR reactions with increasing concentrations of (dT)i8 and dG 
tailed (dT)i8 was carried out with specific 5' and 3' primers, the An PCR product 
disappeared in the presence of 1 ng or more of dG tailed oligo (dT)i8. 400 ng of 
oligo (dT)i8 had no effect on this reaction. Oligo (dT)i8 can be completely removed 
by column chromatography over Biogel A5M (Bio Rad).
A2.1.4J Design, synthesis and purification o f oligonucleotides
Two primers Cp 3' and AN Poly C (Table A2.2) were designed for use 
in Anchor PCR. A Not I site and a Bgl II site were introduced into the AN Poly C 
and Cp primers respectively. These primers were synthesised on an Applied 
Biosystems DNA synthesiser using phosphoramidate chemistry. The oligonucleotide 
sequences were checked against the DNA sequences of human TCR (3 chain
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F ig u re  A2.3 Schematic diagram of Anchored PCR.
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Primer Sequence Tm (°C)
AN Poly C 5’ CT ATCT AG AG AGCTCGCGGCCGCCCCCCCCCCCCC 3’ 124
Ca 3’ 5’ CAGACAGATCTGTCACTGGAT 3* 62
Cp3’ 5’ CGCGAATTCAGATCTCTGCTTCTGATG 3’ 76
Amp 3’ 5’ GTGTGGGAGATCTCTGCTTCTGAT 3’ 76
RADS 5’ AGGACCTGAACAAGGTGTTCCCACCCGAGGTCG 3’ 106
V B U N 5’ GGGGAGCTAGCTAGCTAGCTAGTTATCCTTGGT 3’ 102
CA-JBM 5’ ATATCCAGAACCCTGACCCTGCCGTGT 3’ 84
Ca 3 ’ 5’ GATAGATCTTAGAGTCTCTCAGC 3’ _66
T ab le  A2.2 Primers used in the study of TCR V a  and Vp genes.
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constant region exon 1 using an identity search program. Ammonia cleaves the oligo 
from the resin at room temperature. The protecting groups were removed from the 
terminus by incubating the resin in 0.88 N ammonia solution at 55°C for 16 hours. 
Ammonia was removed by drying the oligo under vacuum. Ethanol precipitated 
oligo can be recovered by a 10 minute spin at 10000 rpm followed by a rinse with 
70% ethanol and then dried. Concentration of the oligo was determined 
spectrophotometrically.
A2.1.4.2 5*phosphorylation o f oligo primers
Cp 3' and the AN Poly C primers were 5' phosphorylated. A 2 picomole 
sample of primer was mixed with 16 pi buffer (0.05 M Tris HC1, pH 7.6; 0.01 M 
MgC12; 5 mM DTT; O.lmM spermidine HC1; 0.1 mM EDTA, pH 8) and 7 units T4 
polynucleotide kinase enzyme (Pharmacia) in a final volume of 20 pi. The reaction 
was performed at 37°C for 30 minutes and the kinase was inactivated by heating at 
70°C for 10 minutes. The 5' phosphorylated primers were stored at -20°C.
A2.1.4.3 Control reactions fo r RACE
Control reactions were used to test the efficiency of reverse transcription 
and to ensure the validity of RACE products.
The efficiency of the cDNA reaction can be determined by using primers 
which amplify ubiquitously expressed mRNAs such as glyceraldehyde 3-phosphate 
dehydrogenase (G3PDH) or p actin.
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A 8 pi aliquot of each reverse transcription reaction was taken in a 50 pi 
PCR mix containing 0.4 pM 5' and 3' cross species G3PDH specific primers, 0.2 
mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM dTTP, 10 mM Tris-HCl, 50 
mM KC1, 1.5 mM MgCl2 and 2.5 Units Taq Polymerase (Perkin Elmer). The 
samples were subjected to PCR under the following conditions: 94°C, 45 seconds; 
60°C, 45 seconds; 72°C, 2 minutes for 35 cycles followed by a time delay of 7 
minutes at 72°C.
Cross species primers used to amplify a 0.45 kb G3PDH PCR product
were:
5' primer
5’ ACCACAGTCCATGCCATCAC 3' Tm = 62°C 
and 3' primer
5' TCCACCACCCTGTTGCTGTA 3' Tm = 62°C 
PCR products having a size of around 0.45 kb can be obtained using cross 
species G3PDH specific primers. A negative control containing no reverse 
transcriptase in the reaction mixture was also included along with each transcription 
reaction. This control reaction was used to determine whether a given RACE 
product is of genomic DNA or cDNA origin. Another control reaction omitting 
RNA from the reaction mixture was included to ensure that there was no 
contamination with PCR products or plasmid DNA.
A2.1.4.4 Anchored PCR
8 pi of the tailed cDNA was subjected to Anchor PCR using 2.5 units
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of Taq Polymerase (Perkin-Elmer) and a Perkin Elmer Cetus Thermocycler under 
the following conditions: 94°C, 5 minutes; 55°C, 2 minutes; 72°C, 10 minutes for 
one cycle followed by 94°C, 45 seconds; 55°C, 2 minutes; 72°C, 10 minutes for 30 
cycles. The reaction was performed using 200 pM dNTPs, 50 mM KC1,10 mM Tris 
HC1, 0.1% Tween 20 and 1.5 mM MgCh. The primers used were Anchor Poly C 
and Cp 3' (Table A2.2) at a concentration of 8.9 pm. The volume was made up to 50 
pi.
A 10 pi aliquot of the sample was run on a 1% agarose gel along with <|)X 
174 RF DNA marker (Figure A2.4).
A2.1.5 PCR using a Vp specific universal primer
For PCR amplification of TCR p cDNA without prior knowledge of its 
Vp sequence, a nucleotide sequence of 5 bases (TGGTA) was chosen as a target 
for upstream PCR primer. This sequence coding for tryptophan and partly tyrosine, 
is highly conserved among all Vp genes known to date. A 18 base long Vp specific 
universal PCR primer designated VBUN containing the above 5 bases at the 3' end 
was designed. The other portion of VBUN contained 2 thymines, various degrees of 
base degeneracy designed on the basis of published Vp sequences, and a stretch of 4 
guanines at the 5' end for stabilisation of annealing.
The oligonucleotide VBUN (Table A2.2) was synthesised on an Applied 
Biosystems DNA Synthesiser using phosphoramidate chemistry. The 
oligonucleotide sequence was checked against the DNA sequences of human TCR p 
chain CDR1 using an identity search program. Ammonia cleaves the oligo from the
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H9
Figure A2.3 Anchored PCR product of TCR Vp gene from KM vs Priess cells seen in 
lane 5 along with tyX 174 RF DNA marker in lane 1.
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resin at room temperature. The protecting groups were removed from the terminus 
by incubation at 55°C for 16 hours. Ammonia was removed by drying the oligo 
under vacuum. Ethanol precipitated oligo can be recovered by 10 minute spin at 
10000 rpm followed by a rinse with 70% ethanol and then dried. Concentration of 
the oligo was determined spectrophotometrically.
4 pi of the tailed cDNA was subjected to PCR using 2.5 units of Taq 
Polymerase (Perkin-Elmer) and a Perkin Elmer Cetus Thermocycler under the 
following conditions: 94°C, 1 minute; 55°C, 1 minute; 72°C, 3 minutes for 25 
cycles. The reaction was performed using 200 pM dNTPs, 50 mM KC1,10 mM Tris 
HC1, 0.1% Tween 20 and 1.5 mM MgCl2 . The primers used were VBUN and Cp 3' 
(Table A2.2) at a concentration of 8.9 pm. The volume was made up to 50 pi.
A 5 pi aliquot of the sample was run on a 1% agarose gel along with <j)X 
174 RF DNA marker.
A2.1.6 Purification of the PCR product
A number of methods were tried for the purification of the PCR product.
A2.1.6.1 Spun columns
1 pg of the PCR product resuspended in 100 pi water was loaded onto a 
1 ml column of Bio Rad P-30 (Bio gel) pre equilibrated with 10 mM Tris HC1, pH 
8; 0.5 mM EDTA, pH 8. A 100 pi fraction was collected after centrifugation at
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1600 rpm for 4 minutes.
A 10 pi aliquot of this fraction sample was run on a 1% agarose gel along 
with (j)X 174 RF DNA marker.
. A2.1.6.2 Crush-Soak method
The amplification product was extracted with an equal volume of 
phenol: chloroform and subsequendy with an equal volume of chloroform. After the 
addition of 0.5% SDS; 10 mM Tris HC1, pH 8; 5 mM EDTA and 50 pg Proteinase 
K the aqueous layer was incubated at 37°C for 30 minutes. The enzyme was then 
inactivated by heating the mixture at 68°C for 10 minutes. This mixture was 
extracted with an equal volume of phenol and subsequently with an equal volume of 
phenol:chloroform. The aqueous layer was then precipitated with 3mM spermine by 
incubation at room temperature for 10 minutes followed by centrifugation at 13000 
rpm for 15 minutes. The pellet was resuspended in 300 pi 0.5 M NaCl and 
incubated at room temperature overnight. DNA was precipitated with ethanol and 
the pellet was rinsed with 70% ethanol. The pellet was then resuspended in 20 pi 
water.
The product was subjected to double digestion with Not I and Bgl II in the 
presence of 100 pg BS A. This product was then run on a 2% Nusieve GTG agarose 
gel in TAE buffer. DNA running at around 600 bp was eluted from the gel by crush- 
soak method. The PCR product was chopped with a Schwann Morton surgical 
blade into small pieces and placed in a Millipore filter eppendorf. After incubation at
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-70°C for 1 hour to lyse agarose, DNA was spun through by centrifugation at 
13000 rpm for 15 minutes.
There was less than 50% recovery of the PCR product by this method and 
hence it was necessary to use another method.
A2.1.6.3 Use o f Mermaid kit
The PCR product was taken in 3 volumes of high salt binding solution 
(concentrated solution of sodium perchlorate). This mixture was then incubated at 
room temperature for 5 -15 minutes with GlassfogTM, a silica based matrix which 
binds the DNA. After centrifugation at 13000 rpm for 30 seconds to pellet 
GlassfogTM, the supernatent was kept aside. The pellet was washed with 200 pi of 
high salt binding buffer followed by a rinse with ethanol to remove salts and other 
contaminants. The pellet was then dried under vacuum to remove traces of ethanol. 
The pellet was resuspended in 16 pi water and incubated at room temperature for 5 
minutes. DNA was eluted from GlassfogTM by centrifugation at 13000 rpm for 1 
minute. The elution step was repeated and the DNA recovered was analysed on a 
1% agarose gel. This method was found to be efficient for purifying low molecular 
weight DNA but not suitable for purifying the PCR product.
A2.1.6.4 Isolation o f DNA fragments from agarose gel using DEAE 
membranes
This technique is derived from the method originally developed
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independently by Winberg and Hammerskjold and Dretzen et al who used DEAE 
paper as the binding medium. The PCR product was allowed to run on a 1% 
agarose gel with TBE buffer containing ethidium bromide (0.4 pg/ml) until the 
tracking dye was in the centre of the gel. The gel was briefly visualised using a hand 
held transilluminator and the gel was slit horizontally 3 mm above and below the 
band with a sterile scalpel. Small pieces of DEAE cellulose paper were soaked in 
2.5 M NaCl for several hours and subsequendy washed with water and stored in 1 
mM EDTA, pH 8 at 4°C. These pieces of DEAE cellulose were inserted into the 
two slits using a pair of tweezers and the gel was squeezed firmly against the paper 
to close the incisions. The paper below collects the PCR product and the paper 
above the band protects against contamination from high molecular weight DNA. 
Electrophoresis was resumed until all the DNA entered the lower paper (observed 
by examination under IJV). The paper was washed in cold distilled water for 10 
minutes, blotted dry with a tissue and placed in a Millipore filter eppendorf. The 
product was then placed in 0.5 ml extraction buffer (1.5M NaCl; ImM EDTA; 
20mM Tris HC1, pH 8) and incubated at 37°C for 2 hours after vigorous shaking to 
shred the paper. The mixture was then centrifuged at 13000 rpm for 5 minutes to 
separate the paper from the filtrate. DNA was extracted with 3 volumes of butanol 
(pre saturated with water) to remove ethidium bromide. The aqueous layer was then 
precipitated with ethanol and the pellet was resuspended in 32 pi of 10% TE, pH 8 
buffer.
This method was found to recover greater than 50% of the PCR product 
and more efficient methods were sought.
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A2.1.6.5 Purification o f PCR product using Schleicher and Schuell 
NA-45 DEAE membrane
A modification of the DEAE paper method using Schleicher and Schuell 
NA-45 DEAE membrane was attempted to improve the efficiency of PCR product 
purification. DEAE cellulose in membrane form is a convenient medium for binding 
DNA and RNA from gels. DEAE membranes are superior to paper because of their 
high wet strength (wet membranes do not release fibres or particulates) and high 
matrix density (0.45 pM pore size). DNA and RNA binding is quantitative only 
up to 7 pgcm'2 while the maximum capacity is 20 pgcm*2. To increase binding 
capacity, membranes were washed in 10 mM EDTA pH 7.6 for 10 minutes and 0.5 
M NaOH for 5 minutes followed by a few rinses in distilled water. Membranes were 
stored at 4°C. The PCR product was then purified as described in method 5.4. The 
purity of the PCR product was adequate for further genetic manipulations including 
restriction enzyme digestions and cloning.
A 4 pi aliquot of this sample was run on a 1% agarose gel to check the size 
of the PCR product.
A2.1.6.6 Purification o f PCR product using P-Agarase I enzyme
p-Agarase I can be used for the purification of both large (> than 50 kb) 
and small DNA fragments. It acts by cleaving carbohydrate bonds, freeing trapped 
DNA and producing carbohydrate molecules which can no longer gel.
The PCR product was allowed to run on a 2% low melting point agarose
188
Appendix 2 KM vs Priess TCR Va and Vp gene cloning
gel at 4°C. The band running at about 600 base pairs was chopped and placed in a 
weighed eppendorf. The chopped band was weighed and then melted at 65°C for 15 
minutes. The reaction mixture was heated at 65°C for 5 minutes in the presence of 
10 mM Tris HC1, pH 6.5 and 1 mM EDTA. The reaction mixture was then placed 
at 40°C for 3 minutes prior to the addition of 4 units of beta- agarase enzyme 
(NEB). The reaction was carried out at 40°C for one hour. The enzyme was 
inactivated by heating at 85°C for 10 minutes and then immediately chilled on ice. 
After centrifugation at 13000 rpm for 30 minutes the supernatant was transferred 
into a fresh eppendorf. DNA was precipitated by the addition of one-tenth volume 
of 3 M sodium acetate, pH 5.2 and 2 volumes of isopropanol at -20°C. The 
supernatant was discarded after centrifugation at 13000 rpm for 30 minutes and the 
pellet resuspended in 12 pi water.
A 2 pi aliquot of this sample was run on a 1 % agarose gel to check its 
purity and concentration.
A2.1.6.7 Purification of PCR products by electro elution
The PCR products were separated on a 1% low melting point agarose gel. 
The band running between 500 and 800 base pairs was chopped and placed in a 
dialysis tubing which was treated as described in Maniatis et al '82. 0.2 ml of TE 
buffer, pH 8 was added into the dialysis tubing. The chopped band was placed 
perpendicular to the applied current. The DNA migrates onto the walls of the tubing 
by applying a current of 60 mA and a voltage of 50 mV. The polarity was reversed 
for a minute to allow the DNA to move into the buffer from the walls of the tubing.
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The DNA was precipitated by the addition of l/10th volume of 3 M sodium acetate, 
pH 6 and 3 volumes of ethanol at -20°C overnight. After centrifugation at 13000 
rpm for 15 minutes, the pellet was washed twice with 70% ethanol and dried. The 
pellet was then resuspended in 20 pi water. This method was found to be highly 
efficient with more than 90% recovery of purified products.
RACE products that appear as discrete bands and prove unambiguous can 
be cloned and sequenced directly, used as probes in Southerns, Northerns and in situ 
hybridisation analysis.
A2.1.7 Preparation of replicative form of M13mpl8
A small scale culture of M l3 infected cells was prepared by inoculating 50 
ml of lx  TY with 50 pi of TGI overnight and a 50 pi aliquot from a phage stock 
and grown at 37°C, 250 rpm overnight. The cells were pelleted by centrifugation at 
4000 rpm for 15 minutes at 4°C. The pellet was resuspended in 100 pi STE buffer 
(0.2M NaCl; 10 mM Tris HC1, pH 8; 1 mM EDTA, pH 8). After centrifugation at 
4000 rpm for 15 minutes at 4°C the pellet was resuspended in 2 ml of ice cold 50 
mM glucose; 25 mM Tris HC1, pH 8; 10 mM EDTA (Solution 1) containing 10 
mg/ml lysozyme and incubated at 4°C for 5 minutes. Cells were completely lysed by 
the addition of 4 ml of 0.2 M NaOH and 1% w/v SDS (Solution 2) and mixed 
gently on ice for 5 minutes. After the addition of 3ml of ice cold 5 M potassium 
acetate, pH 4.8 (Solution 3) the mixture was incubated on ice for 5 minutes. This 
mixture was then centrifuged at 10000 rpm at 4°C for 10 minutes. The supernatant
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containing RF DNA was extracted once with phenol (water equilibrated): 
chloroform and the aqueous layer was precipitated with propanol by incubation at 
room temperature for 30 minutes followed by centrifugation at 10000 rpm for 10 
minutes at 4°C. The pellet was resuspended in 4 ml ethanol. After centrifugation at 
10000 rpm at 4°C for 10 minutes the pellet was resuspended in 1 ml TE buffer.
A2.1.8 Purification of M13mpl8 by gel filtration on Sephacryl-300
The DNA pellet was resuspended in 6 ml of 0.1 M Tris HC1, pH 8; 0.01 M 
EDTA (TE buffer), transferred to a 30 ml Corex tube and 960 pi 2.5 M NaCl was 
added to the mixture. The solution was then precipitated overnight with 2.5 
volumes ethanol after the addition of 5 pi of RNAse A (0.1 mg/ml). After 
incubation the solution was centrifuged at 13000 rpm for 10 minutes. The pellet was 
washed with 70% ethanol and resuspended in 500 pi water.
RF DNA was purified from RNA by gel filtration on a 10 ml column of 
Sephacryl-300 (Pharmacia) pre equilibrated with 0.2 M NaCl; 10 mM Tris HC1, pH 
8; 0.5 mM EDTA. 20 fractions containing DNA were collected and 5 pi of each 
fraction was spotted onto 0.5% agarose containing ethidium bromide (10 mg/ml). 
After drying for 15 minutes at 37°C, the fractions containing DNA were identified 
with UV fluorescence. The first peak of fluorescence corresponds to RF DNA. The 
fractions were pooled and the DNA was precipitated by incubation with 0.5 volume 
of propanol for 30 minutes followed by centrifugation at 13000 rpm for 15 minutes 
at room temperature. The pellet was then resuspended in 50 pi TE buffer (pH 8).
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A 4 pi aliquot of the sample was run on a 1% agarose gel along with 
M13mpl8 single stranded DNA marker (Figure A2.5).
A2.1.9 Cloning of the PCR product into RF M13mpl8
A Not I site was introduced into the AN Poly C primer while a Bgl II site 
was introduced into the Cp primer to make it convenient for cloning into M13mpl8.
The purified PCR product was digested with Not I (10 U/pl) and Bgl II 
(10 U/pl) in the presence of buffer (10 mM Tris-HCl, pH 7.5; 7 mM MgCl2; 100 
mM NaCl and 7 mM 2-mercaptoethanol) by incubation at 37°C overnight. The 
insert was cleaned by extraction with an equal volume of phenol: chloroform 
followed by two extractions with chloroform. This product was then precipitated by 
the addition of 1/10th volume of 3M sodium acetate, pH 6 and three volumes of 
ethanol at -20°C. After centrifugation at 13000 rpm for 15 minutes, the pellet was 
rinsed once with 70% ethanol and dried. This cleaned insert was then cloned into an 
M13mpl8 derived phage vector from which the M13mpl8 gene II Bgl II site had 
been deleted by oligonucleotide site directed mutagenesis, and into which had been 
cloned an in frame poly linker fragment containing Not I and Bgl II restriction 
enzyme sites. This vector was a kind gift from Paul Moss from the Institute of 
Molecular Medicine, Oxford.
RF M13mpl8 was similarly subjected to a double digestion with Not I and 
Bgl II restriction enzymes. 8 ng of the PCR product was ligated into 16 ng of Not I, 
Bgl II digested M13mpl8 derived phage vector using 2.8 Weiss units of T4 DNA 
ligase in 30 mM Tris HC1, pH 7.4; 10 mM DTT; 10 mM MgCl2; 10 mM ATP at
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F igu re  A2.5 Single stranded template of TCR V(3 gene from KM vs Priess 
cells seen in lanes 2,3,5 and 6 along with marker seen in lane 
one.
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16°C for 18hours.
A2.1.10 Transformation of TGI cells
An aliquot (200 pi) of competent cells (as described in Appendix 3) was 
mixed with the ligation mixture in a pre cooled 15 ml polypropylene tube (Falcon). 
The mixture was incubated on ice for 1 hour before incubation at 42°C for 3 
minutes (heat shocking). After 2 minutes on ice 200 pi of exponentially growing 
TGI lawn cells, 40 pi IPTG (lOOmM), 40 pi 2% X-gal and 4 ml molten H-agar (at 
42°C) were added. The mixture was immediately poured onto pre warmed 1 x TY 
plates and when set the plates were inverted and incubated at 37°C for at least 9 
hours.
Single stranded DNA was prepared from the colourless plaques and 
screened for recombinants. Screening of recombinants can be done by a number of 
methods namely oligo probing, PCR screening, Southerns.
A2.1.11 PCR Screening
Protocol 1
After blue/white selection, white plaques were subjected to PCR 
screening. White plaques were inoculated into 41.5 pi water along with 200 nM 
concentration of AN PolyC and Cp primers, 200 pM dNTPs, 50 mM KC1, 10 mM 
Tris HC1, 0.1% Tween 20 and 1.5 mM MgCk. This mixture was denatured at 94°C 
for 5 minutes and 2.5 Units of Taq Polymerase (Perkin Elmer Cetus) was added.
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The mixture was then overlaid with 2 drops of mineral oil and subjected to 25 cycles 
of denaturation at 94°C for 1 minute, annealing at 55°C for 1 minute and extension 
for 2 minutes at 72°C. It was finally subjected to an extension step at 72°C for 10 
minutes.
Protocol 2
White plaques were inoculated into 10 pi water and denatured at 94°C for 
10 minutes. The volume was made upto 50 pi in water with a final concentration of 
200 nM AN Poly C and Cp primers, 200 pM dNTPs, 50 mM KC1, 10 mM Tris HC1, 
0.1% Tween 20, 1.5 mM MgCk and 2.5 units of Taq Polymerase (Perkin Elmer 
Cetus). It was then subjected to 25 cycles of denaturation at 94°C for 1 minute, 
annealing at 55°C for 1 minute and extension for 2 minutes at 72°C. It was then 
extended for 10 minutes at 72°C.
Protocol 3
RF from white and blue plaques was subjected to the same conditions of 
PCR screening as described in protocol 2. The volume was made upto 50 pi with 
water and subjected to 1 cycle of denaturation at 94°C for 5 minutes, annealing at 
55°C for 2 minutes and extension at 72°C for 10 minutes. It was then subjected to 
30 cycles of denaturation at 94°C for 45 seconds, annealing at 55°C for 2 minutes 
and extension at 72°C for 10 minutes.
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A2.1.12 Oligo probing 
A2.1.12J Design o f the probe
A  probe RADS (Table A2.2) was designed by checking against the 
DNA sequences of human TCR p chain C region exon 1 using an identity search 
program. The oligo was synthesised on an Applied Biosystems DNA Synthesiser 
and purified as described in Section A2.1.4.1 using phosphoramidate chemistry.
A2,1.12.2 5 r phosphorylation o f the oligo probe
RADS probe was 5' phosphorylated. A 48 picomole sample of probe 
was mixed with buffer (0.05 M Tris HC1, pH 7.6; 0.01 M MgC^; 5 mM DTT; 0.1 
mM Spermidine HC1; 0.1 mM EDTA, pH 8) 100 pCi f 2P ATP and 7 units T4 
polynucleotide kinase enzyme in a final volume of 20 pi. The reaction was carried 
out at 37°C for 1 hour and stopped by the addition of 20 mM EDTA, pH 8. The 
phosphorylated probe was purified on a P-30 column to remove non incorporated 
ATP. This probe was loaded onto a 1 ml P-30 column pre equilibrated with 0.2 M 
NaCl; lOmM Tris HC1, pH 8; 1 mM EDTA, pH 8. A 100 pi fraction containing the 
purified probe was collected after centrifugation at 1600 rpm for 5 minutes. The 
concentration of the purified probe was determined spectrophotometrically.
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A2.1.12.3 Determination o f efficiency of the phosphorylation 
reaction
The efficiency of the phosphorylation reaction was determined by 
measuring the proportion of radioactive precursors incorporated into the 
probe. This was done by differential adsorption of the product onto a 
positively charged surface like DE-81 (as described in Section A2.1.2.2).
1 pi of the reaction volume was spotted onto the centre of 2 DE-81 
filters. One is used to measure the total amount of radioactivity in the reaction. 
This filter was washed thrice with 0.5 M disodium hydrogen phosphate, pH 7 for 2 
minutes. It was then washed in water for 1 minute followed by a wash in 70% 
ethanol for 4 minutes and then dried. Each of the filters (washed and unwashed) 
was inserted into scintillation vials and the amount of radioactivity on each filter 
was measured. 32P can be determined on dry filters by Cerenkov counting (in 
the 3H channel of a liquid scintillation counter). The amount of radioactivity on 
the unwashed filter can be compared with the amount of radioactivity on the 
washed filter and the % incorporation calculated. Only probes with a specific 
activity of 5 x 105 to 2 X 106 cpm/ml were used for the hybridisations.
A2.1.12.4 Plaque lift
Protocol 1
Recombinant plaques were spotted onto a grid and incubated at 37°C 
overnight, to reduce background signals. These plaques were then transferred onto
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a nylon membrane (Hybond-N) by diffusion at room temperature. The master 
plate was stored at 4°C.
This membrane was placed on a Whatmann 3MM filter soaked in 10% 
SDS for 5 minutes. DNA was denatured by incubation in 1.5 M NaCl; 0.5 M NaOH 
for 5 minutes and then neutralised on Whatmann 3 MM filter soaked in 1 M Tris 
HC1, pH 7.5; 1.5 M NaCl for 10 minutes. The membrane was then dried and baked 
at 80°C for 2 hours. It was washed in 50 mM Tris HC1, pH 8; 1M NaCl; 1.25 mM 
EDTA, pH 8; 0.1% SDS to remove bacterial debris.
Membranes were prehybridised in 5 X SSC; 5 X Denhardts solution; 50 
pg/ml sonicated salmon sperm DNA; 50 mM NaPi pH 6.8; 1 mM NaPPi; 100 pM 
ATP and 20% formamide at 42°C for 12 hours and hybridised with 1 X 106 cpm/ml 
of labelled probe (as described in section 12.1.2) at 42°C for 16 hours. For low 
stringency washes, membranes were washed in 2 X SSC; 0.1% SDS at 40°C for 
20 minutes four times. Stringency can be increased by raising the temperature and 
lowering the salt concentration. Membranes were dried prior to being exposed 
overnight to X-Ray film at -70°C.
Genuine signals resulting from hybridisation of the probe to cloned DNA 
can be distinguished from background artifacts by probing two filters from the same 
master plate. Only signals that duplicated were regarded as authentic positives.
The phage plaques giving positive signals were purified and single 
stranded DNA was prepared from them. These recombinants were sequenced by 
Sanger's dideoxy chain termination method (as described in Appendix 3).
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Protocol 2
Recombinant plaques were transferred onto a nylon membrane (Hybond- 
N), cut to the size of the plate, by diffusion at room temperature. The membrane 
was placed over the plaques for 2 minutes. The master plate was stored at 4°C. 
DNA was denatured by placing the membrane on a Whatmann 3MM paper soaked 
in 0.5M NaOH for 3 minutes. DNA was neutralised by washing the membrane twice 
in 1M Tris HC1 pH 7.5 for a minute each, followed by a wash in 1M Tris HC1 pH 
7.5, 1.5M NaCl for 5 minutes.
The membrane was dried and baked at 80°C for 2 hours to immobilise the 
DNA. It was then washed in 100ml 6 X SSC at 67°C for 5 minutes followed by a 
wash in 10 X Denhardts, 6 X SSC, 0.2% SDS at 67°C for 5 minutes and finally a 
rinse with 100ml 6 X SSC for 5 minutes. The Cp specific probe RADS was 
radiolabelled (as described in section 2.1.12.2), added to 8mls 6 X SSC and stored 
at -20°C till further use. Membranes were hybridised with 1 X 106 cpm/ml of 
labelled probe at 67°C for 30 minutes. It was then cooled to room 
temperature. The membrane was washed in 100ml 6 X SSC thrice. After draining 
off the SSC solution it was covered with clingfilm and exposed overnight to X- 
Ray film at -70°C. The membrane was then washed at 65°C for 1 minute in 6 X 
SSC twice and exposed to film. Similarly it was washed at 75°C for 1 minute in 6 
X SSC and exposed to film at -70°C (Figure A2.6). The phage plaques giving 
positive signals were purified and single stranded DNA was prepared from them. 
These recombinants were sequenced by dideoxy chain termination method as 
described in Appendix 3.
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Figure A2.6 Oligo probing of the TCR Vp gene obtained from KM vs Priess cells. 
Only the recombinant signals which duplicated were sequenced.
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A  quicker strategy to obtain sequence data from PCR products was 
devised. This strategy bypasses the time consuming cloning steps. The PCR 
product is purified by electro elution and then subjected to Southern blotting. All 
positives are directly sequenced by PCR sequencing.
A2.1.13 Transfer of DNA onto nylon filters by Southern 
blotting
RACE products can be examined by Southern blotting to confirm the 
presence of desired cDNAs. The purified PCR product was subjected to agarose 
gel electrophoresis. The gel was immersed in 0.25M HC1 for depurination of 
DNA for 7 minutes. The gel was then soaked in denaturing solution (0.5M NaOH, 
1.5M NaCl) for 30 minutes at room temperature. When the denaturation was 
complete the bromophenol blue dye turned light blue. The gel was then 
neutralised in 0.5 M Tris HC1 pH 7.5, 3M NaCl for 30 minutes after a rinse with 
distilled water. The gel was then placed on 6 sheets of pre wetted (20 X SSC) 
Whatmann 3MM paper. A pre wetted (10 X SSC) nylon filter was placed on the 
gel. Four dry Whatmann 3 MM sheets were placed on a pre wetted Whatmann 3 
MM sheet. All the air trapped in the filter was removed and the filter was wetted 
again. A cling film was placed on the stack in such a way as to prevent contact 
between the reservoir and the 15 cm paper towels kept above the basic sandwich 
placed in a reservoir of 20 X SSC. A glass plate was placed on top of this stack 
along with a 500 gm weight. The transfer was allowed to take place overnight
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by capillary blotting. The filter was then air dried. Transferred DNA was then 
fixed by baking in an oven at 80°C. Alternatively DNA can be fixed using a U.V. 
cross linker for 5 minutes. Filters can be stored in the dark at room temperature for 
a long period.
The filter was pre hybridised i n 3 XSSC,  2 X  Denhardts solution, 20 
pg/ml salmon sperm DNA, 6% PEG 6000) at 65 °C for 1 hour. The filter was then 
placed in 100 ml hybridisation solution (5 X Denhardts solution, 3 X SSC, 20 
pg/ml salmon sperm DNA, 6% PEG 6000) at 65°C overnight with a probe having a 
specific activity between 5 X 105 and 2 X 106 cpm/ml. Probes were prepared as 
described in section A2.1.12.2.
Low stringency washes were carried out in 2 X SSC at 45°C three 
times. For high stringency, filters were washed twice in 2 X SSC, 0.1 % SDS at 
65°C for 15 minutes followed by two washes in 0.1 X SSC, 0.1 % SDS at 65°C 
for 15 minutes. The filter was then air dried, wrapped in cling film and 
subjected to autoradiography at -70°C (Figure A2.7).
A2.1.14 PCR Sequencing
This technique also known as linear amplification sequencing is a 
variation of PCR. The components of a chain termination sequencing reaction 
are cycled through a temperature profile consisting of a heat denaturation step, 
an annealing step and an extension step. There are three basic differences 
between cycle sequencing and PCR amplification. Only one primer is necessary in
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♦
Figure A2.7 Southern blot of TCR Vp gene from KM vs Priess cells.
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the cycle sequencing reaction to prime synthesize a strand of DNA. The resultant 
linear amplification of the sequencing product leads to an increase in the signal 
generated during the sequencing reaction. Another difference is the presence of 
dideoxy nucleotide triphosphates in the sequencing reaction which create the 
base specific terminations required for sequencing. The last difference is the 
addition of an a-labeled nucleotide triphosphate to be incorporated into the 
growing DNA strand, providing the ability to detect the sequence ladder by 
autoradiography.
Protocol 1
90 pm of RADS primer was end labelled with 10 pCi of 32P (ATP) in the 
presence of 0.05 M Tris HC1, pH 7.6; 0.01 M MgCl2; 5 mM DTT; 0.1 mM 
spermidine HC1; 0.1 mM EDTA, pH 8 and 7 units of T4 Polynucleotide kinase. 
The reaction was carried out at 37°C for 30 minutes. The reaction was terminated 
by heating the mixture to 90°C for 2 minutes to inactivate the kinase. Pure PCR 
product was taken in a reaction mixture with 22.5 pm of RADS primer; 2.5 units 
of Taq Polymerase; 50 mM KC1; 10 mM Tris HC1; 0.1% Tween 20 and 1.5 mM 
MgCl2.
To 4 pi of this annealed primer-tempi ate 4 pi of dideoxy termination 
mixtures was added. This mixture was overlayed with a drop of mineral oil. Samples 
were taken in duplicate. One set was subjected to 10 cycles of denaturation at 
95°C for 40 seconds, annealing at 45°C for 30 seconds and extension at 72°C for 2 
minutes. The other set was subjected to 10 cycles of denaturation at 95°C for 40 
seconds, annealing at 52°C for 30 seconds and extension at 72°C for 2 minutes.
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This reaction was stopped by the addition of 4 pi of formamide dye. After 
denaturation at 90°C for 2 minutes, 3 pi of this sample was loaded onto an 8% 
polyacrylamide gel.
Protocol 2
This technique is based on the ability of Taq Polymerase to extend a 
labelled primer hybridised to the template to be sequenced until a chain terminating 
nucleotide is incorporated.
For 5 reactions, 10 pmoles of Qeg primer (66 ng for 20mer) was 
kinased with 10 pmoles of y*2P (dATP)in the presence of 0.05 M Tris HC1, pH 
7.6; 0.01 M MgCl2; 5 mM DTT; 0.1 mM spermidine HC1; 0.1 mM EDTA, pH 8 and 
7 units T4 Polynucleotide kinase. The reaction mixture was incubated at 37°C 
for 15 minutes. The reaction was terminated by heating the mixture at 90°C for 2 
minutes. The efficiency of labelling was determined by finding the % incorporation 
as described in section 2.2.2. The purified PCR product was taken with 2 pmoles of 
labelled primer in the presence of 50 mM KC1, 10 mM Tris, 1.5 mM MgCl2, 0.1% 
Tween 20 and 2.5 units Taq Polymerase. The volume was made upto 17.5 pi with 
water. 4 pi of labelled primer/template was taken separately with 4 pi ddATP, 
ddCTP, ddGTP and ddTTP terminating mixture in 4 tubes marked "A", "G", "C" 
and "T". These mixtures were overlayed with 2 drops of mineral oil and then 
subjected to 10 cycles of denaturation at 94°C for 40 seconds, annealing at 55°C for 
30 seconds and extension at 72°C for 2 minutes. The reaction was stopped by the 
addition of 4 pi formamide dye. 3 pi aliquot of this mixture was run on an 8% 
polyacrylamide gel after denaturation at 75°C for 3 minutes.
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Protocol 3
18 pm of Crcg primer was end labelled with 10 pCi of 32P (ATP)in the 
presence of 0.05 M Tris HC1, pH 7.6; 0.01 M MgCl2; 5 mM DTT; 0.1 mM 
spermidine HC1; 0.1 mM EDTA pH 8 and 7 units of Polynucleotidyl kinase. This 
reaction was incubated at 37°C for 30 minutes and terminated by heating the 
mixture at 55°C for 5 minutes. The labelled primer was taken in the presence of 50 
mM KC1; 10 mM Tris HC1; 0.1% Tween 20; 1.5 mM MgCl2; template DNA and
2.5 units of Taq Polymerase. The volume of the pre reaction mixture was made 
upto 36 pi with water. 8 pi of this pre reaction mixture was taken along with 2 pi 
of ddA, ddG, ddC and ddT termination mixtures respectively. After overlaying 
this mixture with one drop of mineral oil it was heated at 95°C for 5 minutes. In 
the case of partially pure PCR products, the reaction mixture was subjected to 20 
cycles consisting of a denaturation step at 95°C for 30 seconds, annealing step 
at 55°C for 30 seconds and extension at 72°C for 1 minute followed by 10 cycles 
consisting of a denaturation step at 95°C for 30 seconds and an extension step at 
70°C for 1 minute. Pure PCR products were subjected to 20 cycles of 
denaturation at 95°C for 5 seconds and annealing at 55°C for 5 seconds. After 
the addition of 5 pi of the stop solution (95% formamide; 20 mM EDTA; 0.05% 
Bromophenol Blue; 0.05% Xylene Cyanol FF) the mixture was heated to 90°C 
for 5 minutes. A 3 pi aliquot was loaded onto an 8% polyacrylamide gel.
Protocol 4
Pure PCR product was taken in the presence of 40 mM Tris Hcl, pH 7.5; 20
2 0 6
Appendix 2 KM vs Priess TCR Va and Vp gene cloning
mM MgCl2; 50 mM NaCl and 18 pm of AN Poly C primer. This template-primer 
mixture was boiled for 5 minutes, mixed and flash frozen in dry ice/ ethanol. The 
reaction mixture was then allowed to anneal at room temperature for 30 minutes. 
The sequencing reactions were then carried out as recommended in the DNA 
Sequencing kit supplied by USB. This method was used subsequently for direct 
sequencing of PCR products.
A2.1.15 FASTA Analysis
Several GCG programs like FASTA and BLAST.can be used to scan
sequence databases. BLAST or Basic Local Alignment Search Tool, uses the 
method of Altschul et al (1990) to search for similarities between the query 
sequence and all the sequences in a sequence database. It is a statistically driven 
search method that finds regions of similarity between the query sequence and the 
database. These regions of similarity are known as segment pairs. It can either 
search databases on a personal computer or databases maintained at the National 
Centre for Biotechnology Information (NCBI).
BLAST is not as sensitive as FASTA in searching nucleotide sequence 
databases as it ignores high scoring segment pairs that do not contain a perfect 
match of at least 12 nucleotides (24 bits). Many obviously significant relationships 
are not found although nearly identical sequences are found. Since FastA finds 
similarities that BLAST has missed, it was used to determine the identity of the 
unknown sequence.
FASTA uses the method of Pearson and Lipman (1988) to search for
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similarities between the query sequence and any group of sequences. This method 
first identifies the ten best regions of similarity between the query sequence and each 
sequence from the search set using a modification of the algorithm of Wilbur and 
Lipman (1983). These searches belong to a class of comparisons that use ‘direct 
addressing’ or ‘k-tuple preprocessing’ to increase efficiency.
In the first step of this search the comparison can be viewed as a set of 
dotplots with the query as the vertical sequence and the group of sequences to 
which the query is being compared as the different horizontal sequence. First step 
finds the registers of comparison (diagonals) having the largest number of short 
perfect matches (words) for each comparison. In the second step, these ’best' 
regions are rescored using a scoring matrix that allows conservative replacements, 
ambiguity symbols and runs of identities shorter than the size of a word. In the third 
step, the program checks to see if some of these initial highest scoring diagonals can 
be joined together. The highest scoring search set sequences are aligned to the 
query sequence for display. The best scores are displayed below the histogram. It 
displays the alignments of the regions of best overlap between the query and search 
sequences. The scores for matching the new sequence against each data base protein 
was noted and the highest scoring matches are examined as potential homologies
FASTA analysis of the sequence obtained from the KM vs Priess cell line 
established its identity as a TCR Vp sequence. The database sequence which 
showed the highest homology is displayed in Figure A2.8. Thus the strategy 
outlined above can be successfully used to obtain TCR Vp gene sequence 
information from T cells.
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(Nucleotide) FASTA of: rads.seq from: 1 to: 250 January 11, 1994 13:45
beta ter seq
TO: nucleic:* Sequences: 3,355 Symbols: 8,128,496 Word Size: 6

























T-c.ell receptor beta chain V and C r. 
Transduced T-cell antigen receptor b. 
T-ccjII receptor beta chain precursor . 
T-cell receptor beta chain V and C r. 
T-cell receptor beta chain V and C r. 
T-cell receptor beta chain mRNA (ANA . 
T-cell receptor beta-2 chain C regio. 











R;Yanagi, Y., Yoshikai, Y., Leggett, K., Clark, S.P., Aleksander, I., and 
Mak,
T.W.
Nature 308, 145-149, 1984 (Residues 1-1151)
F;38-973/Protein: T-cell receptor beta chain YT35
SCORES Initl: 306 Initn: 306 Opt: 422
58.9% identity in 219 bp overlap
10 20 30 40 50
rads.s CAGTGATCGCTCTTGCAGAGCTGAGGATCGTCTCCACTCTGAAGATCCAGCGCACACA—
:I:I I I I:I:I I I I I : I I I I I I II I
rwhuby GAUUCUCAGCUAAGAUGCCUAAUGCAUCAUUCUCCACUCUGAAGAUCCAGCCCUCAGAAC 
290 300 310 320 330 340
60 70 80 90 100 110
rads.S GCAGGAGACTCCGCCGTG-ATCTCTGTGCCAGCAGCTCCGGGTTTCTAGCGGGAGCT-AC
I I I I I I I : I I I I : I I : I : I : I I I I I I I I : I I II I I : I I
rwhuby CCAGG-GACUCAGCUGUGUACUUCUGUGCCAGCAGUUUCUCGACCUGUUCG GCUAAC
350 360 370 380 390 400
120 130 140 150 160 170
rads.s AATGAGCAGTTCTTCGGGCCAGGGACACGGCTCACCGTGCTAGAGGACCTGAAAAACGTG
I : I I :: I I I I I I I I II I I II I II I I:I II II I : I
rwhuby UAUGGCUACACCUUCGGUUCGGGGACCAGGUUAACCGUUGUAGAGGACCUGAACAAGGUG
410 420 430 440 450 460
180 190 200 210 220 230
rads.S TTCCCACCCGAGGTCGCTGTGTTTGAGCCATCAGAAGCAGAGATCTAGCTTATCGATACC
I I I I I I I I I I I : I I I : I : I ::: I I I I I I : I I I I I II I I I II :
rwhuby UUCCCACCCGAGGUCGCUGUGUUUGAGCCAUCAGAAGCAGAGAUCUCCCACACCCAAAAG
470 480 490 500 510 520
240 250
rads.s GTCGACCTGCAGG 
I I  I : I
rwhuby GCCACACUGGUGU 
530
Figure A2.8 FASTA analysis shows the high homology displayed by the sequence 
obtained from KM vs Priess cell line (rads) to other database TCR 
sequences.
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A2.2 Vn sene sequence analysis
Va gene was purified from the T cell line KM vs Priess using the method 
described below.
A2.2.1 RACE method for Va gene amplification 
A2.2.1J Design, synthesis and purification o f Ca primer
Ca y  primer (Table A2.2) was designed for use in Va Anchor PCR. A 
Sal I site was introduced into the primer to facilitate cloning into M13mpl8. This 
primer was synthesised on an Applied Biosystems DNA synthesiser using 
phosphoramidate chemistry. The oligo sequences were checked against the DNA 
sequences of human TCR chain constant region exon 1 using an identity search 
program. Ammonia cleaves the oligo from the resin at room temperature. The 
protecting groups were removed from the terminus by incubating the resin in 
0.88N ammonia solution at 55°C for 16 hours. Ammonia was removed by drying 
the oligo under vacuum. Ethanol precipitated oligo can be recovered by a 10 
minute spin at 10000 rpm followed by a rinse with 70% ethanol and then dried. 
Concentration of the oligo was determined spectrophotometrically.
A2.2.1.2 5 'phosphorylation of oligo primers
The Ca 3' primer was 5' phosphorylated. A 2 picomole sample of primer 
was mixed with buffer (0.05 M Tris HC1, pH 7.6; 0.01 M MgCb; 5 mM DTT; 0.1 
mM spermidine HC1 ; 0.1 mM EDTA, pH 8) and 1 unit T4 PNK enzyme in a 
final volume of 20 pi. The reaction was performed at 37°C for 30 minutes and
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the kinase was inactivated by heating at 70°C for 10 minutes. The 5' 
phosphorylated primers were stored at -20°C.
A2.2.1.3 Preparation o f template for Anchor PCR
Total RNA was extracted from a DR4 Dw4 restricted T cell clone 
HF53 by the RNAzol method (as described in Section 2.1.3). 1 pg of total RNA 
was used for cDNA synthesis using 0.5 pg of Oligo (dT)i2-i8 annealed at 70°C for 
10 minutes. Reactions were performed using 0.5 mM dNTPs; 10 mM DTT; 75 mM 
KCl; 50 mM Tris HC1 (pH 8.3); 3 mM MgCl2; 10 pCi of a -32P dCTP and 200 units 
of Moloney Murine Leukemia Virus Reverse Transcriptase (BRL) at 37°C for 60 
minutes. The reaction was terminated by the addition of 4 pi of 0.5 M EDTA, pH 8. 
The quality of cDNA was checked by running a 4 pi aliquot of the sample on a 1% 
alkaline gel.
The cDNA was made upto 100 pi and precipitated twice with 4 M 
ammonium acetate and three volumes of ethanol. The precipitate was taken up 
in 500 pi 70% ethanol and spun for 15 minutes. The pellet was then resuspended in 
37.775 pi water and dG tailed using 0.5 M potassium cacodylate (pH 7.2); 
lOmM C0 CI2; ImM DTT and 24.5 pM dGTP for 30 minutes at 37°C. The tailed 
cDNA was then diluted to a volume of 100 pi. It was extracted with an equal 
volume of phenol:chloroform mixture and then twice with chloroform. The 
aqueous phase was used as template for A-PCR.
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A2.2.1.4 Anchor PCR
8 pi of the tailed cDNA was subjected to Anchor PCR using 2.5 units 
of Taq Polymerase (Perkin Elmer) and a Perkin Elmer Cetus Thermocycler under 
the following conditions: 94°C, 5 minutes; 55°C, 2 minutes; 72°C, 10 minutes for 
one cycle followed by denaturation at 94°C for 45 seconds, annealing at 55°C for 2 
minutes and extension at 72°C for 10 minutes for 30 cycles. The reaction was 
performed using 200 pM dNTPs, 50 mM KC1, 10 mM Tris HC1, 0.1% Tween 20 
and 1.5 mM MgCl2 . The primers used for V gene amplification were AN Poly C and 
Ca 3' at a concentration of 8.9 pm. The volume was made upto 50 pi.
A 5 pi aliquot of each sample was run on a 1% agarose gel along with 
<J)X 174 RF DNA marker (Figure A2.9). These PCR products were then purified by 
electroelution.
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Figure A2.9 Anchored PCR product of TCR V a gene from KM vs Priess cells seen in 
lanes 4 and 5 along with <|>X 174 RF DNA marker in lane 1.
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Chemical reagents (analytical grade) were purchased from Sigma, Fisons and 
BDH except where stated otherwise.
A3.1.2 Restriction enzymes and DNA modifying enzymes
All enzymes were purchased from Pharmacia except where stated otherwise.
A3.1.3 Radiochemicals
All radiochemicals were purchased from NEN.
A3.1.4 Media and Antibiotics
Agar (No. 1), tryptone and yeast extract were purchased from Difco and 
antibiotics from Sigma. All media and antibiotics stock solutions were prepared as 
described in Sambrook et al,''89.
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A3.2 Preparation o f solutions 
A3.2.1 RNase free Dnase
Pancreatic RNase A was dissolved in 50 mM EDTA to 10 mg/ml and 
contaminating DNase free was heat inactivated by incubating at 70°C for 15 
minutes. The solution was aliquoted and stored at -20°C.
A3.3 Bacterial strains. plasmids and phase
E.coli strains BMH71.18 and W3110 were used for Gloop2DDFv 
protein expression while TGI was used for all cloning purposes. The expression 
vector used was pUC19. M13mpl8 derived phage vector was used for TCR 
cloning.
A3.4 Maintenance o f bacterial strains. plasmids and phase
A3.4.1 Bacterial strains and plasmids
Stocks of bacterial strains and plasmids in the appropriate host cell were 
prepared for long term storage at -70°C by mixing 0.9 ml of a fresh overnight 
culture with 0.6 ml of sterile 80% glycerol. For short term storage, strains were 
streaked out onto agar or glucose minimal media plates, sealed with Nescofilm and 
stored at 4°C.
A3.4.2 M13mpl8 phage stocks
A 5 ml aliquot of 1 x TY was inoculated with a single plaque and 500 p.1
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of a 1: 100 fold dilution of an overnight culture of TGI was added. The culture was 
incubated with rolling at 37°C for 5 hours. 1.5 ml aliquots were dispensed into 
sterile microfuge tubes and centrifuged for five minutes to remove bacterial cells. 
One ml of the supernatant was transferred to a fresh sterile tube which was sealed 
with nescofilm and stored at 4°C.
A3.5 Isolation o f plasmid from E.coli 
A3.5.1 Small scale preparation of plasmid DNA
The rapid alkaline lysis method was used to isolate plasmid DNA from
1.5 ml of overnight culture. An isolated colony was picked and used to inoculate 
10 mis of liquid media. After overnight growth at 37°C, 250 rpm, a 1.5 ml 
aliquot of the culture was transferred to a microfuge tube and centrifuged for 5 
minutes. The pellet cells were resuspended in 100 |il of ice cold 50mM glucose; 
25mM Tris-HCl, pH 8.0, lOmM EDTA (Solution I) containing 2 mg/ml 
lysozyme and incubated at 4°C for 5 minutes. Cells were completely lysed by the 
addition of 200 jxl of 0.2M NaOH and 1% w/v SDS (Solution II) and mixed gently 
on ice for 5 minutes. 150 |il of ice cold 5M potassium acetate, pH 4.8 [Solution III: 
This solution is 3 M with respect to sodium and 5 M with respect to potassium. 
(To 29 ml of glacial acetic acid, on ice, add water to 80 ml; adjust the pH to 4.8 
with 10 M KOH and then add water to a final volume of 110 m l) was added and 
the mixture incubated on ice for 5 minutes. Chromosomal DNA and cellular debris 
were pelleted by centrifugation at 13000 rpm for 5 minutes. The supernatant 
containing the plasmid DNA was extracted once with an equal volume of phenol
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(water equilibrated): CHCI3 and twice with ether (water equilibrated). DNA was 
precipitated from the aqueous solution by the addition of 0.1 volume of 3M 
sodium acetate (pH 5.2) and 3 volumes of ethanol at -20°C. After centrifugation 
at 13000 rpm for 15 minutes, the pellet was washed in 70% ethanol to remove 
the salt residue and dried. The pellet was resuspended in 50 |il water and stored at 
-20°C.
A3.5.2 Large scale preparation of plasmid
500 ml culture was prepared by inoculating media with 1ml of an 
overnight culture grown at 37°C, 250 rpm. As in the case of small scale 
preparations the DNA was isolated by the method of Bimhoim and Doly (1979) 
with modifications. The cells were pelleted by centrifugation using a GSA rotor in a 
Sorval RC-5 centrifuge by accelerating the rotor to 10,000 rpm. The cells were 
resuspended in 2 mis of Solution I, transferred to a 15 ml Corex tube and lysozyme 
added at a concentration of 5 mg/ml. The solution was incubated at 37°C for 20 
minutes and then 4 ml of Solution II was added and incubated at 4°C. 3 mis of 
Solution III was added and the solution incubated at 4°C for 5 minutes. After 10 
minutes centrifugation at 10,000 rpm the supernatant was poured off and extracted 
once with an equivalent volume of Tris buffered Phenol:Chloroform. The DNA was 
precipitated by the addition of 0.6 volume of isopropanol and incubated at room 
temperature for 30 minutes. After centrifugation, the pellet containing plasmid DNA 
and contaminating RNA was washed in 100% ethanol to remove all traces of 
isopropanol and left to dry. The DNA was then purified from RNA by caesium
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chloride gradient purification.
A3.5.3 Caesium chloride gradient purification
The dried DNA pellet was resuspended in 1 ml of TE buffer and the 
volume made up accurately to 2.4 mis with TE buffer .Then .4.2 g caesium 
chloride was dissolved into the DNA solution and 400 |il of ethidium bromide (10 
mg/ml) was added. 8 mis of a salt cushion, made by dissolving 15.41 g of caesium 
chloride into 20 ml of TE buffer was transferred into a Beckman Quick Seal 
ultracentrifuge tube, with care being taken not to introduce air bubbles. The 
DNA/Ethidium bromide solution was then carefully introduced into the 
centrifuge tube below the salt cushion using a syringe. The tube was filled to the 
neck with the cushion solution and heat sealed. Caesium chloride gradient was 
established by centrifugation in a Beckman (8-M ultracentrifuge using a [70. ITi] 
rotor) accelerating to 55,000 rpm for 17 hours. The DNA bands were identified 
by ultraviolet fluorescence and the solution removed with a syringe. The 
contaminating RNA and proteins were pelleted at the bottom of the tube. The 
DNA solution was extracted 3 times with water- equilibrated butanol to remove the 
ethidium bromide and then an equal volume of TE buffer was added to dilute the 
caesium chloride. The DNA was precipitated in 0.6 volumes of propan-2-ol for 30 
minutes at room temperature and the pellet resuspended in 300 |il 0.3M sodium 
acetate pH 5.5. After transferring to a microfuge tube, the DNA was reprecipitated 
with ethanol. The pellet was washed in 70% ethanol, dried and resuspended in 100 
p.1 water.
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A3.5.4 Preparation of high quality plasmid DNA without caesium 
chloride gradient.
100 ml 2 X TY was inoculated with 1 ml of an exponential culture 
(grown at 37°C, 250 rpm till an optical density of 0.3-0.5) and grown at 37 °C, 
250 rpm overnight. The culture was pelleted by spinning twice at 5000 rpm for 10 
minutes. The pellet was resuspended in 4 ml of TEG (25 mM Tris HC1, pH 8.0; 50 
mM glucose; 10 mM EDTA) and the solution was vortexed to get rid of clumps. 8 
mis of lysis solution (0.2 M NaOH, 1% SDS) was added till the solution became 
viscous. This solution was then left on ice till it became transparent. After the 
addition of 6 mis of ice cold potassium acetate solution, it was kept on ice for 15-30 
minutes. The solution was then spun at 5000 rpm for 15 minutes. 18 mis propan-2- 
ol was added to the supernatant and the mixture was kept on ice for 15 minutes. It 
was then spun at 5000 rpm for 30 minutes. The supernatant was discarded and the 
inside of the tube was wiped with tissue. The pellet was then resuspended in 2 mis 
of TE buffer. After the addition of 2 mis of 6M LiCl solution it was kept on ice for 
15 minutes. RNA and protein were precipitated by centrifugation at 5000 rpm for 
10 minutes. The supernatant was then transferred to another tube and after the 
addition of 10 mis of absolute ethanol it was left on ice for 30 minutes. After 
centrifugation at 5000 rpm for 30 minutes the supernatant was discarded and the 
pellet resuspended completely in 2 mis 70% ethanol to form a turbid solution. It was 
then respun at 5000 rpm for 15 minutes. The pellet was resuspended in 500 \x\ TE 
buffer. After the addition of 1 ml of absolute ethanol the solution was allowed to 
stand on ice for 15 minutes. 50 |il 3 M sodium acetate, pH 6 was added to the
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mixture at this stage if no precipitate was observed. It was then incubated on ice for 
15 minutes. After centrifugation at 13000 rpm for 30 minutes the pellet was rinsed 
with 70% ethanol. It was then respun at 13000 rpm for 5 minutes. The pellet was 
dried for 5 minutes under vacuum and then resuspended in 400 |il TE buffer. It was 
incubated at 37°C for 30 minutes after the addition of 4 |il of Bovine Pancreatic 
RNase fraction V (lOmg/ml). After the addition of 20 }il 10% SDS it was heated at 
75°C for 10 minutes. It was kept at room temperature for 15 minutes after the 
addition of 400 fil 6 M LiCl solution. After centrifugation at 13000 rpm for 10 
minutes the supernatant was taken in 2 eppendorf tubes. It was kept on ice for 30 
minutes after the addition of 1 ml absolute ethanol. If no precipitate was visible at 
this stage, 40 |il 3M sodium acetate, pH 6 was added and the mixture was left on 
ice for another 30 minutes. After centrifugation at 13000 rpm for 30 minutes the 
pellet was rinsed with 70% ethanol. The pellet was resuspended in 400 p.1 water 
after centrifugation at 13000 rpm for 10 minutes. After one extraction with 
phenol/chloroform/isoamyl alcohol it was extracted twice with chloroform. The 
DNA was precipitated with ethanol and resuspended in 100 p.1 water.
A3.6 Azarose se t electrophoresis o f nucleic acids
Agarose gels were cast and run in a Bio-Rad Mini-gel apparatus to form 
gels of dimensions 10cm x 6cm x 0.5cm. Native gels contained varying 
concentrations of agarose (0.8 -1.0% [w/v]) and ethidium bromide at a 
concentration of 0.4 |ig/ml. The DNA samples were mixed with 0.1 volume of 10 x 
loading buffer (3.5% w/v Ficoll; 0.1% w/v bromophenol blue; 0.1% w/v xylene
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cyanol and 4mM EDTA) and the gels were run in 1 x TBE (89 mM Tris-borate; 89 
mM boric acid and 2mM EDTA). Electrophoresis was carried out at voltages and 
times depending on the size and concentration of the gel and the fragment 
separation required. DNA size markers used to determine fragment sizes were <J)X 
174 Hae III or X DNA digested with Hind III. The migration of DNA was visualised 
by exposure to short wave UV irradiation from a UV transilluminator and the image 
photographed using a Polaroid camera.
A3.7 Alkaline 2el electrophoresis
The quality of cDNA was assessed on a 1% alkaline gel (ImM EDTA, pH 
8; 250 mM NaOH) along with X DNA digested with Hind III marker end labelled 
with y 32P dATP. 2 pi of the labelled cDNA sample was loaded onto the gel along 
with 8 pi alkaline gel loading buffer (0.3 M NaOH; 6 mM EDTA, pH 8.0; 18% 
Ficoll, 0.15% Bromophenol Blue, 0.25% Xylene Cyanol). The gel was run at 15-20 
V over a period of 3-4 hours. The cDNA was fixed by soaking the gel in 7% TCA 
solution overnight. The gel was then dried and subjected to autoradiography.
A3.8 Quantification o f DNA and RNA
The concentration of DNA, RNA and oligonucleotides was determined by 
measuring absorbance at wavelengths of 260 and 280 nm. The ratio between the 
readings at 260 nm and 280 nm provided an estimation of purity. Pure preparations 
of DNA and RNA have OD26o/OD28o values of 1.8 and 2.0 respectively. An OD of 1 
unit at 260 nm was assumed to be equivalent to 50 pg/ml for double stranded DNA,
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40 |ig/ml for RNA and 37 jig/ml for oligonucleotides. The concentration of small 
quantities of DNA was estimated by running samples on an agarose gel and 
comparing the intensity of ethidium bromide fluorescence in the sample with known 
amounts of bacteriophage X DNA digested with Hind III.
A3.9 Preparation o f competent cells (strains : W3110. BMH 71.18. 
TGI)
Method 1
A 20 ml overnight culture of the strain was prepared and 100 |il was used 
to inoculate 20 mis of LB medium. The culture was grown at 37 °C, 250 rpm, until 
an ODssonm of about 0.3 units was reached. The cells were cooled briefly on ice 
before pelleting at 3000-4000 rpm at 4°C. The cells were resuspended gently in 10 
mis of sterile ice cold 0.1M CaCL and incubated on ice for 1 hour. The cells were 
pelleted and resuspended in 2 ml of 0.1M CaCL solution prior to transformation.
For transformation of M13mpl8 into TGI, the competent cells were 
prepared by inoculating 20 mis of 1 x TY with 100 |il of an overnight culture 
grown from a colony selected on minimal agar.
Method 2
A more efficient method for the preparation of competent cells was 
adopted. 200 ml of 1 X TY was inoculated with 200 jil of an overnight culture and 
incubated with shaking at 37°C to an OD of 0.3-0.5 measured at 550 nm. After 
incubation on ice for 30 minutes the culture was centrifuged at 2500 rpm for 5 
minutes at 4°C. The pellet was resuspended in 100 ml of ice cold lOOmM MgCb,
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2mM Tris HC1 (pH 7.4). After centrifugation at 2500 rpm for 5 minutes at 4°C, 
the cell pellet was resuspended in 100 ml of ice cold 100 mM CaCL ,2 mM Tris 
HC1 (pH 7.4 ). After incubation on ice for 60 minutes, the cells were pelleted and 
gently resuspended in 10 ml of 100 mM CaCL, 2mM Tris HC1 (pH 7.4), 15% 
glycerol. The competent cells were aliquoted in 200-400 p.1 volume into microfuge 
tubes and either frozen at -70°C or used immediately.
A3.10 Transformation o f plasmid DNA
200 |il aliquots of competent cells were mixed with the transforming DNA 
(10 ng) in a pre-cooled 15 ml polypropylene tube (Falcon). The mixture was 
incubated on ice for 1 hour before incubating at 42°C for 45 seconds (heat 
shocking). After 2 minutes on ice, the volume was increased to 1 ml with LB media 
and incubated at 37°C, 250 rpm for 1 hour. 200 JJ.1 of the transformed mixture 
was plated onto LB media plates containing the appropriate antibiotic and incubated 
inverted at 37 °C.
A 3 .l l  Preparation o f single stranded template
Infected cells from recombinant colourless plaques were grown to produce 
single stranded template for the sequencing reaction. 1 ml of an overnight culture of
E.coli cells was used to inoculate 100 ml 1 X TY. 1.5 ml aliquots of the culture 
were then dispensed into sterile 10 ml culture tubes. A colourless plaque was 
inoculated into each tube. The cells were pelleted by centrifugation at 13000 rpm 
for 5 minutes after incubation at 37°C for 5 hours. The supernatant was then
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recentrifuged to ensure that all cells were removed. After the addition of 4% PEG 
6000 and 0.5 M NaCl themixture was incubated at RT. for 15 minutes. The 
supernatant was discarded after centrifugation at 13000 rpm for 5 minutes. All the 
remaining traces of PEG were removed with a tissue after a subsequent 
centrifugation at 13000 rpm for two minutes. The viral pellet was resuspended in 
100 pi TE buffer. It was then extracted with an equal volume of PhOH followed by 
an extraction with CHCI3 . DNA was precipitated by the addition of 0.1 volume 3M 
sodium acetate, pH 5.2 and 2.5 volumes EtOH followed by incubation at -20°C 
overnight. The pellet was then washed with 1 ml ice cold EtOH and resuspended in 
50 pi TE buffer.
A3.12 SDS-Polvacrvlamide gel Electrophoresis o f proteins
Proteins were analysed by SDS-PAGE in 1.5 mm thick, 12.5 cm long slab 
gels with an upper ‘stacking’ gel and a lower ‘separating’ gel. Electrophoresis was 
carried out with a discontinuous buffer system in which the buffer in the reservoirs 
was of a different pH and ionic strength from the buffer used to cast the gel. The 
sample and the stacking gel contain Tris HC1 (pH 6.8), the upper and lower buffer 
reservoirs contain Tris glycine (pH 8.3) while the resolving gel contains Tris HC1 
(pH 8.8).
The separating gel was prepared by mixing the following solutions: 14 ml 
40% (w/v) acrylamide stock solution [acrylamide: N, N' methylene bis acrylamide; 
19:1]; 9.4 ml pH 8.8 buffer (18.2 g% Tris HC1, 0.23 g% EDTA and 0.4 g% SDS) 
and 14.1 ml water. After the addition of 20 pi TEMED and 160 pi 25% ammonium
224
Appendix 3 Standard biochemical and microbiological techniques
persulphate the separating gel was immediately poured into the gap between 2 glass 
plates. This solution was overlaid with butanol till polymerisation was complete. 
The overlay was then tipped off and the top of the gel rinsed several times with Milli 
Q water. The stacking gel was then prepared by mixing the following solutions: 3.6 
ml 40% (w/v) acrylamide stock solution [acrylamide: N, N' methylene bis 
acrylamide; 19:1] solution; 6 ml pH 6.8 buffer (3g% Tris HC1, 0.12 g% EDTA, 0.2 
g% SDS) and 14 ml water. After the addition of 12 (il TEMED and 300 p.1 25% 
ammonium persulphate the stacking gel was poured onto the surface of the 
polymerised separating gel and a Teflon comb was immediately inserted into the 
stacking gel solution carefully. The gel was allowed to set in a vertical position at 
room temperature for at least 40 minutes
Samples were taken up in 50 mM Tris HC1, pH 6.8; 25% (v/v) glycerol; 
0.1% (v/v) bromophenol blue; 6% (w/v) SDS. In the case of reducing SDS-PAGE, 
4% (v/v) p- mercapto ethanol was included in the loading buffer. The PAGE 
running buffer used in both electrode compartments contained 0.025 M Tris HC1, 
0.192 M glycine and 0.1% w/v SDS (pH 8.3). The gels were run at 50V overnight. 
Proteins were stained by gently shaking the gel in 0.1% (w/v) Coomassie Brilliant 
Blue R; 50% (v/v) methanol and 10% (v/v) acetic acid and subsequently destained 
with 10% acetic acid, 10% methanol.
A3.13 DNA Sequencing
DNA sequencing was performed according to Sanger's dideoxy chain 
termination method which involves the synthesis of a DNA strand in vitro using a
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DNA polymerase with a single stranded DNA template.
For every set of four sequencing lanes a single annealing and subsequent 
labelling reaction was used. In a micro centrifuge tube 1 pg of single stranded DNA 
template was taken in the presence of 40 mM Tris HC1 pH 7.5, 20 mM MgCk, 50 
mM NaCl and 0.5 pmole -40 primer. The total volume was made upto 10 pi. It was 
then warmed to 65°C and allowed to cool to room temperature. After the addition 
of 6.3 mM DTT, labelling mixture (1.5 pM dGTP, 1.5 pM dCTP, 1.5 pM dTTP), 5 
pCi [35S] dATP and Sequenase Version 2.0 enzyme, the annealed template primer 
was incubated at room temperature for 5 minutes. 3.5 pi of this mixture was then 
added to 2.5 pi of ddGTP, ddCTP, ddTTP and ddATP termination mixtures 
respectively. This mixture was then warmed at 37°C for 5 minutes. After the 
addition of 4 pi of stop solution (95% formamide, 20 mM EDTA, 0.05% 
bromophenol blue, 0.05% xylene cyanol FF) the mixture was stored at -20°C until 
further use.
Sequencing reactions were analysed by polyacrylamide gel electrophoresis 
on 0.4 mm 6% denaturing polyacrylamide gels. Gels were prepared by dissolving 
31.5 g urea in a solution containing 15 ml 40% (w/v) acrylamide stock (acrylamide : 
N,N‘ methylenebisacrylamide; 19:1 ), 7.5 ml 10 x TBE and 450 pi 10% ammonium 
persulphate made upto a volume of 75 ml with water. Gels were poured after the 
addition of 45 pi TEMED. Gels were run on a gel apparatus in TBE buffer.Gels 
were pre electrophoresed at 40 W for 1 hour to remove the unpolymerised 
acrylamide monomer and to pre warm the gel to its optimum temperature of 55°C. 
The sequencing reactions were denatured by heating at 75°C for 3 minutes before
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loading onto the gel. For each sequencing reaction 2-3 |il of each sample was 
loaded per well and run at a constant power of 40 W. Electrophoresis was 
continued until the bromophenol blue dye reached the bottom of the gel for short 
runs, or twice the length of the gel for long runs. After electrophoresis the gels were 
washed for 20- 30 minutes with a solution of 10% v/v methanol, 10% v/v acetic 
acid to fix DNA and to leach urea. The gel was then transferred onto Whatmann 3 
MM paper and dried under vacuum at 80°C on a slab drier for 1 hour. 
Autoradiography was performed overnight without an intensifying screen.
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